JP4793692B2 - 新規なblt2介在性疾患、blt2結合剤および化合物 - Google Patents
新規なblt2介在性疾患、blt2結合剤および化合物 Download PDFInfo
- Publication number
- JP4793692B2 JP4793692B2 JP2006512614A JP2006512614A JP4793692B2 JP 4793692 B2 JP4793692 B2 JP 4793692B2 JP 2006512614 A JP2006512614 A JP 2006512614A JP 2006512614 A JP2006512614 A JP 2006512614A JP 4793692 B2 JP4793692 B2 JP 4793692B2
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- biphenyl
- amino
- carboxylic acid
- phenylpropyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000001875 compounds Chemical class 0.000 title claims description 177
- 101001017969 Homo sapiens Leukotriene B4 receptor 2 Proteins 0.000 title description 108
- 102100033375 Leukotriene B4 receptor 2 Human genes 0.000 title description 107
- 201000010099 disease Diseases 0.000 title description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 27
- 230000001404 mediated effect Effects 0.000 title description 14
- 239000011230 binding agent Substances 0.000 title description 8
- -1 phenylbutyl group Chemical group 0.000 claims description 409
- 125000001424 substituent group Chemical group 0.000 claims description 98
- 150000003839 salts Chemical class 0.000 claims description 40
- 239000012453 solvate Substances 0.000 claims description 33
- 125000005843 halogen group Chemical group 0.000 claims description 26
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 24
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 20
- 125000004043 oxo group Chemical group O=* 0.000 claims description 19
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 13
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 10
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 9
- IUJTVDNJFPZYBL-UHFFFAOYSA-N [1,1'-biphenyl]-2-carboxylic acid, 4'-[[(1-oxopentyl)phenylamino]methyl]- Chemical compound C=1C=CC=CC=1N(C(=O)CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O IUJTVDNJFPZYBL-UHFFFAOYSA-N 0.000 claims description 6
- JXUWHKKVGRWWCB-UHFFFAOYSA-N 2-[4-[[benzyl(pentanoyl)amino]methyl]phenyl]benzoic acid Chemical compound C=1C=C(C=2C(=CC=CC=2)C(O)=O)C=CC=1CN(C(=O)CCCC)CC1=CC=CC=C1 JXUWHKKVGRWWCB-UHFFFAOYSA-N 0.000 claims description 4
- VJKIXGAMLUFKII-UHFFFAOYSA-N 2-[4-[[(2-phenylacetyl)amino]methyl]phenyl]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(C=C1)=CC=C1CNC(=O)CC1=CC=CC=C1 VJKIXGAMLUFKII-UHFFFAOYSA-N 0.000 claims description 3
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 3
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000004344 phenylpropyl group Chemical group 0.000 claims description 3
- 125000001999 4-Methoxybenzoyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C(*)=O 0.000 claims description 2
- UENIXJSFYVZOBY-UHFFFAOYSA-N 2-[2-[[benzyl-(2-phenylacetyl)amino]methyl]phenyl]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C1=CC=CC=C1CN(C(=O)CC=1C=CC=CC=1)CC1=CC=CC=C1 UENIXJSFYVZOBY-UHFFFAOYSA-N 0.000 claims 3
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 3
- HMVXRINXBLLXGY-UHFFFAOYSA-N 2-[2-[[2-phenylethyl(3-phenylpropanoyl)amino]methyl]phenyl]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C1=CC=CC=C1CN(C(=O)CCC=1C=CC=CC=1)CCC1=CC=CC=C1 HMVXRINXBLLXGY-UHFFFAOYSA-N 0.000 claims 2
- VDCGXTABYAFDCB-UHFFFAOYSA-N 2-[3-[[benzyl-[(4-chlorophenyl)methyl]amino]methyl]phenyl]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C1=CC=CC(CN(CC=2C=CC=CC=2)CC=2C=CC(Cl)=CC=2)=C1 VDCGXTABYAFDCB-UHFFFAOYSA-N 0.000 claims 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 2
- WLJCMSJEWWLQOZ-UHFFFAOYSA-N 3-[3-[[(4-methoxybenzoyl)-(4-phenylbutyl)amino]methyl]phenyl]benzoic acid Chemical compound C1=CC(OC)=CC=C1C(=O)N(CC=1C=C(C=CC=1)C=1C=C(C=CC=1)C(O)=O)CCCCC1=CC=CC=C1 WLJCMSJEWWLQOZ-UHFFFAOYSA-N 0.000 claims 2
- DUGFEIIGFMWOPY-UHFFFAOYSA-N 4-[3-[[(4-cyanophenyl)methyl-(2-phenylethyl)amino]methyl]phenyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CC=CC(CN(CCC=2C=CC=CC=2)CC=2C=CC(=CC=2)C#N)=C1 DUGFEIIGFMWOPY-UHFFFAOYSA-N 0.000 claims 2
- GNHPQUHKRWIOGM-UHFFFAOYSA-N 4-[4-[(dibenzylamino)methyl]phenyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C(C=C1)=CC=C1CN(CC=1C=CC=CC=1)CC1=CC=CC=C1 GNHPQUHKRWIOGM-UHFFFAOYSA-N 0.000 claims 2
- GQVOVCNDGYEUCN-UHFFFAOYSA-N 4-[4-[[benzyl(cyclohexylmethyl)amino]methyl]phenyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C(C=C1)=CC=C1CN(CC=1C=CC=CC=1)CC1CCCCC1 GQVOVCNDGYEUCN-UHFFFAOYSA-N 0.000 claims 2
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000000242 4-chlorobenzoyl group Chemical group ClC1=CC=C(C(=O)*)C=C1 0.000 claims 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 claims 1
- 125000006505 p-cyanobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C#N)C([H])([H])* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 120
- 230000014759 maintenance of location Effects 0.000 description 118
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 66
- 239000003814 drug Substances 0.000 description 64
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 63
- 150000002430 hydrocarbons Chemical group 0.000 description 56
- JJBWFKJWSAKJTP-QHCPKHFHSA-N (2s)-3-[(2-methylpropan-2-yl)oxy]-2-[[pentyl-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]carbamoyl]amino]propanoic acid Chemical compound C1=CC(CN(CCCCC)C(=O)N[C@@H](COC(C)(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=NN1 JJBWFKJWSAKJTP-QHCPKHFHSA-N 0.000 description 47
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 45
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 41
- 239000000243 solution Substances 0.000 description 41
- 239000000203 mixture Substances 0.000 description 39
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 38
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 36
- 229940079593 drug Drugs 0.000 description 35
- 238000002360 preparation method Methods 0.000 description 34
- 125000003277 amino group Chemical group 0.000 description 32
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 31
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 29
- 239000003795 chemical substances by application Substances 0.000 description 29
- 238000000034 method Methods 0.000 description 28
- 230000027455 binding Effects 0.000 description 27
- 229940002612 prodrug Drugs 0.000 description 27
- 239000000651 prodrug Substances 0.000 description 27
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 26
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 23
- 208000017520 skin disease Diseases 0.000 description 23
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 22
- 206010020649 Hyperkeratosis Diseases 0.000 description 22
- 229930195733 hydrocarbon Natural products 0.000 description 22
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 21
- 208000001126 Keratosis Diseases 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 21
- 238000010511 deprotection reaction Methods 0.000 description 21
- 239000004215 Carbon black (E152) Substances 0.000 description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 20
- 210000002510 keratinocyte Anatomy 0.000 description 20
- 241000699666 Mus <mouse, genus> Species 0.000 description 19
- 239000000556 agonist Substances 0.000 description 19
- 125000000753 cycloalkyl group Chemical group 0.000 description 19
- 239000002904 solvent Substances 0.000 description 19
- 201000004384 Alopecia Diseases 0.000 description 18
- 239000005557 antagonist Substances 0.000 description 18
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 18
- 229940124597 therapeutic agent Drugs 0.000 description 18
- 201000004681 Psoriasis Diseases 0.000 description 17
- 230000003834 intracellular effect Effects 0.000 description 17
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 16
- 125000004093 cyano group Chemical group *C#N 0.000 description 16
- 230000014509 gene expression Effects 0.000 description 16
- 239000007924 injection Substances 0.000 description 16
- 238000002347 injection Methods 0.000 description 16
- 238000011282 treatment Methods 0.000 description 16
- 201000004624 Dermatitis Diseases 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 15
- 125000000464 thioxo group Chemical group S=* 0.000 description 15
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 15
- 101100236208 Homo sapiens LTB4R gene Proteins 0.000 description 14
- 102100033374 Leukotriene B4 receptor 1 Human genes 0.000 description 14
- 125000001931 aliphatic group Chemical group 0.000 description 14
- 231100000360 alopecia Toxicity 0.000 description 14
- 239000002585 base Substances 0.000 description 14
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 14
- 208000015181 infectious disease Diseases 0.000 description 14
- 229940090044 injection Drugs 0.000 description 14
- 108020004999 messenger RNA Proteins 0.000 description 14
- 239000011541 reaction mixture Substances 0.000 description 14
- 238000005481 NMR spectroscopy Methods 0.000 description 13
- 101100437750 Schizosaccharomyces pombe (strain 972 / ATCC 24843) blt1 gene Proteins 0.000 description 13
- 239000013543 active substance Substances 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 125000000623 heterocyclic group Chemical group 0.000 description 13
- 239000003960 organic solvent Substances 0.000 description 13
- 230000003449 preventive effect Effects 0.000 description 13
- 210000003491 skin Anatomy 0.000 description 13
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 12
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 239000002253 acid Substances 0.000 description 12
- 125000004429 atom Chemical group 0.000 description 12
- 239000011575 calcium Substances 0.000 description 12
- 201000011510 cancer Diseases 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 239000003112 inhibitor Substances 0.000 description 12
- 102000005962 receptors Human genes 0.000 description 12
- 108020003175 receptors Proteins 0.000 description 12
- 239000011347 resin Substances 0.000 description 12
- 229920005989 resin Polymers 0.000 description 12
- 201000010153 skin papilloma Diseases 0.000 description 12
- 238000004809 thin layer chromatography Methods 0.000 description 12
- 125000003396 thiol group Chemical group [H]S* 0.000 description 12
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 11
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 11
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 11
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 11
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 11
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 10
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 10
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 10
- 230000026731 phosphorylation Effects 0.000 description 10
- 238000006366 phosphorylation reaction Methods 0.000 description 10
- 239000003755 preservative agent Substances 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 9
- PCMXOXPHCQCDDB-UHFFFAOYSA-N 1-butyl-3-[2-(4-methoxyphenyl)ethyl]-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]urea Chemical compound C=1C=C(OC)C=CC=1CCNC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 PCMXOXPHCQCDDB-UHFFFAOYSA-N 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 208000002874 Acne Vulgaris Diseases 0.000 description 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- 229940126062 Compound A Drugs 0.000 description 9
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 9
- 208000012641 Pigmentation disease Diseases 0.000 description 9
- 206010000496 acne Diseases 0.000 description 9
- 208000026935 allergic disease Diseases 0.000 description 9
- 239000003242 anti bacterial agent Substances 0.000 description 9
- 229940088710 antibiotic agent Drugs 0.000 description 9
- 210000000056 organ Anatomy 0.000 description 9
- 230000019612 pigmentation Effects 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 8
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 8
- 241000701806 Human papillomavirus Species 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- 208000000260 Warts Diseases 0.000 description 8
- 125000003545 alkoxy group Chemical group 0.000 description 8
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 8
- 229910052791 calcium Inorganic materials 0.000 description 8
- 235000001465 calcium Nutrition 0.000 description 8
- 229910001424 calcium ion Inorganic materials 0.000 description 8
- 208000034557 congenital alopecia Diseases 0.000 description 8
- 239000003246 corticosteroid Substances 0.000 description 8
- 229960003957 dexamethasone Drugs 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 230000002335 preservative effect Effects 0.000 description 8
- 125000006239 protecting group Chemical group 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- SRUYVNNMBGRVTB-UHFFFAOYSA-N 1-butyl-3-(2-phenylethyl)-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]urea Chemical compound C=1C=CC=CC=1CCNC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 SRUYVNNMBGRVTB-UHFFFAOYSA-N 0.000 description 7
- 206010003210 Arteriosclerosis Diseases 0.000 description 7
- 206010012438 Dermatitis atopic Diseases 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 7
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 7
- 230000001270 agonistic effect Effects 0.000 description 7
- 230000003042 antagnostic effect Effects 0.000 description 7
- 230000003110 anti-inflammatory effect Effects 0.000 description 7
- 239000000739 antihistaminic agent Substances 0.000 description 7
- 239000003963 antioxidant agent Substances 0.000 description 7
- 235000006708 antioxidants Nutrition 0.000 description 7
- 208000011775 arteriosclerosis disease Diseases 0.000 description 7
- 201000008937 atopic dermatitis Diseases 0.000 description 7
- 229960001334 corticosteroids Drugs 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 235000013355 food flavoring agent Nutrition 0.000 description 7
- 150000004820 halides Chemical class 0.000 description 7
- 238000009396 hybridization Methods 0.000 description 7
- 229960000890 hydrocortisone Drugs 0.000 description 7
- 238000007911 parenteral administration Methods 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- 229940083542 sodium Drugs 0.000 description 7
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 7
- WXMWQAXZQJKXKG-UHFFFAOYSA-N 1-butyl-3-[2-(4-hydroxyphenyl)ethyl]-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]urea Chemical compound C=1C=C(O)C=CC=1CCNC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 WXMWQAXZQJKXKG-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 description 6
- 206010059313 Anogenital warts Diseases 0.000 description 6
- 208000023275 Autoimmune disease Diseases 0.000 description 6
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 6
- 206010016654 Fibrosis Diseases 0.000 description 6
- 208000009329 Graft vs Host Disease Diseases 0.000 description 6
- 206010025323 Lymphomas Diseases 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 206010052779 Transplant rejections Diseases 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 208000025865 Ulcer Diseases 0.000 description 6
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 6
- 230000002378 acidificating effect Effects 0.000 description 6
- 229940125715 antihistaminic agent Drugs 0.000 description 6
- 230000003078 antioxidant effect Effects 0.000 description 6
- 229960002537 betamethasone Drugs 0.000 description 6
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 6
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 6
- 230000007882 cirrhosis Effects 0.000 description 6
- 208000019425 cirrhosis of liver Diseases 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 239000003889 eye drop Substances 0.000 description 6
- 229940012356 eye drops Drugs 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 208000024908 graft versus host disease Diseases 0.000 description 6
- 210000004209 hair Anatomy 0.000 description 6
- 208000006454 hepatitis Diseases 0.000 description 6
- 231100000283 hepatitis Toxicity 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 6
- 208000032839 leukemia Diseases 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- 238000002844 melting Methods 0.000 description 6
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 6
- 125000002950 monocyclic group Chemical group 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000000069 prophylactic effect Effects 0.000 description 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
- 229960002477 riboflavin Drugs 0.000 description 6
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 6
- 238000010898 silica gel chromatography Methods 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000007921 spray Substances 0.000 description 6
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- 231100000397 ulcer Toxicity 0.000 description 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 5
- 208000030507 AIDS Diseases 0.000 description 5
- 208000010201 Exanthema Diseases 0.000 description 5
- 208000031886 HIV Infections Diseases 0.000 description 5
- 208000037357 HIV infectious disease Diseases 0.000 description 5
- 208000000453 Skin Neoplasms Diseases 0.000 description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 150000001298 alcohols Chemical class 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 230000000692 anti-sense effect Effects 0.000 description 5
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 5
- 201000005884 exanthem Diseases 0.000 description 5
- 125000000524 functional group Chemical group 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 5
- 239000003018 immunosuppressive agent Substances 0.000 description 5
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 229960004584 methylprednisolone Drugs 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000002674 ointment Substances 0.000 description 5
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 5
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 5
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 description 5
- 230000000704 physical effect Effects 0.000 description 5
- 125000003367 polycyclic group Chemical group 0.000 description 5
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 229960005205 prednisolone Drugs 0.000 description 5
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 5
- 150000003180 prostaglandins Chemical class 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 5
- 206010037844 rash Diseases 0.000 description 5
- 201000000849 skin cancer Diseases 0.000 description 5
- 210000000813 small intestine Anatomy 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- 125000000213 sulfino group Chemical group [H]OS(*)=O 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 5
- XTPMKUKWAMGWIQ-FQEVSTJZSA-N (2s)-3-hydroxy-2-[[pentyl-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]carbamoyl]amino]propanoic acid Chemical compound C1=CC(CN(CCCCC)C(=O)N[C@@H](CO)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=NN1 XTPMKUKWAMGWIQ-FQEVSTJZSA-N 0.000 description 4
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 4
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- 206010004146 Basal cell carcinoma Diseases 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 206010009900 Colitis ulcerative Diseases 0.000 description 4
- 206010010356 Congenital anomaly Diseases 0.000 description 4
- 206010012442 Dermatitis contact Diseases 0.000 description 4
- 206010014970 Ephelides Diseases 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 208000003794 Follicular Mucinosis Diseases 0.000 description 4
- 206010016936 Folliculitis Diseases 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 208000002260 Keloid Diseases 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 208000003351 Melanosis Diseases 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 4
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 4
- 238000000636 Northern blotting Methods 0.000 description 4
- HVRLZEKDTUEKQH-NOILCQHBSA-N Olopatadine hydrochloride Chemical compound Cl.C1OC2=CC=C(CC(O)=O)C=C2C(=C/CCN(C)C)\C2=CC=CC=C21 HVRLZEKDTUEKQH-NOILCQHBSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 4
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 4
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 4
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 4
- 206010037575 Pustular psoriasis Diseases 0.000 description 4
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 4
- 206010039796 Seborrhoeic keratosis Diseases 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 235000021355 Stearic acid Nutrition 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 4
- 206010042496 Sunburn Diseases 0.000 description 4
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 4
- 102100031274 Translocator protein Human genes 0.000 description 4
- 101710166801 Translocator protein Proteins 0.000 description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 description 4
- 229930003471 Vitamin B2 Natural products 0.000 description 4
- FPVRUILUEYSIMD-RPRRAYFGSA-N [(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(OC(C)=O)[C@@]1(C)C[C@@H]2O FPVRUILUEYSIMD-RPRRAYFGSA-N 0.000 description 4
- 208000009621 actinic keratosis Diseases 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 125000004414 alkyl thio group Chemical group 0.000 description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
- 208000010640 alopecia mucinosa Diseases 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 4
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 4
- SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 description 4
- 229960004311 betamethasone valerate Drugs 0.000 description 4
- 125000001626 borono group Chemical group [H]OB([*])O[H] 0.000 description 4
- 239000006172 buffering agent Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 229940000425 combination drug Drugs 0.000 description 4
- 208000010247 contact dermatitis Diseases 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 229960003657 dexamethasone acetate Drugs 0.000 description 4
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000032050 esterification Effects 0.000 description 4
- 238000005886 esterification reaction Methods 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 230000003325 follicular Effects 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 4
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 4
- 229960003444 immunosuppressant agent Drugs 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000007901 in situ hybridization Methods 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 208000028774 intestinal disease Diseases 0.000 description 4
- 210000001117 keloid Anatomy 0.000 description 4
- 201000011486 lichen planus Diseases 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 206010025135 lupus erythematosus Diseases 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 4
- SGBSKUMYIRZGCO-UHFFFAOYSA-N methyl 2-[butyl-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]carbamoyl]oxy-3-phenylpropanoate Chemical compound C=1C=CC=CC=1CC(C(=O)OC)OC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 SGBSKUMYIRZGCO-UHFFFAOYSA-N 0.000 description 4
- 201000005962 mycosis fungoides Diseases 0.000 description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 4
- 229960003139 olopatadine hydrochloride Drugs 0.000 description 4
- 239000002997 ophthalmic solution Substances 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 125000005646 oximino group Chemical group 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 208000008742 seborrheic dermatitis Diseases 0.000 description 4
- 201000003385 seborrheic keratosis Diseases 0.000 description 4
- 125000006850 spacer group Chemical group 0.000 description 4
- 239000008117 stearic acid Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 238000000844 transformation Methods 0.000 description 4
- 230000008733 trauma Effects 0.000 description 4
- 229960005294 triamcinolone Drugs 0.000 description 4
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 4
- 229960002117 triamcinolone acetonide Drugs 0.000 description 4
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 4
- 235000019164 vitamin B2 Nutrition 0.000 description 4
- 239000011716 vitamin B2 Substances 0.000 description 4
- 230000037303 wrinkles Effects 0.000 description 4
- 239000011787 zinc oxide Substances 0.000 description 4
- 235000014692 zinc oxide Nutrition 0.000 description 4
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 3
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 description 3
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- IHUSOJYDTMEDRP-UHFFFAOYSA-N 1-butyl-3-(2,2-diphenylethyl)-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]urea Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)CNC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 IHUSOJYDTMEDRP-UHFFFAOYSA-N 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 208000011231 Crohn disease Diseases 0.000 description 3
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 206010015278 Erythrodermic psoriasis Diseases 0.000 description 3
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 206010023330 Keloid scar Diseases 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 101001056472 Mus musculus Keratin, type II cytoskeletal 5 Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 3
- 208000007256 Nevus Diseases 0.000 description 3
- 101150003085 Pdcl gene Proteins 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 3
- LXNHXLLTXMVWPM-UHFFFAOYSA-N Vitamin B6 Natural products CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 239000003875 Wang resin Substances 0.000 description 3
- NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 description 3
- 239000003655 absorption accelerator Substances 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 229940022663 acetate Drugs 0.000 description 3
- 150000008065 acid anhydrides Chemical class 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 208000004631 alopecia areata Diseases 0.000 description 3
- 150000003863 ammonium salts Chemical class 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 229940124599 anti-inflammatory drug Drugs 0.000 description 3
- 230000001139 anti-pruritic effect Effects 0.000 description 3
- 239000000043 antiallergic agent Substances 0.000 description 3
- 239000003908 antipruritic agent Substances 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 229940092705 beclomethasone Drugs 0.000 description 3
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 3
- 229960000686 benzalkonium chloride Drugs 0.000 description 3
- 229940049706 benzodiazepine Drugs 0.000 description 3
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 3
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 3
- 229960002071 bepotastine Drugs 0.000 description 3
- YWGDOWXRIALTES-NRFANRHFSA-N bepotastine Chemical compound C1CN(CCCC(=O)O)CCC1O[C@H](C=1N=CC=CC=1)C1=CC=C(Cl)C=C1 YWGDOWXRIALTES-NRFANRHFSA-N 0.000 description 3
- AKUJBENLRBOFTD-QZIXMDIESA-N betamethasone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]1(C)C[C@@H]2O AKUJBENLRBOFTD-QZIXMDIESA-N 0.000 description 3
- 229960004648 betamethasone acetate Drugs 0.000 description 3
- 229960001102 betamethasone dipropionate Drugs 0.000 description 3
- CIWBQSYVNNPZIQ-XYWKZLDCSA-N betamethasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CIWBQSYVNNPZIQ-XYWKZLDCSA-N 0.000 description 3
- PLCQGRYPOISRTQ-LWCNAHDDSA-L betamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-LWCNAHDDSA-L 0.000 description 3
- 229960005354 betamethasone sodium phosphate Drugs 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 208000028446 bullous lichen planus Diseases 0.000 description 3
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 206010009887 colitis Diseases 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- BMCQMVFGOVHVNG-TUFAYURCSA-N cortisol 17-butyrate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CO)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O BMCQMVFGOVHVNG-TUFAYURCSA-N 0.000 description 3
- 210000003464 cuspid Anatomy 0.000 description 3
- 229960003596 cyproheptadine hydrochloride Drugs 0.000 description 3
- ZPMVNZLARAEGHB-UHFFFAOYSA-N cyproheptadine hydrochloride (anhydrous) Chemical compound Cl.C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 ZPMVNZLARAEGHB-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 description 3
- YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 3
- 229960000520 diphenhydramine Drugs 0.000 description 3
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 3
- 230000001804 emulsifying effect Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- WHWZLSFABNNENI-UHFFFAOYSA-N epinastine Chemical compound C1C2=CC=CC=C2C2CN=C(N)N2C2=CC=CC=C21 WHWZLSFABNNENI-UHFFFAOYSA-N 0.000 description 3
- 229960002548 epinastine hydrochloride Drugs 0.000 description 3
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 229960001347 fluocinolone acetonide Drugs 0.000 description 3
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 3
- 229960000785 fluocinonide Drugs 0.000 description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 208000024963 hair loss Diseases 0.000 description 3
- 230000003676 hair loss Effects 0.000 description 3
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 3
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 3
- 229960001524 hydrocortisone butyrate Drugs 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 125000001841 imino group Chemical group [H]N=* 0.000 description 3
- 229960000905 indomethacin Drugs 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 208000002551 irritable bowel syndrome Diseases 0.000 description 3
- 239000007951 isotonicity adjuster Substances 0.000 description 3
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 3
- 229960000991 ketoprofen Drugs 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 3
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 3
- 229950000688 phenothiazine Drugs 0.000 description 3
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 3
- 229960002702 piroxicam Drugs 0.000 description 3
- 210000004508 polar body Anatomy 0.000 description 3
- 125000004585 polycyclic heterocycle group Chemical group 0.000 description 3
- 230000003405 preventing effect Effects 0.000 description 3
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 3
- 238000000197 pyrolysis Methods 0.000 description 3
- 229940044601 receptor agonist Drugs 0.000 description 3
- 239000000018 receptor agonist Substances 0.000 description 3
- 229940044551 receptor antagonist Drugs 0.000 description 3
- 239000002464 receptor antagonist Substances 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 239000000021 stimulant Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 235000019155 vitamin A Nutrition 0.000 description 3
- 239000011719 vitamin A Substances 0.000 description 3
- 235000019158 vitamin B6 Nutrition 0.000 description 3
- 239000011726 vitamin B6 Substances 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 229940045997 vitamin a Drugs 0.000 description 3
- 229940011671 vitamin b6 Drugs 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 2
- MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 description 2
- OQANPHBRHBJGNZ-FYJGNVAPSA-N (3e)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=C\C1=N\NC1=CC=C(S(=O)(=O)NC=2N=CC=CC=2)C=C1 OQANPHBRHBJGNZ-FYJGNVAPSA-N 0.000 description 2
- 125000004768 (C1-C4) alkylsulfinyl group Chemical group 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- FWLKKPKZQYVAFR-LVEZLNDCSA-N (e)-but-2-enedioic acid;1-(2-ethoxyethyl)-2-(4-methyl-1,4-diazepan-1-yl)benzimidazole Chemical compound OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C(O)=O.N=1C2=CC=CC=C2N(CCOCC)C=1N1CCCN(C)CC1 FWLKKPKZQYVAFR-LVEZLNDCSA-N 0.000 description 2
- RXBYRTSOWREATF-UHFFFAOYSA-N 1,2,3,4-tetrahydroacridine Chemical compound C1=CC=C2C=C(CCCC3)C3=NC2=C1 RXBYRTSOWREATF-UHFFFAOYSA-N 0.000 description 2
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 2
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
- CIISBYKBBMFLEZ-UHFFFAOYSA-N 1,2-oxazolidine Chemical compound C1CNOC1 CIISBYKBBMFLEZ-UHFFFAOYSA-N 0.000 description 2
- CZSRXHJVZUBEGW-UHFFFAOYSA-N 1,2-thiazolidine Chemical compound C1CNSC1 CZSRXHJVZUBEGW-UHFFFAOYSA-N 0.000 description 2
- NETOFWKJBRGPAG-UHFFFAOYSA-N 1,3-dibutyl-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]urea Chemical compound C1=CC(CN(CCCC)C(=O)NCCCC)=CC=C1C1=CC=CC=C1C1=NN=NN1 NETOFWKJBRGPAG-UHFFFAOYSA-N 0.000 description 2
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- YUQOINNACFOQFK-UHFFFAOYSA-N 1-butyl-3-cyclohexyl-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]urea Chemical compound C1CCCCC1NC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 YUQOINNACFOQFK-UHFFFAOYSA-N 0.000 description 2
- WBJOGFVHYTZWJT-UHFFFAOYSA-N 1-butyl-3-propan-2-yl-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]urea Chemical compound C1=CC(CN(CCCC)C(=O)NC(C)C)=CC=C1C1=CC=CC=C1C1=NN=NN1 WBJOGFVHYTZWJT-UHFFFAOYSA-N 0.000 description 2
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
- XKLNOVWDVMWTOB-UHFFFAOYSA-N 2,3,4,9-tetrahydro-1h-carbazole Chemical compound N1C2=CC=CC=C2C2=C1CCCC2 XKLNOVWDVMWTOB-UHFFFAOYSA-N 0.000 description 2
- HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical compound C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 description 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- ILYSAKHOYBPSPC-UHFFFAOYSA-N 2-phenylbenzoic acid Chemical compound OC(=O)C1=CC=CC=C1C1=CC=CC=C1 ILYSAKHOYBPSPC-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- LUXXPXJGDQNGIG-UHFFFAOYSA-N 4-[4-[[benzyl(3-phenylpropyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(C(=O)O)=CC=C1C(C=C1)=CC=C1CN(CC=1C=CC=CC=1)CCCC1=CC=CC=C1 LUXXPXJGDQNGIG-UHFFFAOYSA-N 0.000 description 2
- QTQGHKVYLQBJLO-UHFFFAOYSA-N 4-methylbenzenesulfonate;(4-methyl-1-oxo-1-phenylmethoxypentan-2-yl)azanium Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.CC(C)CC(N)C(=O)OCC1=CC=CC=C1 QTQGHKVYLQBJLO-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- PJJGZPJJTHBVMX-UHFFFAOYSA-N 5,7-Dihydroxyisoflavone Chemical compound C=1C(O)=CC(O)=C(C2=O)C=1OC=C2C1=CC=CC=C1 PJJGZPJJTHBVMX-UHFFFAOYSA-N 0.000 description 2
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 description 2
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000007848 Bronsted acid Substances 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 2
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 2
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 2
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 2
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 2
- 102100037853 C-C chemokine receptor type 4 Human genes 0.000 description 2
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 2
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 2
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 2
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108010008951 Chemokine CXCL12 Proteins 0.000 description 2
- 102000006573 Chemokine CXCL12 Human genes 0.000 description 2
- 102000009410 Chemokine receptor Human genes 0.000 description 2
- 108050000299 Chemokine receptor Proteins 0.000 description 2
- 229940122444 Chemokine receptor antagonist Drugs 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 241000725101 Clea Species 0.000 description 2
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- WYQPLTPSGFELIB-JTQPXKBDSA-N Difluprednate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2CC[C@@](C(=O)COC(C)=O)(OC(=O)CCC)[C@@]2(C)C[C@@H]1O WYQPLTPSGFELIB-JTQPXKBDSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
- RRJFVPUCXDGFJB-UHFFFAOYSA-N Fexofenadine hydrochloride Chemical compound Cl.C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RRJFVPUCXDGFJB-UHFFFAOYSA-N 0.000 description 2
- POPFMWWJOGLOIF-XWCQMRHXSA-N Flurandrenolide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O POPFMWWJOGLOIF-XWCQMRHXSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- MUQNGPZZQDCDFT-JNQJZLCISA-N Halcinonide Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@@H]2O MUQNGPZZQDCDFT-JNQJZLCISA-N 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- FOGXJPFPZOHSQS-AYVLZSQQSA-N Hydrocortisone butyrate propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)CC)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O FOGXJPFPZOHSQS-AYVLZSQQSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 229940124790 IL-6 inhibitor Drugs 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- ACEWLPOYLGNNHV-UHFFFAOYSA-N Ibuprofen piconol Chemical compound C1=CC(CC(C)C)=CC=C1C(C)C(=O)OCC1=CC=CC=N1 ACEWLPOYLGNNHV-UHFFFAOYSA-N 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 229940123650 Interferon gamma agonist Drugs 0.000 description 2
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 2
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 102000044589 Mitogen-Activated Protein Kinase 1 Human genes 0.000 description 2
- 108700015928 Mitogen-activated protein kinase 13 Proteins 0.000 description 2
- 102000010909 Monoamine Oxidase Human genes 0.000 description 2
- 108010062431 Monoamine oxidase Proteins 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- TVQZAMVBTVNYLA-UHFFFAOYSA-N Pranoprofen Chemical compound C1=CC=C2CC3=CC(C(C(O)=O)C)=CC=C3OC2=N1 TVQZAMVBTVNYLA-UHFFFAOYSA-N 0.000 description 2
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 2
- 102000009389 Prostaglandin D receptors Human genes 0.000 description 2
- 108050000258 Prostaglandin D receptors Proteins 0.000 description 2
- 102000015433 Prostaglandin Receptors Human genes 0.000 description 2
- 108010050183 Prostaglandin Receptors Proteins 0.000 description 2
- 229940123950 Prostaglandin synthase inhibitor Drugs 0.000 description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- CGNLCCVKSWNSDG-UHFFFAOYSA-N SYBR Green I Chemical compound CN(C)CCCN(CCC)C1=CC(C=C2N(C3=CC=CC=C3S2)C)=C2C=CC=CC2=[N+]1C1=CC=CC=C1 CGNLCCVKSWNSDG-UHFFFAOYSA-N 0.000 description 2
- 101000935814 Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720) Periplasmic beta-glucosidase Proteins 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229940123155 T cell inhibitor Drugs 0.000 description 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- JDLSRXWHEBFHNC-UHFFFAOYSA-N Ufenamate Chemical compound CCCCOC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 JDLSRXWHEBFHNC-UHFFFAOYSA-N 0.000 description 2
- MUXFZBHBYYYLTH-UHFFFAOYSA-N Zaltoprofen Chemical compound O=C1CC2=CC(C(C(O)=O)C)=CC=C2SC2=CC=CC=C21 MUXFZBHBYYYLTH-UHFFFAOYSA-N 0.000 description 2
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- MGVGMXLGOKTYKP-ZFOBEOMCSA-N acetic acid;(6s,8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-one Chemical compound CC(O)=O.C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 MGVGMXLGOKTYKP-ZFOBEOMCSA-N 0.000 description 2
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- 239000001361 adipic acid Substances 0.000 description 2
- 235000011037 adipic acid Nutrition 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 125000004450 alkenylene group Chemical group 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 125000004419 alkynylene group Chemical group 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 238000007112 amidation reaction Methods 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 230000001760 anti-analgesic effect Effects 0.000 description 2
- 230000003092 anti-cytokine Effects 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 239000003435 antirheumatic agent Substances 0.000 description 2
- 229940064004 antiseptic throat preparations Drugs 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 239000003212 astringent agent Substances 0.000 description 2
- AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical compound CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 description 2
- 229960005207 auranofin Drugs 0.000 description 2
- YEJAJYAHJQIWNU-UHFFFAOYSA-N azelastine hydrochloride Chemical compound Cl.C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 YEJAJYAHJQIWNU-UHFFFAOYSA-N 0.000 description 2
- 229960004335 azelastine hydrochloride Drugs 0.000 description 2
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 2
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 2
- 229910001863 barium hydroxide Inorganic materials 0.000 description 2
- 150000001557 benzodiazepines Chemical class 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 229950008408 betamethasone butyrate propionate Drugs 0.000 description 2
- VXOWJCTXWVWLLC-REGDIAEZSA-N betamethasone butyrate propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O VXOWJCTXWVWLLC-REGDIAEZSA-N 0.000 description 2
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- QRZAKQDHEVVFRX-UHFFFAOYSA-N biphenyl-4-ylacetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1C1=CC=CC=C1 QRZAKQDHEVVFRX-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- MXJWRABVEGLYDG-UHFFFAOYSA-N bufexamac Chemical compound CCCCOC1=CC=C(CC(=O)NO)C=C1 MXJWRABVEGLYDG-UHFFFAOYSA-N 0.000 description 2
- 229960000962 bufexamac Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Chemical compound [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 2
- 239000000920 calcium hydroxide Substances 0.000 description 2
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 2
- 229960002079 calcium pantothenate Drugs 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 239000002559 chemokine receptor antagonist Substances 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 229960004703 clobetasol propionate Drugs 0.000 description 2
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 229940124579 cold medicine Drugs 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 150000004696 coordination complex Chemical class 0.000 description 2
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 2
- 229960003290 cortisone acetate Drugs 0.000 description 2
- 229960003338 crotamiton Drugs 0.000 description 2
- DNTGGZPQPQTDQF-XBXARRHUSA-N crotamiton Chemical compound C/C=C/C(=O)N(CC)C1=CC=CC=C1C DNTGGZPQPQTDQF-XBXARRHUSA-N 0.000 description 2
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
- ZSWFCLXCOIISFI-UHFFFAOYSA-N cyclopentadiene Chemical compound C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 2
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 2
- 229930182912 cyclosporin Natural products 0.000 description 2
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- CIWBQSYVNNPZIQ-PKWREOPISA-N dexamethasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CIWBQSYVNNPZIQ-PKWREOPISA-N 0.000 description 2
- 229950000250 dexamethasone dipropionate Drugs 0.000 description 2
- RPBJOYICBFNIMN-RDWMNNCQSA-M dexamethasone sodium m-sulfobenzoate Chemical compound [Na+].O=C([C@]1(O)[C@@]2(C)C[C@H](O)[C@]3(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)COC(=O)C1=CC=CC(S([O-])(=O)=O)=C1 RPBJOYICBFNIMN-RDWMNNCQSA-M 0.000 description 2
- TXCDCPKCNAJMEE-UHFFFAOYSA-N dibenzofuran Chemical compound C1=CC=C2C3=CC=CC=C3OC2=C1 TXCDCPKCNAJMEE-UHFFFAOYSA-N 0.000 description 2
- IYYZUPMFVPLQIF-UHFFFAOYSA-N dibenzothiophene Chemical compound C1=CC=C2C3=CC=CC=C3SC2=C1 IYYZUPMFVPLQIF-UHFFFAOYSA-N 0.000 description 2
- 229960004875 difluprednate Drugs 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- KZTYYGOKRVBIMI-UHFFFAOYSA-N diphenyl sulfone Chemical compound C=1C=CC=CC=1S(=O)(=O)C1=CC=CC=C1 KZTYYGOKRVBIMI-UHFFFAOYSA-N 0.000 description 2
- 239000002988 disease modifying antirheumatic drug Substances 0.000 description 2
- 108010007093 dispase Proteins 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003602 elastase inhibitor Substances 0.000 description 2
- 229960000325 emedastine Drugs 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 229960002549 enoxacin Drugs 0.000 description 2
- IDYZIJYBMGIQMJ-UHFFFAOYSA-N enoxacin Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 IDYZIJYBMGIQMJ-UHFFFAOYSA-N 0.000 description 2
- 229960003720 enoxolone Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229960000354 fexofenadine hydrochloride Drugs 0.000 description 2
- 229960004511 fludroxycortide Drugs 0.000 description 2
- JWRMHDSINXPDHB-OJAGFMMFSA-N flumethasone pivalate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)COC(=O)C(C)(C)C)(O)[C@@]2(C)C[C@@H]1O JWRMHDSINXPDHB-OJAGFMMFSA-N 0.000 description 2
- 229940042902 flumethasone pivalate Drugs 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 229960002390 flurbiprofen Drugs 0.000 description 2
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 229960002383 halcinonide Drugs 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 239000000938 histamine H1 antagonist Substances 0.000 description 2
- 229960001067 hydrocortisone acetate Drugs 0.000 description 2
- 229960001401 hydrocortisone sodium succinate Drugs 0.000 description 2
- 238000007327 hydrogenolysis reaction Methods 0.000 description 2
- 229950005954 ibuprofen piconol Drugs 0.000 description 2
- 230000001861 immunosuppressant effect Effects 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 2
- 229940096397 interleukin-8 Drugs 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000008141 laxative Substances 0.000 description 2
- 229940125722 laxative agent Drugs 0.000 description 2
- 239000000865 liniment Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 229940040511 liver extract Drugs 0.000 description 2
- 229960002373 loxoprofen Drugs 0.000 description 2
- BAZQYVYVKYOAGO-UHFFFAOYSA-M loxoprofen sodium hydrate Chemical compound O.O.[Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 BAZQYVYVKYOAGO-UHFFFAOYSA-M 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000010841 mRNA extraction Methods 0.000 description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 235000001055 magnesium Nutrition 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229960003464 mefenamic acid Drugs 0.000 description 2
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- DZNKOAWEHDKBEP-UHFFFAOYSA-N methyl 2-[6-[bis(2-methoxy-2-oxoethyl)amino]-5-[2-[2-[bis(2-methoxy-2-oxoethyl)amino]-5-methylphenoxy]ethoxy]-1-benzofuran-2-yl]-1,3-oxazole-5-carboxylate Chemical compound COC(=O)CN(CC(=O)OC)C1=CC=C(C)C=C1OCCOC(C(=C1)N(CC(=O)OC)CC(=O)OC)=CC2=C1OC(C=1OC(=CN=1)C(=O)OC)=C2 DZNKOAWEHDKBEP-UHFFFAOYSA-N 0.000 description 2
- 125000006261 methyl amino sulfonyl group Chemical group [H]N(C([H])([H])[H])S(*)(=O)=O 0.000 description 2
- 229960001293 methylprednisolone acetate Drugs 0.000 description 2
- 229960000334 methylprednisolone sodium succinate Drugs 0.000 description 2
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 229960001664 mometasone Drugs 0.000 description 2
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 2
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 description 2
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- OIXVKQDWLFHVGR-WQDIDPJDSA-N neomycin B sulfate Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO OIXVKQDWLFHVGR-WQDIDPJDSA-N 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- BKIMMITUMNQMOS-UHFFFAOYSA-N nonane Chemical compound CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 2
- DTHHUAXKOMWYBI-UHFFFAOYSA-N oxadiazolidine Chemical compound C1CONN1 DTHHUAXKOMWYBI-UHFFFAOYSA-N 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 2
- 229960002739 oxaprozin Drugs 0.000 description 2
- BAINIUMDFURPJM-UHFFFAOYSA-N oxatomide Chemical compound O=C1NC2=CC=CC=C2N1CCCN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 BAINIUMDFURPJM-UHFFFAOYSA-N 0.000 description 2
- 229960002698 oxatomide Drugs 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- XGISHOFUAFNYQF-UHFFFAOYSA-N pentanoyl chloride Chemical compound CCCCC(Cl)=O XGISHOFUAFNYQF-UHFFFAOYSA-N 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 2
- RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- 229960003101 pranoprofen Drugs 0.000 description 2
- 229960002800 prednisolone acetate Drugs 0.000 description 2
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 2
- 229960003081 probenecid Drugs 0.000 description 2
- NSETWVJZUWGCKE-UHFFFAOYSA-N propylphosphonic acid Chemical compound CCCP(O)(O)=O NSETWVJZUWGCKE-UHFFFAOYSA-N 0.000 description 2
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 2
- 239000003223 protective agent Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 2
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 2
- 229960001327 pyridoxal phosphate Drugs 0.000 description 2
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 2
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 2
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- 238000006268 reductive amination reaction Methods 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 229960001755 resorcinol Drugs 0.000 description 2
- 235000019192 riboflavin Nutrition 0.000 description 2
- 239000002151 riboflavin Substances 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
- JNZZMJWKTIVKEI-UHFFFAOYSA-M sodium;4-[4-[[(4-methoxybenzoyl)-(3-phenylpropyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(OC)=CC=C1C(=O)N(CC=1C=CC(=CC=1)C=1C=CC(=CC=1)C([O-])=O)CCCC1=CC=CC=C1 JNZZMJWKTIVKEI-UHFFFAOYSA-M 0.000 description 2
- YNEHXQGCTHFUQY-UHFFFAOYSA-M sodium;4-[4-[[cyclopentanecarbonyl(2-phenylethyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(C(=O)[O-])=CC=C1C(C=C1)=CC=C1CN(C(=O)C1CCCC1)CCC1=CC=CC=C1 YNEHXQGCTHFUQY-UHFFFAOYSA-M 0.000 description 2
- FDBRUENSKHUUFK-UHFFFAOYSA-M sodium;4-[4-[[cyclopentanecarbonyl(3-phenylpropyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(C(=O)[O-])=CC=C1C(C=C1)=CC=C1CN(C(=O)C1CCCC1)CCCC1=CC=CC=C1 FDBRUENSKHUUFK-UHFFFAOYSA-M 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 125000005750 substituted cyclic group Chemical group 0.000 description 2
- 229960001940 sulfasalazine Drugs 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 229960004492 suprofen Drugs 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- RLTPJVKHGBFGQA-UHFFFAOYSA-N thiadiazolidine Chemical compound C1CSNN1 RLTPJVKHGBFGQA-UHFFFAOYSA-N 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 229940098465 tincture Drugs 0.000 description 2
- 229960005342 tranilast Drugs 0.000 description 2
- NZHGWWWHIYHZNX-CSKARUKUSA-N tranilast Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C(=O)NC1=CC=CC=C1C(O)=O NZHGWWWHIYHZNX-CSKARUKUSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 2
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 2
- 229950010121 ufenamate Drugs 0.000 description 2
- 229940070710 valerate Drugs 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 229950004227 zaltoprofen Drugs 0.000 description 2
- AIFRHYZBTHREPW-UHFFFAOYSA-N β-carboline Chemical compound N1=CC=C2C3=CC=CC=C3NC2=C1 AIFRHYZBTHREPW-UHFFFAOYSA-N 0.000 description 2
- GRWFGVWFFZKLTI-IUCAKERBSA-N (-)-α-pinene Chemical compound CC1=CC[C@@H]2C(C)(C)[C@H]1C2 GRWFGVWFFZKLTI-IUCAKERBSA-N 0.000 description 1
- RRKODOZNUZCUBN-CCAGOZQPSA-N (1z,3z)-cycloocta-1,3-diene Chemical group C1CC\C=C/C=C\C1 RRKODOZNUZCUBN-CCAGOZQPSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- AJZJIYUOOJLBAU-CEAXSRTFSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;n,n,2-trimethyl-3-phenothiazin-10-ylpropan-1-amine Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1=CC=C2N(CC(CN(C)C)C)C3=CC=CC=C3SC2=C1.C1=CC=C2N(CC(CN(C)C)C)C3=CC=CC=C3SC2=C1 AJZJIYUOOJLBAU-CEAXSRTFSA-N 0.000 description 1
- SDOFMBGMRVAJNF-SLPGGIOYSA-N (2r,3r,4r,5s)-6-aminohexane-1,2,3,4,5-pentol Chemical compound NC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO SDOFMBGMRVAJNF-SLPGGIOYSA-N 0.000 description 1
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- VUAFHZCUKUDDBC-SCSAIBSYSA-N (2s)-2-[(2-methyl-2-sulfanylpropanoyl)amino]-3-sulfanylpropanoic acid Chemical compound CC(C)(S)C(=O)N[C@H](CS)C(O)=O VUAFHZCUKUDDBC-SCSAIBSYSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- MYZDPUZXMFCPMU-LRIWMWCYSA-N (6r,8s,9r,10s,11s,13s,14s,17r)-2-bromo-6,9-difluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one Chemical compound O=C1C(Br)=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3C[C@@H](F)C2=C1 MYZDPUZXMFCPMU-LRIWMWCYSA-N 0.000 description 1
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 description 1
- 125000004760 (C1-C4) alkylsulfonylamino group Chemical group 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- SYTBZMRGLBWNTM-SNVBAGLBSA-N (R)-flurbiprofen Chemical compound FC1=CC([C@H](C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-SNVBAGLBSA-N 0.000 description 1
- PMGQWSIVQFOFOQ-BDUVBVHRSA-N (e)-but-2-enedioic acid;(2r)-2-[2-[1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine Chemical compound OC(=O)\C=C\C(O)=O.CN1CCC[C@@H]1CCOC(C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 PMGQWSIVQFOFOQ-BDUVBVHRSA-N 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N 1,1'-Carbonyldiimidazole Substances C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- AEBWATHAIVJLTA-UHFFFAOYSA-N 1,2,3,3a,4,5,6,6a-octahydropentalene Chemical compound C1CCC2CCCC21 AEBWATHAIVJLTA-UHFFFAOYSA-N 0.000 description 1
- ODJQFZXHKPCJMD-UHFFFAOYSA-N 1,2,3,3a,4,5,6,7,8,8a-decahydroazulene Chemical compound C1CCCCC2CCCC21 ODJQFZXHKPCJMD-UHFFFAOYSA-N 0.000 description 1
- IXTPCSZJZAKJTO-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a,9,9a,10,10a-tetradecahydroacridine Chemical compound N1C2CCCCC2CC2C1CCCC2 IXTPCSZJZAKJTO-UHFFFAOYSA-N 0.000 description 1
- PIHAUZGWAXLKCA-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydro-1,8-naphthyridine Chemical compound N1CCCC2CCCNC21 PIHAUZGWAXLKCA-UHFFFAOYSA-N 0.000 description 1
- VKJHANNFFHMLBB-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydrocinnoline Chemical compound N1NCCC2CCCCC21 VKJHANNFFHMLBB-UHFFFAOYSA-N 0.000 description 1
- NENLYAQPNATJSU-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline Chemical compound C1NCCC2CCCCC21 NENLYAQPNATJSU-UHFFFAOYSA-N 0.000 description 1
- HZNXIPDYYIWDNM-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydroquinazoline Chemical compound N1CNCC2CCCCC21 HZNXIPDYYIWDNM-UHFFFAOYSA-N 0.000 description 1
- POTIYWUALSJREP-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydroquinoline Chemical compound N1CCCC2CCCCC21 POTIYWUALSJREP-UHFFFAOYSA-N 0.000 description 1
- MDEXMBGPIZUUBI-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydroquinoxaline Chemical compound N1CCNC2CCCCC21 MDEXMBGPIZUUBI-UHFFFAOYSA-N 0.000 description 1
- XTDNMGZRUWMVLT-UHFFFAOYSA-N 1,2,3,4,4a,5a,6,7,8,9,9a,9b-dodecahydrodibenzofuran Chemical compound C1CCCC2C3CCCCC3OC21 XTDNMGZRUWMVLT-UHFFFAOYSA-N 0.000 description 1
- XMJFSCXZDZSDJS-UHFFFAOYSA-N 1,2,3,4,4a,5a,6,7,8,9,9a,9b-dodecahydrodibenzothiophene Chemical compound C1CCCC2C3CCCCC3SC21 XMJFSCXZDZSDJS-UHFFFAOYSA-N 0.000 description 1
- LOWDSHXWDYULHF-UHFFFAOYSA-N 1,2,3,4,5,5a,6,7,8,9,10,10a-dodecahydroheptalene Chemical compound C1CCCCC2CCCCCC21 LOWDSHXWDYULHF-UHFFFAOYSA-N 0.000 description 1
- ZCZVGQCBSJLDDS-UHFFFAOYSA-N 1,2,3,4-tetrahydro-1,8-naphthyridine Chemical compound C1=CC=C2CCCNC2=N1 ZCZVGQCBSJLDDS-UHFFFAOYSA-N 0.000 description 1
- WXRSSOIHEAVYLL-UHFFFAOYSA-N 1,2,3,4-tetrahydrocinnoline Chemical compound C1=CC=C2NNCCC2=C1 WXRSSOIHEAVYLL-UHFFFAOYSA-N 0.000 description 1
- LREHXNMBUBVFHA-UHFFFAOYSA-N 1,2,3,4-tetrahydrodibenzofuran Chemical compound O1C2=CC=CC=C2C2=C1CCCC2 LREHXNMBUBVFHA-UHFFFAOYSA-N 0.000 description 1
- STIWEDICJHIFJT-UHFFFAOYSA-N 1,2,3,4-tetrahydrophthalazine Chemical compound C1=CC=C2CNNCC2=C1 STIWEDICJHIFJT-UHFFFAOYSA-N 0.000 description 1
- OQJVXNHMUWQQEW-UHFFFAOYSA-N 1,2,3,4-tetrahydropyrazine Chemical compound C1CNC=CN1 OQJVXNHMUWQQEW-UHFFFAOYSA-N 0.000 description 1
- JQIZHNLEFQMDCQ-UHFFFAOYSA-N 1,2,3,4-tetrahydropyridazine Chemical compound C1CC=CNN1 JQIZHNLEFQMDCQ-UHFFFAOYSA-N 0.000 description 1
- OTPDWCMLUKMQNO-UHFFFAOYSA-N 1,2,3,4-tetrahydropyrimidine Chemical compound C1NCC=CN1 OTPDWCMLUKMQNO-UHFFFAOYSA-N 0.000 description 1
- PKORYTIUMAOPED-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinazoline Chemical compound C1=CC=C2NCNCC2=C1 PKORYTIUMAOPED-UHFFFAOYSA-N 0.000 description 1
- HORKYAIEVBUXGM-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoxaline Chemical compound C1=CC=C2NCCNC2=C1 HORKYAIEVBUXGM-UHFFFAOYSA-N 0.000 description 1
- FIDRAVVQGKNYQK-UHFFFAOYSA-N 1,2,3,4-tetrahydrotriazine Chemical compound C1NNNC=C1 FIDRAVVQGKNYQK-UHFFFAOYSA-N 0.000 description 1
- KAOYLRLQZXRRBD-UHFFFAOYSA-N 1,2,3-benzothiadiazepine Chemical compound S1N=NC=CC2=CC=CC=C12 KAOYLRLQZXRRBD-UHFFFAOYSA-N 0.000 description 1
- DMTVEFFTCXZRHY-UHFFFAOYSA-N 1,2,3-benzoxadiazepine Chemical compound O1N=NC=CC2=CC=CC=C12 DMTVEFFTCXZRHY-UHFFFAOYSA-N 0.000 description 1
- UGUHFDPGDQDVGX-UHFFFAOYSA-N 1,2,3-thiadiazole Chemical group C1=CSN=N1 UGUHFDPGDQDVGX-UHFFFAOYSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- UUZJJNBYJDFQHL-UHFFFAOYSA-N 1,2,3-triazolidine Chemical compound C1CNNN1 UUZJJNBYJDFQHL-UHFFFAOYSA-N 0.000 description 1
- ZCXLTWVZYXBHJS-UHFFFAOYSA-N 1,2-benzoxazepine Chemical compound O1N=CC=CC2=CC=CC=C12 ZCXLTWVZYXBHJS-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 125000005837 1,2-cyclopentylene group Chemical group [H]C1([H])C([H])([H])C([H])([*:1])C([H])([*:2])C1([H])[H] 0.000 description 1
- LRANPJDWHYRCER-UHFFFAOYSA-N 1,2-diazepine Chemical compound N1C=CC=CC=N1 LRANPJDWHYRCER-UHFFFAOYSA-N 0.000 description 1
- XEYKWYIXHMEQGM-UHFFFAOYSA-N 1,2-dihydro-1,8-naphthyridine Chemical compound C1=CC=C2C=CCNC2=N1 XEYKWYIXHMEQGM-UHFFFAOYSA-N 0.000 description 1
- UXJHQQLYKUVLIE-UHFFFAOYSA-N 1,2-dihydroacridine Chemical compound C1=CC=C2N=C(C=CCC3)C3=CC2=C1 UXJHQQLYKUVLIE-UHFFFAOYSA-N 0.000 description 1
- QRDNXAYNXUKMOO-UHFFFAOYSA-N 1,2-dihydrocinnoline Chemical compound C1=CC=C2C=CNNC2=C1 QRDNXAYNXUKMOO-UHFFFAOYSA-N 0.000 description 1
- AYMOVGCUZMUZSI-UHFFFAOYSA-N 1,2-dihydrodibenzothiophene Chemical compound S1C2=CC=CC=C2C2=C1C=CCC2 AYMOVGCUZMUZSI-UHFFFAOYSA-N 0.000 description 1
- IOEPOEDBBPRAEI-UHFFFAOYSA-N 1,2-dihydroisoquinoline Chemical compound C1=CC=C2CNC=CC2=C1 IOEPOEDBBPRAEI-UHFFFAOYSA-N 0.000 description 1
- KEIFWROAQVVDBN-UHFFFAOYSA-N 1,2-dihydronaphthalene Chemical compound C1=CC=C2C=CCCC2=C1 KEIFWROAQVVDBN-UHFFFAOYSA-N 0.000 description 1
- QYMGRIFMUQCAJW-UHFFFAOYSA-N 1,2-dihydropyrazine Chemical compound C1NC=CN=C1 QYMGRIFMUQCAJW-UHFFFAOYSA-N 0.000 description 1
- BKWQKVJYXODDAC-UHFFFAOYSA-N 1,2-dihydropyridazine Chemical compound N1NC=CC=C1 BKWQKVJYXODDAC-UHFFFAOYSA-N 0.000 description 1
- WCFAPJDPAPDDAQ-UHFFFAOYSA-N 1,2-dihydropyrimidine Chemical compound C1NC=CC=N1 WCFAPJDPAPDDAQ-UHFFFAOYSA-N 0.000 description 1
- IRFSXVIRXMYULF-UHFFFAOYSA-N 1,2-dihydroquinoline Chemical compound C1=CC=C2C=CCNC2=C1 IRFSXVIRXMYULF-UHFFFAOYSA-N 0.000 description 1
- XXBQLHATYQHJQC-UHFFFAOYSA-N 1,2-dihydroquinoxaline Chemical compound C1=CC=C2N=CCNC2=C1 XXBQLHATYQHJQC-UHFFFAOYSA-N 0.000 description 1
- PXGILEVFPBXLEB-UHFFFAOYSA-N 1,2-dimethyl-3-propan-2-ylazulene Chemical compound C1=CC=CC=C2C(C(C)C)=C(C)C(C)=C21 PXGILEVFPBXLEB-UHFFFAOYSA-N 0.000 description 1
- CXWGKAYMVASWDQ-UHFFFAOYSA-N 1,2-dithiane Chemical group C1CCSSC1 CXWGKAYMVASWDQ-UHFFFAOYSA-N 0.000 description 1
- HGQBCKVFVUCIML-UHFFFAOYSA-N 1,3,3a,4,5,6,7,7a-octahydro-2-benzofuran Chemical compound C1CCCC2COCC21 HGQBCKVFVUCIML-UHFFFAOYSA-N 0.000 description 1
- SJXUGVWKLLOJDR-UHFFFAOYSA-N 1,3,3a,4,5,6,7,7a-octahydro-2-benzothiophene Chemical compound C1CCCC2CSCC21 SJXUGVWKLLOJDR-UHFFFAOYSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- GWYPDXLJACEENP-UHFFFAOYSA-N 1,3-cycloheptadiene Chemical compound C1CC=CC=CC1 GWYPDXLJACEENP-UHFFFAOYSA-N 0.000 description 1
- 125000005838 1,3-cyclopentylene group Chemical group [H]C1([H])C([H])([H])C([H])([*:2])C([H])([H])C1([H])[*:1] 0.000 description 1
- DKYBVKMIZODYKL-UHFFFAOYSA-N 1,3-diazinane Chemical compound C1CNCNC1 DKYBVKMIZODYKL-UHFFFAOYSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- IMLSAISZLJGWPP-UHFFFAOYSA-N 1,3-dithiolane Chemical compound C1CSCS1 IMLSAISZLJGWPP-UHFFFAOYSA-N 0.000 description 1
- ORZQDTYXWJPWES-UHFFFAOYSA-N 1,3-oxazolidine Chemical compound C1COCN1.C1COCN1 ORZQDTYXWJPWES-UHFFFAOYSA-N 0.000 description 1
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- DQFQCHIDRBIESA-UHFFFAOYSA-N 1-benzazepine Chemical compound N1C=CC=CC2=CC=CC=C12 DQFQCHIDRBIESA-UHFFFAOYSA-N 0.000 description 1
- LWZYUACNWRVDDJ-UHFFFAOYSA-N 1-benzoxepine Chemical compound O1C=CC=CC2=CC=CC=C12 LWZYUACNWRVDDJ-UHFFFAOYSA-N 0.000 description 1
- ZWTHOJQGPPRVII-UHFFFAOYSA-N 1-butyl-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]-3-[4-(trifluoromethoxy)phenyl]urea Chemical compound C=1C=C(OC(F)(F)F)C=CC=1NC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 ZWTHOJQGPPRVII-UHFFFAOYSA-N 0.000 description 1
- CXLCPLGBCQNHCO-UHFFFAOYSA-N 1-butyl-3-(2-ethoxyphenyl)-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]urea Chemical compound C=1C=CC=C(OCC)C=1NC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 CXLCPLGBCQNHCO-UHFFFAOYSA-N 0.000 description 1
- MKWUMTAKQNXEGR-UHFFFAOYSA-N 1-butyl-3-(2-hydroxyphenyl)-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]urea Chemical compound C=1C=CC=C(O)C=1NC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 MKWUMTAKQNXEGR-UHFFFAOYSA-N 0.000 description 1
- MCPYYQBZYTUZLU-UHFFFAOYSA-N 1-butyl-3-(2-methylsulfanylphenyl)-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]urea Chemical compound C=1C=CC=C(SC)C=1NC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 MCPYYQBZYTUZLU-UHFFFAOYSA-N 0.000 description 1
- YVSRBMLOEHNZCG-UHFFFAOYSA-N 1-butyl-3-(2-morpholin-4-ylethyl)-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]urea Chemical compound C1COCCN1CCNC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 YVSRBMLOEHNZCG-UHFFFAOYSA-N 0.000 description 1
- DYCANSCKTVMTOU-UHFFFAOYSA-N 1-butyl-3-(2-nitrophenyl)-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]urea Chemical compound C=1C=CC=C([N+]([O-])=O)C=1NC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 DYCANSCKTVMTOU-UHFFFAOYSA-N 0.000 description 1
- XLNIEFRTPCKACT-UHFFFAOYSA-N 1-butyl-3-(2-phenylphenyl)-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]urea Chemical compound C=1C=CC=C(C=2C=CC=CC=2)C=1NC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 XLNIEFRTPCKACT-UHFFFAOYSA-N 0.000 description 1
- DTCSZZPFIGHOEX-UHFFFAOYSA-N 1-butyl-3-(3,4-difluorophenyl)-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]urea Chemical compound C=1C=C(F)C(F)=CC=1NC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 DTCSZZPFIGHOEX-UHFFFAOYSA-N 0.000 description 1
- CKMZPJSROIEWCS-UHFFFAOYSA-N 1-butyl-3-(3-ethylphenyl)-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]urea Chemical compound C=1C=CC(CC)=CC=1NC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 CKMZPJSROIEWCS-UHFFFAOYSA-N 0.000 description 1
- JQTYXJWWAKAROD-UHFFFAOYSA-N 1-butyl-3-(3-methoxyphenyl)-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]urea Chemical compound C=1C=CC(OC)=CC=1NC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 JQTYXJWWAKAROD-UHFFFAOYSA-N 0.000 description 1
- RYTVKHWRXNIOOQ-UHFFFAOYSA-N 1-butyl-3-(4-ethylphenyl)-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]urea Chemical compound C=1C=C(CC)C=CC=1NC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 RYTVKHWRXNIOOQ-UHFFFAOYSA-N 0.000 description 1
- ODUPPJOVFXSOLC-UHFFFAOYSA-N 1-butyl-3-(4-methoxyphenyl)-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]urea Chemical compound C=1C=C(OC)C=CC=1NC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 ODUPPJOVFXSOLC-UHFFFAOYSA-N 0.000 description 1
- CWWOJBNJIJARNX-UHFFFAOYSA-N 1-butyl-3-(4-methyl-2-nitrophenyl)-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]urea Chemical compound C=1C=C(C)C=C([N+]([O-])=O)C=1NC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 CWWOJBNJIJARNX-UHFFFAOYSA-N 0.000 description 1
- ZLKZRNUPSHXYEG-UHFFFAOYSA-N 1-butyl-3-(4-methylphenyl)-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]urea Chemical compound C=1C=C(C)C=CC=1NC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 ZLKZRNUPSHXYEG-UHFFFAOYSA-N 0.000 description 1
- BBDLPNYAVLBTGX-UHFFFAOYSA-N 1-butyl-3-(4-phenylphenyl)-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]urea Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1NC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 BBDLPNYAVLBTGX-UHFFFAOYSA-N 0.000 description 1
- HIZKJJLBSIFQDB-UHFFFAOYSA-N 1-butyl-3-(oxolan-2-ylmethyl)-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]urea Chemical compound C1CCOC1CNC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 HIZKJJLBSIFQDB-UHFFFAOYSA-N 0.000 description 1
- XLCUOPXYQHEUNL-FQEVSTJZSA-N 1-butyl-3-[(1s)-1-phenylethyl]-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]urea Chemical compound N([C@@H](C)C=1C=CC=CC=1)C(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 XLCUOPXYQHEUNL-FQEVSTJZSA-N 0.000 description 1
- PFJJROMLQFHIPR-UHFFFAOYSA-N 1-butyl-3-[2,6-di(propan-2-yl)phenyl]-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]urea Chemical compound CC(C)C=1C=CC=C(C(C)C)C=1NC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C=1N=NNN=1 PFJJROMLQFHIPR-UHFFFAOYSA-N 0.000 description 1
- UVTKWWZXRSYBCI-UHFFFAOYSA-N 1-butyl-3-[2-(3-prop-1-en-2-ylphenyl)propan-2-yl]-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]urea Chemical compound C=1C=CC(C(C)=C)=CC=1C(C)(C)NC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 UVTKWWZXRSYBCI-UHFFFAOYSA-N 0.000 description 1
- PRLZJYZHZRFPHM-UHFFFAOYSA-N 1-butyl-3-phenyl-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]urea Chemical compound C=1C=CC=CC=1NC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 PRLZJYZHZRFPHM-UHFFFAOYSA-N 0.000 description 1
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- AWBOSXFRPFZLOP-UHFFFAOYSA-N 2,1,3-benzoxadiazole Chemical compound C1=CC=CC2=NON=C21 AWBOSXFRPFZLOP-UHFFFAOYSA-N 0.000 description 1
- LJCZNYWLQZZIOS-UHFFFAOYSA-N 2,2,2-trichlorethoxycarbonyl chloride Chemical group ClC(=O)OCC(Cl)(Cl)Cl LJCZNYWLQZZIOS-UHFFFAOYSA-N 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- OGHHATWOTABYKY-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1,3-benzothiazole Chemical compound C1CCCC2SCNC21 OGHHATWOTABYKY-UHFFFAOYSA-N 0.000 description 1
- DNZWAKVIOXCEHH-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1-benzofuran Chemical compound C1CCCC2OCCC21 DNZWAKVIOXCEHH-UHFFFAOYSA-N 0.000 description 1
- NZOBCFVNZQYCCZ-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1-benzothiophene Chemical compound C1CCCC2SCCC21 NZOBCFVNZQYCCZ-UHFFFAOYSA-N 0.000 description 1
- MDNGXAFGRWQHNZ-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1h-benzimidazole Chemical compound C1CCCC2NCNC21 MDNGXAFGRWQHNZ-UHFFFAOYSA-N 0.000 description 1
- LVJPACZOEKXFAY-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1h-indazole Chemical compound C1CCCC2CNNC21 LVJPACZOEKXFAY-UHFFFAOYSA-N 0.000 description 1
- LOPOBSRXDVBTHH-UHFFFAOYSA-N 2,3,4,4a,4b,5,6,7,8,8a,9,9a-dodecahydro-1h-pyrido[3,4-b]indole Chemical compound C1NCCC2C3CCCCC3NC21 LOPOBSRXDVBTHH-UHFFFAOYSA-N 0.000 description 1
- UDMSIVPAVKUOKF-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1,2-benzoxazepine Chemical compound C1CCNOC2=CC=CC=C21 UDMSIVPAVKUOKF-UHFFFAOYSA-N 0.000 description 1
- QEYQSYAGLRIYBE-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1h-1,2-benzodiazepine Chemical compound C1CCNNC2=CC=CC=C21 QEYQSYAGLRIYBE-UHFFFAOYSA-N 0.000 description 1
- MZBVNYACSSGXID-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1h-1-benzazepine Chemical compound N1CCCCC2=CC=CC=C21 MZBVNYACSSGXID-UHFFFAOYSA-N 0.000 description 1
- SCEIUGQQBYRBPP-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1h-azepine Chemical compound C1CCC=CNC1 SCEIUGQQBYRBPP-UHFFFAOYSA-N 0.000 description 1
- YYVKQFQZKSLYFN-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1h-diazepine Chemical compound C1CNNC=CC1 YYVKQFQZKSLYFN-UHFFFAOYSA-N 0.000 description 1
- GLCYMVDVOVIDBB-UHFFFAOYSA-N 2,3,4,5-tetrahydrooxadiazepine Chemical compound C1CC=CONN1 GLCYMVDVOVIDBB-UHFFFAOYSA-N 0.000 description 1
- ABQOPHYTASMWLA-UHFFFAOYSA-N 2,3,4,5-tetrahydrooxazepine Chemical compound C1CNOC=CC1 ABQOPHYTASMWLA-UHFFFAOYSA-N 0.000 description 1
- SOHIYESEPVZKHS-UHFFFAOYSA-N 2,3,4,5-tetrahydrooxepine Chemical compound C1CCC=COC1 SOHIYESEPVZKHS-UHFFFAOYSA-N 0.000 description 1
- IFPKIMVCYSSDDJ-UHFFFAOYSA-N 2,3,4,5-tetrahydrothiazepine Chemical compound C1CNSC=CC1 IFPKIMVCYSSDDJ-UHFFFAOYSA-N 0.000 description 1
- VRKPANGTGANDRQ-UHFFFAOYSA-N 2,3,4,5-tetrahydrothiepine Chemical compound C1CCC=CSC1 VRKPANGTGANDRQ-UHFFFAOYSA-N 0.000 description 1
- CFTOTSJVQRFXOF-UHFFFAOYSA-N 2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole Chemical compound N1C2=CC=CC=C2C2=C1CNCC2 CFTOTSJVQRFXOF-UHFFFAOYSA-N 0.000 description 1
- OXBLVCZKDOZZOJ-UHFFFAOYSA-N 2,3-Dihydrothiophene Chemical compound C1CC=CS1 OXBLVCZKDOZZOJ-UHFFFAOYSA-N 0.000 description 1
- RIUSCLBEBIOIRP-UHFFFAOYSA-N 2,3-dihydro-1,2-benzoxazepine Chemical compound C1=CCNOC2=CC=CC=C21 RIUSCLBEBIOIRP-UHFFFAOYSA-N 0.000 description 1
- FJRPOHLDJUJARI-UHFFFAOYSA-N 2,3-dihydro-1,2-oxazole Chemical compound C1NOC=C1 FJRPOHLDJUJARI-UHFFFAOYSA-N 0.000 description 1
- YTQQIHUQLOZOJI-UHFFFAOYSA-N 2,3-dihydro-1,2-thiazole Chemical compound C1NSC=C1 YTQQIHUQLOZOJI-UHFFFAOYSA-N 0.000 description 1
- HRCMXYXVAWHBTH-UHFFFAOYSA-N 2,3-dihydro-1,3-benzoxazole Chemical compound C1=CC=C2OCNC2=C1 HRCMXYXVAWHBTH-UHFFFAOYSA-N 0.000 description 1
- ZABMHLDQFJHDSC-UHFFFAOYSA-N 2,3-dihydro-1,3-oxazole Chemical compound C1NC=CO1 ZABMHLDQFJHDSC-UHFFFAOYSA-N 0.000 description 1
- OYJGEOAXBALSMM-UHFFFAOYSA-N 2,3-dihydro-1,3-thiazole Chemical compound C1NC=CS1 OYJGEOAXBALSMM-UHFFFAOYSA-N 0.000 description 1
- YJUFGFXVASPYFQ-UHFFFAOYSA-N 2,3-dihydro-1-benzothiophene Chemical compound C1=CC=C2SCCC2=C1 YJUFGFXVASPYFQ-UHFFFAOYSA-N 0.000 description 1
- ZWWWYOKRVNYQHF-UHFFFAOYSA-N 2,3-dihydro-1h-1,2-benzodiazepine Chemical compound C1=CCNNC2=CC=CC=C21 ZWWWYOKRVNYQHF-UHFFFAOYSA-N 0.000 description 1
- WSSWXGZEJNNFSN-UHFFFAOYSA-N 2,3-dihydro-1h-1-benzazepine Chemical compound N1CCC=CC2=CC=CC=C21 WSSWXGZEJNNFSN-UHFFFAOYSA-N 0.000 description 1
- BEWVAZNECYSPMT-UHFFFAOYSA-N 2,3-dihydro-1h-azepine Chemical compound C1CC=CC=CN1 BEWVAZNECYSPMT-UHFFFAOYSA-N 0.000 description 1
- QHYXWSXPPUTDRA-UHFFFAOYSA-N 2,3-dihydro-1h-diazepine Chemical compound C1NNC=CC=C1 QHYXWSXPPUTDRA-UHFFFAOYSA-N 0.000 description 1
- QDKGOMZIPXGDDJ-UHFFFAOYSA-N 2,3-dihydro-1h-indazole Chemical compound C1=CC=C2CNNC2=C1 QDKGOMZIPXGDDJ-UHFFFAOYSA-N 0.000 description 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
- WLGQUBABAPAJNB-UHFFFAOYSA-N 2,3-dihydrooxepine Chemical compound C1CC=CC=CO1 WLGQUBABAPAJNB-UHFFFAOYSA-N 0.000 description 1
- IZEOXCXHDBQQAP-UHFFFAOYSA-N 2,3-dihydrothiazepine Chemical compound C1NSC=CC=C1 IZEOXCXHDBQQAP-UHFFFAOYSA-N 0.000 description 1
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- PZJFUNZDCRKXPZ-UHFFFAOYSA-N 2,5-dihydro-1h-tetrazole Chemical compound C1NNN=N1 PZJFUNZDCRKXPZ-UHFFFAOYSA-N 0.000 description 1
- ZECQLHQEHJJSAN-UHFFFAOYSA-N 2,9-dihydro-1h-carbazole Chemical compound N1C2=CC=CC=C2C2=C1CCC=C2 ZECQLHQEHJJSAN-UHFFFAOYSA-N 0.000 description 1
- BIAPMJDDPWPHOP-UHFFFAOYSA-N 2,9-dihydro-1h-pyrido[3,4-b]indole Chemical compound N1C2=CC=CC=C2C2=C1CNC=C2 BIAPMJDDPWPHOP-UHFFFAOYSA-N 0.000 description 1
- JECYNCQXXKQDJN-UHFFFAOYSA-N 2-(2-methylhexan-2-yloxymethyl)oxirane Chemical compound CCCCC(C)(C)OCC1CO1 JECYNCQXXKQDJN-UHFFFAOYSA-N 0.000 description 1
- WWJBDSBGLBEFSH-UHFFFAOYSA-N 2-(4-methoxyphenyl)azepane Chemical compound C1=CC(OC)=CC=C1C1NCCCCC1 WWJBDSBGLBEFSH-UHFFFAOYSA-N 0.000 description 1
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- WYUYEJNGHIOFOC-VVTVMFAVSA-N 2-[(z)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridine;hydrochloride Chemical compound Cl.C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C\CN1CCCC1 WYUYEJNGHIOFOC-VVTVMFAVSA-N 0.000 description 1
- DGAHJUDAVWYUDW-UHFFFAOYSA-N 2-[3-[[benzyl-[(4-chlorophenyl)methyl]amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C1=CC=CC=C1C1=CC=CC(CN(CC=2C=CC=CC=2)CC=2C=CC(Cl)=CC=2)=C1 DGAHJUDAVWYUDW-UHFFFAOYSA-N 0.000 description 1
- CPSBQDRGXXXNBX-UHFFFAOYSA-N 2-[4-[[(4-cyanophenyl)methyl-heptan-4-ylamino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=1C=C(C=2C(=CC=CC=2)C(O)=O)C=CC=1CN(C(CCC)CCC)CC1=CC=C(C#N)C=C1 CPSBQDRGXXXNBX-UHFFFAOYSA-N 0.000 description 1
- VXYDHPDQMSVQCU-UHFFFAOYSA-N 2-[4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)piperidin-1-yl]-n-hydroxyacetamide Chemical compound COC1=CC=C(C2(CCN(CC(=O)NO)CC2)C#N)C=C1OC1CCCC1 VXYDHPDQMSVQCU-UHFFFAOYSA-N 0.000 description 1
- KJYYQILGVKQZHT-UHFFFAOYSA-N 2-[[butyl-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]carbamoyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylic acid Chemical compound S1C=2CCCCC=2C(C(O)=O)=C1NC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 KJYYQILGVKQZHT-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 1
- LYTMVABTDYMBQK-UHFFFAOYSA-N 2-benzothiophene Chemical compound C1=CC=CC2=CSC=C21 LYTMVABTDYMBQK-UHFFFAOYSA-N 0.000 description 1
- SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 1
- XULHFMYCBKQGEE-UHFFFAOYSA-N 2-hexyl-1-Decanol Chemical compound CCCCCCCCC(CO)CCCCCC XULHFMYCBKQGEE-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- CJNZAXGUTKBIHP-UHFFFAOYSA-N 2-iodobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1I CJNZAXGUTKBIHP-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- FGLBSLMDCBOPQK-UHFFFAOYSA-N 2-nitropropane Chemical compound CC(C)[N+]([O-])=O FGLBSLMDCBOPQK-UHFFFAOYSA-N 0.000 description 1
- ILPBINAXDRFYPL-UHFFFAOYSA-N 2-octene Chemical group CCCCCC=CC ILPBINAXDRFYPL-UHFFFAOYSA-N 0.000 description 1
- VMZCDNSFRSVYKQ-UHFFFAOYSA-N 2-phenylacetyl chloride Chemical compound ClC(=O)CC1=CC=CC=C1 VMZCDNSFRSVYKQ-UHFFFAOYSA-N 0.000 description 1
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- QMEQBOSUJUOXMX-UHFFFAOYSA-N 2h-oxadiazine Chemical compound N1OC=CC=N1 QMEQBOSUJUOXMX-UHFFFAOYSA-N 0.000 description 1
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 1
- AGIJRRREJXSQJR-UHFFFAOYSA-N 2h-thiazine Chemical compound N1SC=CC=C1 AGIJRRREJXSQJR-UHFFFAOYSA-N 0.000 description 1
- WGTASENVNYJZBK-UHFFFAOYSA-N 3,4,5-trimethoxyamphetamine Chemical compound COC1=CC(CC(C)N)=CC(OC)=C1OC WGTASENVNYJZBK-UHFFFAOYSA-N 0.000 description 1
- FSUYMKXZLQOFQY-UHFFFAOYSA-N 3,4-dihydro-1,2-benzodithiine Chemical compound C1=CC=C2SSCCC2=C1 FSUYMKXZLQOFQY-UHFFFAOYSA-N 0.000 description 1
- NTOIMCSZPGZTND-UHFFFAOYSA-N 3,4-dihydro-1,2-benzoxathiine Chemical compound C1=CC=C2OSCCC2=C1 NTOIMCSZPGZTND-UHFFFAOYSA-N 0.000 description 1
- IDUSJBBWEKNWAK-UHFFFAOYSA-N 3,4-dihydro-2h-1,2-benzothiazine Chemical compound C1=CC=C2SNCCC2=C1 IDUSJBBWEKNWAK-UHFFFAOYSA-N 0.000 description 1
- BGDOLELXXPTPFX-UHFFFAOYSA-N 3,4-dihydro-2h-1,2-benzoxazine Chemical compound C1=CC=C2ONCCC2=C1 BGDOLELXXPTPFX-UHFFFAOYSA-N 0.000 description 1
- BOLMDIXLULGTBD-UHFFFAOYSA-N 3,4-dihydro-2h-oxazine Chemical compound C1CC=CON1 BOLMDIXLULGTBD-UHFFFAOYSA-N 0.000 description 1
- NDTSIDOTKVWMRI-UHFFFAOYSA-N 3,4-dihydro-2h-pyrazino[2,3-b][1,4]oxazine Chemical compound C1=CN=C2NCCOC2=N1 NDTSIDOTKVWMRI-UHFFFAOYSA-N 0.000 description 1
- NWWJFMCCTZLKNT-UHFFFAOYSA-N 3,4-dihydro-2h-thiazine Chemical compound C1CC=CSN1 NWWJFMCCTZLKNT-UHFFFAOYSA-N 0.000 description 1
- ATVJJNGVPSKBGO-UHFFFAOYSA-N 3,4-dihydro-2h-thiopyran Chemical compound C1CSC=CC1 ATVJJNGVPSKBGO-UHFFFAOYSA-N 0.000 description 1
- ICHMVLMXGWNBOX-UHFFFAOYSA-N 3-(2-bromophenyl)-1-butyl-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]urea Chemical compound C=1C=CC=C(Br)C=1NC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 ICHMVLMXGWNBOX-UHFFFAOYSA-N 0.000 description 1
- KLPQJJKXRIDASJ-UHFFFAOYSA-N 3-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]-N-ethyl-8-propan-2-yl-7H-purin-6-imine Chemical compound CCN=C1C2=C(N=C(N2)C(C)C)N(C=N1)CC3=CC(=C(C=C3)OC)OC4CCCC4 KLPQJJKXRIDASJ-UHFFFAOYSA-N 0.000 description 1
- DOTGLEDGHCUFJJ-UHFFFAOYSA-N 3-[2-[(dibenzylamino)methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C1=CC=CC(C=2C(=CC=CC=2)CN(CC=2C=CC=CC=2)CC=2C=CC=CC=2)=C1 DOTGLEDGHCUFJJ-UHFFFAOYSA-N 0.000 description 1
- TWKYRKLMXPHFRJ-UHFFFAOYSA-N 3-[2-[[(4-chlorophenyl)methyl-(3-phenylpropyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C1=CC=CC(C=2C(=CC=CC=2)CN(CCCC=2C=CC=CC=2)CC=2C=CC(Cl)=CC=2)=C1 TWKYRKLMXPHFRJ-UHFFFAOYSA-N 0.000 description 1
- JCVLKIANADXUDG-UHFFFAOYSA-N 3-[2-[[2-phenylethyl(3-phenylpropyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C1=CC=CC(C=2C(=CC=CC=2)CN(CCCC=2C=CC=CC=2)CCC=2C=CC=CC=2)=C1 JCVLKIANADXUDG-UHFFFAOYSA-N 0.000 description 1
- MTEBKCOVNYANFQ-UHFFFAOYSA-N 3-[2-[[benzyl(3-phenylpropyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C1=CC=CC(C=2C(=CC=CC=2)CN(CCCC=2C=CC=CC=2)CC=2C=CC=CC=2)=C1 MTEBKCOVNYANFQ-UHFFFAOYSA-N 0.000 description 1
- JDDXIQVQFKUVEK-UHFFFAOYSA-N 3-[3-[[(4-cyanophenyl)methyl-(3-phenylpropyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C1=CC=CC(C=2C=C(CN(CCCC=3C=CC=CC=3)CC=3C=CC(=CC=3)C#N)C=CC=2)=C1 JDDXIQVQFKUVEK-UHFFFAOYSA-N 0.000 description 1
- XKXMITTZVZSHJW-UHFFFAOYSA-N 3-[3-[[benzyl(3-phenylpropyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C1=CC=CC(C=2C=C(CN(CCCC=3C=CC=CC=3)CC=3C=CC=CC=3)C=CC=2)=C1 XKXMITTZVZSHJW-UHFFFAOYSA-N 0.000 description 1
- UOHAJGACJGSUHU-UHFFFAOYSA-N 3-[3-[[bis(3-phenylpropyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C1=CC=CC(C=2C=C(CN(CCCC=3C=CC=CC=3)CCCC=3C=CC=CC=3)C=CC=2)=C1 UOHAJGACJGSUHU-UHFFFAOYSA-N 0.000 description 1
- CTTKTXWEBLACQG-UHFFFAOYSA-N 3-[4-[[(4-methoxyphenyl)methyl-(2-phenylethyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(OC)=CC=C1CN(CC=1C=CC(=CC=1)C=1C=C(C=CC=1)C(O)=O)CCC1=CC=CC=C1 CTTKTXWEBLACQG-UHFFFAOYSA-N 0.000 description 1
- XPHKMYWUKNOIMH-UHFFFAOYSA-N 3-benzyl-1-butyl-1-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]urea Chemical compound C=1C=CC=CC=1CNC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 XPHKMYWUKNOIMH-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- XQJMXPAEFMWDOZ-UHFFFAOYSA-N 3exo-benzoyloxy-tropane Natural products CN1C(C2)CCC1CC2OC(=O)C1=CC=CC=C1 XQJMXPAEFMWDOZ-UHFFFAOYSA-N 0.000 description 1
- WHGMHGPIJZTKTI-UHFFFAOYSA-N 3h-1,2-benzodithiole Chemical compound C1=CC=C2CSSC2=C1 WHGMHGPIJZTKTI-UHFFFAOYSA-N 0.000 description 1
- GPYDBWWOYRNOBL-UHFFFAOYSA-N 4,5-dihydro-3h-1,2-benzodioxepine Chemical compound C1CCOOC2=CC=CC=C21 GPYDBWWOYRNOBL-UHFFFAOYSA-N 0.000 description 1
- WTJXVDPDEQKTCV-UHFFFAOYSA-N 4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydron;chloride Chemical compound Cl.C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2C1CC1C(N(C)C)C(=O)C(C(N)=O)=C(O)C1(O)C2=O WTJXVDPDEQKTCV-UHFFFAOYSA-N 0.000 description 1
- MNHXYNNKDDXKNP-UHFFFAOYSA-N 4-(3-chlorophenyl)-1,7-diethyl-2-pyrido[2,3-d]pyrimidinone Chemical compound N=1C(=O)N(CC)C2=NC(CC)=CC=C2C=1C1=CC=CC(Cl)=C1 MNHXYNNKDDXKNP-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- PTNZGHXUZDHMIQ-UHFFFAOYSA-N 4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC=C2C(C)C(C(O)C3C(C(O)=C(C(N)=O)C(=O)C3N(C)C)(O)C3=O)C3=C(O)C2=C1O PTNZGHXUZDHMIQ-UHFFFAOYSA-N 0.000 description 1
- KHWIDEDSLKUQDL-UHFFFAOYSA-N 4-[2-[[(4-chlorophenyl)methyl-(3-phenylpropyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(C(=O)O)=CC=C1C1=CC=CC=C1CN(CC=1C=CC(Cl)=CC=1)CCCC1=CC=CC=C1 KHWIDEDSLKUQDL-UHFFFAOYSA-N 0.000 description 1
- HUMPLPIFUFNHHU-UHFFFAOYSA-N 4-[2-[[(4-cyanophenyl)methyl-(3-phenylpropyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(C(=O)O)=CC=C1C1=CC=CC=C1CN(CC=1C=CC(=CC=1)C#N)CCCC1=CC=CC=C1 HUMPLPIFUFNHHU-UHFFFAOYSA-N 0.000 description 1
- OTPVIQLCLXGYBE-UHFFFAOYSA-N 4-[2-[[benzyl(3-phenylpropyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(C(=O)O)=CC=C1C1=CC=CC=C1CN(CC=1C=CC=CC=1)CCCC1=CC=CC=C1 OTPVIQLCLXGYBE-UHFFFAOYSA-N 0.000 description 1
- JHNRQBUYGDTRRM-UHFFFAOYSA-N 4-[2-[[benzyl(cyclohexylmethyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(C(=O)O)=CC=C1C1=CC=CC=C1CN(CC=1C=CC=CC=1)CC1CCCCC1 JHNRQBUYGDTRRM-UHFFFAOYSA-N 0.000 description 1
- VXNMHXLQIYPPBZ-UHFFFAOYSA-N 4-[2-[[benzyl-[(4-cyanophenyl)methyl]amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(C(=O)O)=CC=C1C1=CC=CC=C1CN(CC=1C=CC(=CC=1)C#N)CC1=CC=CC=C1 VXNMHXLQIYPPBZ-UHFFFAOYSA-N 0.000 description 1
- KNHKYWIDKHSYTF-UHFFFAOYSA-N 4-[2-[[bis(3-phenylpropyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(C(=O)O)=CC=C1C1=CC=CC=C1CN(CCCC=1C=CC=CC=1)CCCC1=CC=CC=C1 KNHKYWIDKHSYTF-UHFFFAOYSA-N 0.000 description 1
- NTRDEDPJUXFFSV-UHFFFAOYSA-N 4-[2-[[butyl-[(4-chlorophenyl)methyl]amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=1C=CC=C(C=2C=CC(=CC=2)C(O)=O)C=1CN(CCCC)CC1=CC=C(Cl)C=C1 NTRDEDPJUXFFSV-UHFFFAOYSA-N 0.000 description 1
- LEPUFWKHCHNHLL-UHFFFAOYSA-N 4-[3-[[(4-cyanophenyl)methyl-(2-phenylethyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(C(=O)O)=CC=C1C1=CC=CC(CN(CCC=2C=CC=CC=2)CC=2C=CC(=CC=2)C#N)=C1 LEPUFWKHCHNHLL-UHFFFAOYSA-N 0.000 description 1
- QGIMNLYFHRTOEG-UHFFFAOYSA-N 4-[3-[[benzyl(3-phenylpropyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(C(=O)O)=CC=C1C1=CC=CC(CN(CCCC=2C=CC=CC=2)CC=2C=CC=CC=2)=C1 QGIMNLYFHRTOEG-UHFFFAOYSA-N 0.000 description 1
- HNINTMWCLKRSHV-UHFFFAOYSA-N 4-[3-[[cyclohexylmethyl(2-phenylethyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(C(=O)O)=CC=C1C1=CC=CC(CN(CCC=2C=CC=CC=2)CC2CCCCC2)=C1 HNINTMWCLKRSHV-UHFFFAOYSA-N 0.000 description 1
- QJHYDKZHEUEGEE-UHFFFAOYSA-N 4-[4-[(dibenzylamino)methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(C(=O)O)=CC=C1C(C=C1)=CC=C1CN(CC=1C=CC=CC=1)CC1=CC=CC=C1 QJHYDKZHEUEGEE-UHFFFAOYSA-N 0.000 description 1
- WTHKSDWVQOFUHX-UHFFFAOYSA-N 4-[4-[[(4-chlorophenyl)methyl-(2-methoxyethyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=1C=C(C=2C=CC(=CC=2)C(O)=O)C=CC=1CN(CCOC)CC1=CC=C(Cl)C=C1 WTHKSDWVQOFUHX-UHFFFAOYSA-N 0.000 description 1
- PUVVWYCEOUKMID-UHFFFAOYSA-N 4-[4-[[(4-chlorophenyl)methyl-(2-phenylethyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(C(=O)O)=CC=C1C(C=C1)=CC=C1CN(CC=1C=CC(Cl)=CC=1)CCC1=CC=CC=C1 PUVVWYCEOUKMID-UHFFFAOYSA-N 0.000 description 1
- WMWLZMTZEPAUQV-UHFFFAOYSA-N 4-[4-[[(4-chlorophenyl)methyl-(3-phenylpropyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(C(=O)O)=CC=C1C(C=C1)=CC=C1CN(CC=1C=CC(Cl)=CC=1)CCCC1=CC=CC=C1 WMWLZMTZEPAUQV-UHFFFAOYSA-N 0.000 description 1
- VTFLMXUZXCXBDS-UHFFFAOYSA-N 4-[4-[[(4-cyanophenyl)methyl-(2-phenylethyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(C(=O)O)=CC=C1C(C=C1)=CC=C1CN(CC=1C=CC(=CC=1)C#N)CCC1=CC=CC=C1 VTFLMXUZXCXBDS-UHFFFAOYSA-N 0.000 description 1
- SAMUKQGBKBIDKZ-UHFFFAOYSA-N 4-[4-[[(4-cyanophenyl)methyl-(3-phenylpropyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(C(=O)O)=CC=C1C(C=C1)=CC=C1CN(CC=1C=CC(=CC=1)C#N)CCCC1=CC=CC=C1 SAMUKQGBKBIDKZ-UHFFFAOYSA-N 0.000 description 1
- AQNIQEACTGAWFN-UHFFFAOYSA-N 4-[4-[[(4-methoxyphenyl)methyl-(2-phenylethyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(OC)=CC=C1CN(CC=1C=CC(=CC=1)C=1C=CC(=CC=1)C(O)=O)CCC1=CC=CC=C1 AQNIQEACTGAWFN-UHFFFAOYSA-N 0.000 description 1
- SUSHMFOTSVWABK-UHFFFAOYSA-N 4-[4-[[(4-methoxyphenyl)methyl-(3-phenylpropyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(OC)=CC=C1CN(CC=1C=CC(=CC=1)C=1C=CC(=CC=1)C(O)=O)CCCC1=CC=CC=C1 SUSHMFOTSVWABK-UHFFFAOYSA-N 0.000 description 1
- RSXPTGRUWIBIKJ-UHFFFAOYSA-N 4-[4-[[2-phenylethyl(3-phenylpropyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(C(=O)O)=CC=C1C(C=C1)=CC=C1CN(CCC=1C=CC=CC=1)CCCC1=CC=CC=C1 RSXPTGRUWIBIKJ-UHFFFAOYSA-N 0.000 description 1
- BZELGTSDMWRDCK-UHFFFAOYSA-N 4-[4-[[3-phenylpropyl(pyridin-2-ylmethyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(C(=O)O)=CC=C1C(C=C1)=CC=C1CN(CC=1N=CC=CC=1)CCCC1=CC=CC=C1 BZELGTSDMWRDCK-UHFFFAOYSA-N 0.000 description 1
- JMYJVAASQDONJS-UHFFFAOYSA-N 4-[4-[[benzyl(2-phenylethyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(C(=O)O)=CC=C1C(C=C1)=CC=C1CN(CC=1C=CC=CC=1)CCC1=CC=CC=C1 JMYJVAASQDONJS-UHFFFAOYSA-N 0.000 description 1
- FITUDDDMFJILPF-UHFFFAOYSA-N 4-[4-[[benzyl(butyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=1C=C(C=2C=CC(=CC=2)C(O)=O)C=CC=1CN(CCCC)CC1=CC=CC=C1 FITUDDDMFJILPF-UHFFFAOYSA-N 0.000 description 1
- RWSJWDKLNJGNCM-UHFFFAOYSA-N 4-[4-[[benzyl(cyclohexylmethyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(C(=O)O)=CC=C1C(C=C1)=CC=C1CN(CC=1C=CC=CC=1)CC1CCCCC1 RWSJWDKLNJGNCM-UHFFFAOYSA-N 0.000 description 1
- PJNNYIKMCFMVSF-UHFFFAOYSA-N 4-[4-[[benzyl(pentyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=1C=C(C=2C=CC(=CC=2)C(O)=O)C=CC=1CN(CCCCC)CC1=CC=CC=C1 PJNNYIKMCFMVSF-UHFFFAOYSA-N 0.000 description 1
- MCTGINWQHVYQRI-UHFFFAOYSA-N 4-[4-[[bis(3-phenylpropyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(C(=O)O)=CC=C1C(C=C1)=CC=C1CN(CCCC=1C=CC=CC=1)CCCC1=CC=CC=C1 MCTGINWQHVYQRI-UHFFFAOYSA-N 0.000 description 1
- VEAIWPADBYMFOB-UHFFFAOYSA-N 4-[4-[[butyl(cyclohexylmethyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=1C=C(C=2C=CC(=CC=2)C(O)=O)C=CC=1CN(CCCC)CC1CCCCC1 VEAIWPADBYMFOB-UHFFFAOYSA-N 0.000 description 1
- SHWVCXXXTFBFCJ-UHFFFAOYSA-N 4-[4-[[butyl-[(4-chlorophenyl)methyl]amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=1C=C(C=2C=CC(=CC=2)C(O)=O)C=CC=1CN(CCCC)CC1=CC=C(Cl)C=C1 SHWVCXXXTFBFCJ-UHFFFAOYSA-N 0.000 description 1
- GMRDUBKTXKGLRK-UHFFFAOYSA-N 4-[4-[[butyl-[(4-cyanophenyl)methyl]amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=1C=C(C=2C=CC(=CC=2)C(O)=O)C=CC=1CN(CCCC)CC1=CC=C(C#N)C=C1 GMRDUBKTXKGLRK-UHFFFAOYSA-N 0.000 description 1
- CLUNYRKDAODAMW-UHFFFAOYSA-N 4-[4-[[cyclohexylmethyl(2-phenylethyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(C(=O)O)=CC=C1C(C=C1)=CC=C1CN(CC1CCCCC1)CCC1=CC=CC=C1 CLUNYRKDAODAMW-UHFFFAOYSA-N 0.000 description 1
- XOAONLBLHYLGGM-UHFFFAOYSA-N 4-[4-[[heptan-4-yl(3-phenylpropyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=1C=C(C=2C=CC(=CC=2)C(O)=O)C=CC=1CN(C(CCC)CCC)CCCC1=CC=CC=C1 XOAONLBLHYLGGM-UHFFFAOYSA-N 0.000 description 1
- PVYMYYGMZPFMPA-UHFFFAOYSA-N 4-[4-[[pentyl(2-phenylethyl)amino]methyl]phenyl]benzoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=1C=C(C=2C=CC(=CC=2)C(O)=O)C=CC=1CN(CCCCC)CCC1=CC=CC=C1 PVYMYYGMZPFMPA-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- WNWVKZTYMQWFHE-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound [CH2]CN1CCOCC1 WNWVKZTYMQWFHE-UHFFFAOYSA-N 0.000 description 1
- 229940124125 5 Lipoxygenase inhibitor Drugs 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- WUWFMDMBOJLQIV-UHFFFAOYSA-N 7-(3-aminopyrrolidin-1-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid Chemical compound C1C(N)CCN1C(C(=C1)F)=NC2=C1C(=O)C(C(O)=O)=CN2C1=CC=C(F)C=C1F WUWFMDMBOJLQIV-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- JRLTTZUODKEYDH-UHFFFAOYSA-N 8-methylquinoline Chemical group C1=CN=C2C(C)=CC=CC2=C1 JRLTTZUODKEYDH-UHFFFAOYSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- IYLLULUTZPKQBW-UHFFFAOYSA-N Acrinol Chemical compound CC(O)C(O)=O.C1=C(N)C=CC2=C(N)C3=CC(OCC)=CC=C3N=C21 IYLLULUTZPKQBW-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- MROJXXOCABQVEF-UHFFFAOYSA-N Actarit Chemical compound CC(=O)NC1=CC=C(CC(O)=O)C=C1 MROJXXOCABQVEF-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 102400000345 Angiotensin-2 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102000008682 Argonaute Proteins Human genes 0.000 description 1
- 108010088141 Argonaute Proteins Proteins 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- XHVAWZZCDCWGBK-WYRLRVFGSA-M Aurothioglucose Chemical compound OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O XHVAWZZCDCWGBK-WYRLRVFGSA-M 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108010004032 Bromelains Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 description 1
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 description 1
- 102100023702 C-C motif chemokine 13 Human genes 0.000 description 1
- 101710112613 C-C motif chemokine 13 Proteins 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 102100034871 C-C motif chemokine 8 Human genes 0.000 description 1
- 101710155833 C-C motif chemokine 8 Proteins 0.000 description 1
- 102100036166 C-X-C chemokine receptor type 1 Human genes 0.000 description 1
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 description 1
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 108700012434 CCL3 Proteins 0.000 description 1
- 108010061299 CXCR4 Receptors Proteins 0.000 description 1
- 102000012000 CXCR4 Receptors Human genes 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000131283 Cantharis Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- QYQDKDWGWDOFFU-IUODEOHRSA-N Cefotiam Chemical compound CN(C)CCN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CC=3N=C(N)SC=3)[C@H]2SC1 QYQDKDWGWDOFFU-IUODEOHRSA-N 0.000 description 1
- KEJCWVGMRLCZQQ-YJBYXUATSA-N Cefuroxime axetil Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(=O)OC(C)OC(C)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 KEJCWVGMRLCZQQ-YJBYXUATSA-N 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 1
- 102000000013 Chemokine CCL3 Human genes 0.000 description 1
- 102000001326 Chemokine CCL4 Human genes 0.000 description 1
- 108010055165 Chemokine CCL4 Proteins 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- CHDYFQLLAKGGJR-UHFFFAOYSA-N Cl.C1(=CC=CC=C1)C1=C(C(OC=C1)N)C1=CC=CC=C1 Chemical compound Cl.C1(=CC=CC=C1)C1=C(C(OC=C1)N)C1=CC=CC=C1 CHDYFQLLAKGGJR-UHFFFAOYSA-N 0.000 description 1
- FBRAWBYQGRLCEK-AVVSTMBFSA-N Clobetasone butyrate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CCC)[C@@]1(C)CC2=O FBRAWBYQGRLCEK-AVVSTMBFSA-N 0.000 description 1
- 108010078777 Colistin Proteins 0.000 description 1
- 229940122010 Corticotropin releasing factor antagonist Drugs 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- UYUXSRADSPPKRZ-UHFFFAOYSA-N D-glucuronic acid gamma-lactone Natural products O=CC(O)C1OC(=O)C(O)C1O UYUXSRADSPPKRZ-UHFFFAOYSA-N 0.000 description 1
- UYUXSRADSPPKRZ-SKNVOMKLSA-N D-glucurono-6,3-lactone Chemical compound O=C[C@H](O)[C@H]1OC(=O)[C@@H](O)[C@H]1O UYUXSRADSPPKRZ-SKNVOMKLSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 206010012455 Dermatitis exfoliative Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- DBAKFASWICGISY-DASCVMRKSA-N Dexchlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C1([C@H](CCN(C)C)C=2N=CC=CC=2)=CC=C(Cl)C=C1 DBAKFASWICGISY-DASCVMRKSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- 229940123907 Disease modifying antirheumatic drug Drugs 0.000 description 1
- 102100031107 Disintegrin and metalloproteinase domain-containing protein 11 Human genes 0.000 description 1
- 101710121366 Disintegrin and metalloproteinase domain-containing protein 11 Proteins 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 102100023688 Eotaxin Human genes 0.000 description 1
- 101710139422 Eotaxin Proteins 0.000 description 1
- 208000032541 Epidermal naevus Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 239000001293 FEMA 3089 Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010000916 Fimbriae Proteins Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- ALIVXCSEERJYHU-UHFFFAOYSA-N Flurbiprofen axetil Chemical compound FC1=CC(C(C)C(=O)OC(OC(C)=O)C)=CC=C1C1=CC=CC=C1 ALIVXCSEERJYHU-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 206010061459 Gastrointestinal ulcer Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229940121797 Glycosaminoglycan inhibitor Drugs 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229940033332 HIV-1 vaccine Drugs 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000947174 Homo sapiens C-X-C chemokine receptor type 1 Proteins 0.000 description 1
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 101000864393 Homo sapiens Protein BUD31 homolog Proteins 0.000 description 1
- 101000693265 Homo sapiens Sphingosine 1-phosphate receptor 1 Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 1
- 108010018951 Interleukin-8B Receptors Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 102000003680 Leukotriene B4 receptors Human genes 0.000 description 1
- 108090000093 Leukotriene B4 receptors Proteins 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- DTXXSJZBSTYZKE-ZDQKKZTESA-N Maxacalcitol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](OCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C DTXXSJZBSTYZKE-ZDQKKZTESA-N 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- HOKDBMAJZXIPGC-UHFFFAOYSA-N Mequitazine Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1CC1C(CC2)CCN2C1 HOKDBMAJZXIPGC-UHFFFAOYSA-N 0.000 description 1
- 101710170181 Metalloproteinase inhibitor Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 102000046795 Mitogen-Activated Protein Kinase 3 Human genes 0.000 description 1
- 108700027649 Mitogen-Activated Protein Kinase 3 Proteins 0.000 description 1
- DJEIHHYCDCTAAH-UHFFFAOYSA-N Mofezolac (TN) Chemical compound C1=CC(OC)=CC=C1C1=NOC(CC(O)=O)=C1C1=CC=C(OC)C=C1 DJEIHHYCDCTAAH-UHFFFAOYSA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 101100236212 Mus musculus Ltb4r2 gene Proteins 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- QQXLDOJGLXJCSE-UHFFFAOYSA-N N-methylnortropinone Natural products C1C(=O)CC2CCC1N2C QQXLDOJGLXJCSE-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 102400001103 Neurotensin Human genes 0.000 description 1
- 101800001814 Neurotensin Proteins 0.000 description 1
- 206010029400 Nicotinic acid deficiency Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- STJFYCWYHROASW-UHFFFAOYSA-N O-methyl-glaucamine Natural products CN1CCC2=CC(OC)=C(OC)C=C2C2OC(OC)C3=C4OCOC4=CC=C3C12 STJFYCWYHROASW-UHFFFAOYSA-N 0.000 description 1
- 102000003840 Opioid Receptors Human genes 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- DJWYOLJPSHDSAL-UHFFFAOYSA-N Pantethine Natural products OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)C(O)C(C)(C)CO DJWYOLJPSHDSAL-UHFFFAOYSA-N 0.000 description 1
- HYRKAAMZBDSJFJ-LFDBJOOHSA-N Paramethasone acetate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]2(C)C[C@@H]1O HYRKAAMZBDSJFJ-LFDBJOOHSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000002141 Pellagra Diseases 0.000 description 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002675 Polyoxyl Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- HUMXXHTVHHLNRO-KAJVQRHHSA-N Prednisolone tebutate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)CC(C)(C)C)(O)[C@@]1(C)C[C@@H]2O HUMXXHTVHHLNRO-KAJVQRHHSA-N 0.000 description 1
- YWYQTGBBEZQBGO-BERLURQNSA-N Pregnanediol Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](O)C)[C@@]2(C)CC1 YWYQTGBBEZQBGO-BERLURQNSA-N 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 102100026476 Prostacyclin receptor Human genes 0.000 description 1
- 101710170814 Prostacyclin receptor Proteins 0.000 description 1
- 102000008866 Prostaglandin E receptors Human genes 0.000 description 1
- 108010088540 Prostaglandin E receptors Proteins 0.000 description 1
- 102000000471 Prostaglandin F receptors Human genes 0.000 description 1
- 108050008995 Prostaglandin F receptors Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100030160 Protein BUD31 homolog Human genes 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- QIZDQFOVGFDBKW-DHBOJHSNSA-N Pseudotropine Natural products OC1C[C@@H]2[N+](C)[C@H](C1)CC2 QIZDQFOVGFDBKW-DHBOJHSNSA-N 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- MJNIWUJSIGSWKK-BBANNHEPSA-N Riboflavin butyrate Chemical compound CCCC(=O)OC[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)CN1C2=CC(C)=C(C)C=C2N=C2C1=NC(=O)NC2=O MJNIWUJSIGSWKK-BBANNHEPSA-N 0.000 description 1
- OHSHFZJLPYLRIP-BMZHGHOISA-M Riboflavin sodium phosphate Chemical compound [Na+].OP(=O)([O-])OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O OHSHFZJLPYLRIP-BMZHGHOISA-M 0.000 description 1
- 229920002536 Scavenger resin Polymers 0.000 description 1
- 208000005770 Secondary Hyperparathyroidism Diseases 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- 206010040840 Skin erosion Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 102100025750 Sphingosine 1-phosphate receptor 1 Human genes 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- DYZJXZOQQRXDLE-UHFFFAOYSA-O Suplatast tosilate Chemical compound CCOCC(O)COC1=CC=C(NC(=O)CC[S+](C)C)C=C1 DYZJXZOQQRXDLE-UHFFFAOYSA-O 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- JZFICWYCTCCINF-UHFFFAOYSA-N Thiadiazin Chemical compound S=C1SC(C)NC(C)N1CCN1C(=S)SC(C)NC1C JZFICWYCTCCINF-UHFFFAOYSA-N 0.000 description 1
- YPWFISCTZQNZAU-UHFFFAOYSA-N Thiane Chemical compound C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- UKNGDQSYPNBJAO-UHFFFAOYSA-N Tiaramide hydrochloride Chemical compound Cl.C1CN(CCO)CCN1C(=O)CN1C(=O)SC2=CC=C(Cl)C=C21 UKNGDQSYPNBJAO-UHFFFAOYSA-N 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- YWYQTGBBEZQBGO-UHFFFAOYSA-N UC1011 Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(O)C)C1(C)CC2 YWYQTGBBEZQBGO-UHFFFAOYSA-N 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- FXXSETTYJSGMCR-GLCLSGQWSA-N Valacillin (TN) Chemical compound [Cl-].O1C(=O)OC(COC(=O)[C@H]2C(S[C@H]3[NH+]2C([C@H]3NC(=O)[C@H](N)C=2C=CC=CC=2)=O)(C)C)=C1C FXXSETTYJSGMCR-GLCLSGQWSA-N 0.000 description 1
- 229930003756 Vitamin B7 Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- FBRAWBYQGRLCEK-UHFFFAOYSA-N [17-(2-chloroacetyl)-9-fluoro-10,13,16-trimethyl-3,11-dioxo-7,8,12,14,15,16-hexahydro-6h-cyclopenta[a]phenanthren-17-yl] butanoate Chemical compound C1CC2=CC(=O)C=CC2(C)C2(F)C1C1CC(C)C(C(=O)CCl)(OC(=O)CCC)C1(C)CC2=O FBRAWBYQGRLCEK-UHFFFAOYSA-N 0.000 description 1
- HOGQKHLSLTVXHT-VWUMJDOOSA-N [2-[(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] hydrogen sulfate Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COS(O)(=O)=O)[C@@H]4[C@@H]3CCC2=C1 HOGQKHLSLTVXHT-VWUMJDOOSA-N 0.000 description 1
- PRLGAHUPIXAOLK-UHFFFAOYSA-N [I+].C[N+]1=CC=CC=C1Cl Chemical compound [I+].C[N+]1=CC=CC=C1Cl PRLGAHUPIXAOLK-UHFFFAOYSA-N 0.000 description 1
- OGFZEDMIYDGMQJ-UHFFFAOYSA-N [Na].COC(C)=O Chemical compound [Na].COC(C)=O OGFZEDMIYDGMQJ-UHFFFAOYSA-N 0.000 description 1
- PVQATPQSBYNMGE-UHFFFAOYSA-N [benzhydryloxy(phenyl)methyl]benzene Chemical class C=1C=CC=CC=1C(C=1C=CC=CC=1)OC(C=1C=CC=CC=1)C1=CC=CC=C1 PVQATPQSBYNMGE-UHFFFAOYSA-N 0.000 description 1
- ZVQOOHYFBIDMTQ-UHFFFAOYSA-N [methyl(oxido){1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-lambda(6)-sulfanylidene]cyanamide Chemical compound N#CN=S(C)(=O)C(C)C1=CC=C(C(F)(F)F)N=C1 ZVQOOHYFBIDMTQ-UHFFFAOYSA-N 0.000 description 1
- BJHYXTXCXXTZOG-UHFFFAOYSA-N ab26257 Chemical group N1C2=NC=CC=C2C2=C1CCNC2 BJHYXTXCXXTZOG-UHFFFAOYSA-N 0.000 description 1
- 230000007488 abnormal function Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 229960004892 acemetacin Drugs 0.000 description 1
- FSQKKOOTNAMONP-UHFFFAOYSA-N acemetacin Chemical compound CC1=C(CC(=O)OCC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 FSQKKOOTNAMONP-UHFFFAOYSA-N 0.000 description 1
- HXGDTGSAIMULJN-UHFFFAOYSA-N acetnaphthylene Natural products C1=CC(C=C2)=C3C2=CC=CC3=C1 HXGDTGSAIMULJN-UHFFFAOYSA-N 0.000 description 1
- PMZXXNPJQYDFJX-UHFFFAOYSA-N acetonitrile;2,2,2-trifluoroacetic acid Chemical compound CC#N.OC(=O)C(F)(F)F PMZXXNPJQYDFJX-UHFFFAOYSA-N 0.000 description 1
- JUGOREOARAHOCO-UHFFFAOYSA-M acetylcholine chloride Chemical compound [Cl-].CC(=O)OCC[N+](C)(C)C JUGOREOARAHOCO-UHFFFAOYSA-M 0.000 description 1
- 229960004266 acetylcholine chloride Drugs 0.000 description 1
- 229950003218 actarit Drugs 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 239000005456 alcohol based solvent Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical class O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003302 alkenyloxy group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 125000005133 alkynyloxy group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
- 108010074587 aminooxypentane-RANTES Proteins 0.000 description 1
- 150000003927 aminopyridines Chemical class 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229940043312 ampicillin / sulbactam Drugs 0.000 description 1
- LSNWBKACGXCGAJ-UHFFFAOYSA-N ampiroxicam Chemical compound CN1S(=O)(=O)C2=CC=CC=C2C(OC(C)OC(=O)OCC)=C1C(=O)NC1=CC=CC=N1 LSNWBKACGXCGAJ-UHFFFAOYSA-N 0.000 description 1
- 229950011249 ampiroxicam Drugs 0.000 description 1
- 229960004238 anakinra Drugs 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 125000005577 anthracene group Chemical group 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003627 anti-cholesterol Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000648 anti-parkinson Effects 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003793 antidiarrheal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003972 antineoplastic antibiotic Substances 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000003420 antiserotonin agent Substances 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- KNNXFYIMEYKHBZ-UHFFFAOYSA-N as-indacene Chemical compound C1=CC2=CC=CC2=C2C=CC=C21 KNNXFYIMEYKHBZ-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 210000000467 autonomic pathway Anatomy 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- QXNDZONIWRINJR-UHFFFAOYSA-N azocane Chemical compound C1CCCNCCC1 QXNDZONIWRINJR-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229960005149 bendazac Drugs 0.000 description 1
- BYFMCKSPFYVMOU-UHFFFAOYSA-N bendazac Chemical compound C12=CC=CC=C2C(OCC(=O)O)=NN1CC1=CC=CC=C1 BYFMCKSPFYVMOU-UHFFFAOYSA-N 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- MXMZCLLIUQEKSN-UHFFFAOYSA-N benzimidazoline Chemical compound C1=CC=C2NCNC2=C1 MXMZCLLIUQEKSN-UHFFFAOYSA-N 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- VOIFKEWOFUNPBN-QIUUJYRFSA-N beta-D-glucuronamide Chemical compound NC(=O)[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O VOIFKEWOFUNPBN-QIUUJYRFSA-N 0.000 description 1
- VQODGRNSFPNSQE-DVTGEIKXSA-N betamethasone phosphate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COP(O)(O)=O)(O)[C@@]1(C)C[C@@H]2O VQODGRNSFPNSQE-DVTGEIKXSA-N 0.000 description 1
- 229950006991 betamethasone phosphate Drugs 0.000 description 1
- GPRLTFBKWDERLU-UHFFFAOYSA-N bicyclo[2.2.2]octane Chemical compound C1CC2CCC1CC2 GPRLTFBKWDERLU-UHFFFAOYSA-N 0.000 description 1
- SHOMMGQAMRXRRK-UHFFFAOYSA-N bicyclo[3.1.1]heptane Chemical compound C1C2CC1CCC2 SHOMMGQAMRXRRK-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 125000002529 biphenylenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C12)* 0.000 description 1
- 229930189065 blasticidin Natural products 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 235000019835 bromelain Nutrition 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 229960004272 bucillamine Drugs 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- GRADOOOISCPIDG-UHFFFAOYSA-N buta-1,3-diyne Chemical group [C]#CC#C GRADOOOISCPIDG-UHFFFAOYSA-N 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 229940105847 calamine Drugs 0.000 description 1
- LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 1
- 229960002882 calcipotriol Drugs 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- RAYXYZDUQHIPIH-UHFFFAOYSA-N carbonic acid;furan Chemical compound OC(O)=O.C=1C=COC=1 RAYXYZDUQHIPIH-UHFFFAOYSA-N 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 229960003184 carprofen Drugs 0.000 description 1
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 1
- RZMKWKZIJJNSLQ-UHFFFAOYSA-M carpronium chloride Chemical compound [Cl-].COC(=O)CCC[N+](C)(C)C RZMKWKZIJJNSLQ-UHFFFAOYSA-M 0.000 description 1
- 229950003631 carpronium chloride Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 229960001242 cefotiam Drugs 0.000 description 1
- LTINZAODLRIQIX-FBXRGJNPSA-N cefpodoxime proxetil Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(=O)OC(C)OC(=O)OC(C)C)C(=O)C(=N/OC)\C1=CSC(N)=N1 LTINZAODLRIQIX-FBXRGJNPSA-N 0.000 description 1
- 229960004797 cefpodoxime proxetil Drugs 0.000 description 1
- 229960002620 cefuroxime axetil Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 150000001782 cephems Chemical class 0.000 description 1
- 229960004342 cetirizine hydrochloride Drugs 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- XMEVHPAGJVLHIG-FMZCEJRJSA-N chembl454950 Chemical compound [Cl-].C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H]([NH+](C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O XMEVHPAGJVLHIG-FMZCEJRJSA-N 0.000 description 1
- CFBUZOUXXHZCFB-OYOVHJISSA-N chembl511115 Chemical compound COC1=CC=C([C@@]2(CC[C@H](CC2)C(O)=O)C#N)C=C1OC1CCCC1 CFBUZOUXXHZCFB-OYOVHJISSA-N 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- SFHUSLFRIKHKPE-UHFFFAOYSA-L chloro-[(2,5-dioxoimidazolidin-4-yl)carbamoylamino]aluminum;hydrate Chemical compound O.NC(=O)NC1NC(=O)N([Al]Cl)C1=O SFHUSLFRIKHKPE-UHFFFAOYSA-L 0.000 description 1
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical compound C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 description 1
- 229960003728 ciclesonide Drugs 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- GPUVGQIASQNZET-CCEZHUSRSA-N cinnoxicam Chemical compound C=1C=CC=CC=1/C=C/C(=O)OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 GPUVGQIASQNZET-CCEZHUSRSA-N 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 229960002689 clemastine fumarate Drugs 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229960001146 clobetasone Drugs 0.000 description 1
- 229960005465 clobetasone butyrate Drugs 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
- 229960001127 colistin sulfate Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002769 corticotropin releasing factor antagonist Substances 0.000 description 1
- RYJIRNNXCHOUTQ-OJJGEMKLSA-L cortisol sodium phosphate Chemical compound [Na+].[Na+].O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP([O-])([O-])=O)[C@@H]4[C@@H]3CCC2=C1 RYJIRNNXCHOUTQ-OJJGEMKLSA-L 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- 150000001925 cycloalkenes Chemical class 0.000 description 1
- 125000000000 cycloalkoxy group Chemical group 0.000 description 1
- LMGZGXSXHCMSAA-UHFFFAOYSA-N cyclodecane Chemical compound C1CCCCCCCCC1 LMGZGXSXHCMSAA-UHFFFAOYSA-N 0.000 description 1
- DDTBPAQBQHZRDW-UHFFFAOYSA-N cyclododecane Chemical compound C1CCCCCCCCCCC1 DDTBPAQBQHZRDW-UHFFFAOYSA-N 0.000 description 1
- ZXIJMRYMVAMXQP-UHFFFAOYSA-N cycloheptene Chemical compound C1CCC=CCC1 ZXIJMRYMVAMXQP-UHFFFAOYSA-N 0.000 description 1
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 description 1
- GPTJTTCOVDDHER-UHFFFAOYSA-N cyclononane Chemical compound C1CCCCCCCC1 GPTJTTCOVDDHER-UHFFFAOYSA-N 0.000 description 1
- WJTCGQSWYFHTAC-UHFFFAOYSA-N cyclooctane Chemical compound C1CCCCCCC1 WJTCGQSWYFHTAC-UHFFFAOYSA-N 0.000 description 1
- 239000004914 cyclooctane Substances 0.000 description 1
- URYYVOIYTNXXBN-UPHRSURJSA-N cyclooctene Chemical compound C1CCC\C=C/CC1 URYYVOIYTNXXBN-UPHRSURJSA-N 0.000 description 1
- 239000004913 cyclooctene Substances 0.000 description 1
- KFGVRWGDTLZAAO-UHFFFAOYSA-N cyclopenta-1,3-diene dicyclohexyl(cyclopenta-1,3-dien-1-yl)phosphane iron(2+) Chemical compound [Fe++].c1cc[cH-]c1.C1CCC(CC1)P(C1CCCCC1)c1ccc[cH-]1 KFGVRWGDTLZAAO-UHFFFAOYSA-N 0.000 description 1
- SRONXYPFSAKOGH-UHFFFAOYSA-N cyclopentadecane Chemical group C1CCCCCCCCCCCCCC1 SRONXYPFSAKOGH-UHFFFAOYSA-N 0.000 description 1
- NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- KATXJJSCAPBIOB-UHFFFAOYSA-N cyclotetradecane Chemical compound C1CCCCCCCCCCCCC1 KATXJJSCAPBIOB-UHFFFAOYSA-N 0.000 description 1
- UEVXKGPJXXDGCX-UHFFFAOYSA-N cyclotridecane Chemical compound C1CCCCCCCCCCCC1 UEVXKGPJXXDGCX-UHFFFAOYSA-N 0.000 description 1
- KYTNZWVKKKJXFS-UHFFFAOYSA-N cycloundecane Chemical compound C1CCCCCCCCCC1 KYTNZWVKKKJXFS-UHFFFAOYSA-N 0.000 description 1
- MTZXHKAPOZYPCQ-NHVFNMKISA-N d05511 Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1.OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1.OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO.OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO.OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO.OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO.OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO MTZXHKAPOZYPCQ-NHVFNMKISA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000013527 degreasing agent Substances 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229950000812 dexamethasone palmitate Drugs 0.000 description 1
- 229960002344 dexamethasone sodium phosphate Drugs 0.000 description 1
- 229950006825 dexamethasone valerate Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- QPMLSUSACCOBDK-UHFFFAOYSA-N diazepane Chemical compound C1CCNNCC1 QPMLSUSACCOBDK-UHFFFAOYSA-N 0.000 description 1
- HTFFABIIOAKIBH-UHFFFAOYSA-N diazinane Chemical compound C1CCNNC1 HTFFABIIOAKIBH-UHFFFAOYSA-N 0.000 description 1
- MIOUTPXNKVBIFR-UHFFFAOYSA-J dicalcium 2-hydroxyacetate Chemical compound C(CO)(=O)[O-].[Ca+2].[Ca+2].C(CO)(=O)[O-].C(CO)(=O)[O-].C(CO)(=O)[O-] MIOUTPXNKVBIFR-UHFFFAOYSA-J 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- PWHROYKAGRUWDQ-UHFFFAOYSA-N difenpiramide Chemical compound C=1C=CC=NC=1NC(=O)CC(C=C1)=CC=C1C1=CC=CC=C1 PWHROYKAGRUWDQ-UHFFFAOYSA-N 0.000 description 1
- 229960001536 difenpiramide Drugs 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 1
- 229940043276 diisopropanolamine Drugs 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- BADXJIPKFRBFOT-UHFFFAOYSA-N dimedone Chemical compound CC1(C)CC(=O)CC(=O)C1 BADXJIPKFRBFOT-UHFFFAOYSA-N 0.000 description 1
- JGKVKXPDDVRUKC-UHFFFAOYSA-N dimethothiazine mesylate Chemical compound CS(O)(=O)=O.C1=C(S(=O)(=O)N(C)C)C=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 JGKVKXPDDVRUKC-UHFFFAOYSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- 229960004646 diphenhydramine tannate Drugs 0.000 description 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- OWQUZNMMYNAXSL-UHFFFAOYSA-N diphenylpyraline Chemical compound C1CN(C)CCC1OC(C=1C=CC=CC=1)C1=CC=CC=C1 OWQUZNMMYNAXSL-UHFFFAOYSA-N 0.000 description 1
- 229960000879 diphenylpyraline Drugs 0.000 description 1
- 229940120889 dipyrone Drugs 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 230000002554 disease preventive effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
- NWOYIVRVSJDTLK-YSDBFZIDSA-L disodium;(2s,5r,6r)-6-[[(2r)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate;(1r,4s)-3,3-dimethyl-2,2,6-trioxo-2$l^{6}-thiabicyclo[3.2.0]heptane-4-carboxylate Chemical compound [Na+].[Na+].O=S1(=O)C(C)(C)[C@H](C([O-])=O)C2C(=O)C[C@H]21.C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C([O-])=O)(C)C)=CC=CC=C1 NWOYIVRVSJDTLK-YSDBFZIDSA-L 0.000 description 1
- MOGICMVNWAUWMK-HIXRZVNASA-L disodium;(5r,6s)-6-[(1r)-1-hydroxyethyl]-7-oxo-3-[(2r)-oxolan-2-yl]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate;pentahydrate Chemical compound O.O.O.O.O.[Na+].[Na+].S([C@@H]1[C@H](C(N1C=1C([O-])=O)=O)[C@H](O)C)C=1[C@H]1CCCO1.S([C@@H]1[C@H](C(N1C=1C([O-])=O)=O)[C@H](O)C)C=1[C@H]1CCCO1 MOGICMVNWAUWMK-HIXRZVNASA-L 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960004082 doxycycline hydrochloride Drugs 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- KYFWUBJMTHVBIF-QFIPXVFZSA-N dsstox_cid_27248 Chemical compound N([C@@H]1N=C(C=2C=3N(C1=O)CCC=3C=C(C=2)C)C=1C=CC=CC=1)C(=O)C1=CC=NC=C1 KYFWUBJMTHVBIF-QFIPXVFZSA-N 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 229960001971 ebastine Drugs 0.000 description 1
- MJJALKDDGIKVBE-UHFFFAOYSA-N ebastine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)CCCN1CCC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 MJJALKDDGIKVBE-UHFFFAOYSA-N 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 239000012156 elution solvent Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 239000003248 enzyme activator Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- DXIDZJKAMMFMDK-XIFFEERXSA-N ethyl (2S)-2-[[butyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]carbamoyl]oxy-ethylamino]-3-(4-hydroxyphenyl)-2-methylpropanoate Chemical compound C(CCC)N(C(=O)ON([C@@](CC1=CC=C(C=C1)O)(C(=O)OCC)C)CC)CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1 DXIDZJKAMMFMDK-XIFFEERXSA-N 0.000 description 1
- QJIQPLMVMPPAAL-UHFFFAOYSA-N ethyl 2-[[butyl-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]carbamoyl]amino]-4-nitrobenzoate Chemical compound C=1C([N+]([O-])=O)=CC=C(C(=O)OCC)C=1NC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 QJIQPLMVMPPAAL-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- HQMNCQVAMBCHCO-DJRRULDNSA-N etretinate Chemical compound CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=C(OC)C(C)=C1C HQMNCQVAMBCHCO-DJRRULDNSA-N 0.000 description 1
- 229960002199 etretinate Drugs 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 229960000379 faropenem Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229960000192 felbinac Drugs 0.000 description 1
- 229960001395 fenbufen Drugs 0.000 description 1
- ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 1
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 description 1
- 239000011714 flavin adenine dinucleotide Substances 0.000 description 1
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 description 1
- SYWHXTATXSMDSB-GSLJADNHSA-N fludrocortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O SYWHXTATXSMDSB-GSLJADNHSA-N 0.000 description 1
- 229960004369 flufenamic acid Drugs 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- ARPYQKTVRGFPIS-VIFPVBQESA-N flunoxaprofen Chemical compound N=1C2=CC([C@@H](C(O)=O)C)=CC=C2OC=1C1=CC=C(F)C=C1 ARPYQKTVRGFPIS-VIFPVBQESA-N 0.000 description 1
- 229960001321 flunoxaprofen Drugs 0.000 description 1
- RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 229960003336 fluorocortisol acetate Drugs 0.000 description 1
- 229950005941 flurbiprofen axetil Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229960000289 fluticasone propionate Drugs 0.000 description 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- VPSRLGDRGCKUTK-UHFFFAOYSA-N fura-2-acetoxymethyl ester Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC(C(=C1)N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=CC2=C1OC(C=1OC(=CN=1)C(=O)OCOC(C)=O)=C2 VPSRLGDRGCKUTK-UHFFFAOYSA-N 0.000 description 1
- 150000002244 furazanes Chemical class 0.000 description 1
- 229960004675 fusidic acid Drugs 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229950002441 glucurolactone Drugs 0.000 description 1
- 229950004542 glucuronamide Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- AZMMUMQYPBKXHS-UHFFFAOYSA-N gold sodium Chemical compound [Na].[Au] AZMMUMQYPBKXHS-UHFFFAOYSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 229910052864 hemimorphite Inorganic materials 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 239000002628 heparin derivative Substances 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- POOYFSLWYLDQMD-UHFFFAOYSA-N heptacalcium;zinc Chemical compound [Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Zn+2] POOYFSLWYLDQMD-UHFFFAOYSA-N 0.000 description 1
- DDTGNKBZWQHIEH-UHFFFAOYSA-N heptalene Chemical compound C1=CC=CC=C2C=CC=CC=C21 DDTGNKBZWQHIEH-UHFFFAOYSA-N 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005446 heptyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- BNRNAKTVFSZAFA-UHFFFAOYSA-N hydrindane Chemical compound C1CCCC2CCCC21 BNRNAKTVFSZAFA-UHFFFAOYSA-N 0.000 description 1
- 229960004204 hydrocortisone sodium phosphate Drugs 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000000640 hydroxylating effect Effects 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 1
- 229960003220 hydroxyzine hydrochloride Drugs 0.000 description 1
- 229960001560 hydroxyzine pamoate Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 238000012760 immunocytochemical staining Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 229940041682 inhalant solution Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical compound C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- XJSFLOJWULLJQS-NGVXBBESSA-N josamycin Chemical compound CO[C@H]1[C@H](OC(C)=O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]2O[C@@H](C)[C@H](OC(=O)CC(C)C)[C@](C)(O)C2)[C@@H](C)O1 XJSFLOJWULLJQS-NGVXBBESSA-N 0.000 description 1
- 229960004144 josamycin Drugs 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229960000194 kebuzone Drugs 0.000 description 1
- LGYTZKPVOAIUKX-UHFFFAOYSA-N kebuzone Chemical compound O=C1C(CCC(=O)C)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 LGYTZKPVOAIUKX-UHFFFAOYSA-N 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- YNQQEYBLVYAWNX-WLHGVMLRSA-N ketotifen fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 YNQQEYBLVYAWNX-WLHGVMLRSA-N 0.000 description 1
- 229960003630 ketotifen fumarate Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- 229950005831 lenampicillin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 208000002741 leukoplakia Diseases 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 229960003814 lomefloxacin hydrochloride Drugs 0.000 description 1
- 229960003088 loratadine Drugs 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 229960002202 lornoxicam Drugs 0.000 description 1
- OXROWJKCGCOJDO-JLHYYAGUSA-N lornoxicam Chemical compound O=C1C=2SC(Cl)=CC=2S(=O)(=O)N(C)\C1=C(\O)NC1=CC=CC=N1 OXROWJKCGCOJDO-JLHYYAGUSA-N 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229950006319 maxacalcitol Drugs 0.000 description 1
- AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940075473 medical gases Drugs 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- 229960005042 mequitazine Drugs 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- 229940126170 metalloproteinase inhibitor Drugs 0.000 description 1
- DJGAAPFSPWAYTJ-UHFFFAOYSA-M metamizole sodium Chemical compound [Na+].O=C1C(N(CS([O-])(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 DJGAAPFSPWAYTJ-UHFFFAOYSA-M 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 108010086335 methionine stromal cell-derived factor-1beta Proteins 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- IHNIAWHITVGYJJ-UHFFFAOYSA-N methyl 2-(4-methylphenyl)benzoate Chemical compound COC(=O)C1=CC=CC=C1C1=CC=C(C)C=C1 IHNIAWHITVGYJJ-UHFFFAOYSA-N 0.000 description 1
- OHHITJYTTZWFBQ-UHFFFAOYSA-N methyl 2-[4-(aminomethyl)phenyl]benzoate;hydrochloride Chemical compound Cl.COC(=O)C1=CC=CC=C1C1=CC=C(CN)C=C1 OHHITJYTTZWFBQ-UHFFFAOYSA-N 0.000 description 1
- RMXGTMRDXKUUDJ-UHFFFAOYSA-N methyl 2-[4-(bromomethyl)phenyl]benzoate Chemical compound COC(=O)C1=CC=CC=C1C1=CC=C(CBr)C=C1 RMXGTMRDXKUUDJ-UHFFFAOYSA-N 0.000 description 1
- HCRFHWQUDDECED-UHFFFAOYSA-N methyl 2-[4-(hydroxymethyl)phenyl]benzoate Chemical compound COC(=O)C1=CC=CC=C1C1=CC=C(CO)C=C1 HCRFHWQUDDECED-UHFFFAOYSA-N 0.000 description 1
- ZRAYQYYGRUJUBO-UHFFFAOYSA-N methyl 2-[4-[[benzyl(pentanoyl)amino]methyl]phenyl]benzoate Chemical compound C=1C=C(C=2C(=CC=CC=2)C(=O)OC)C=CC=1CN(C(=O)CCCC)CC1=CC=CC=C1 ZRAYQYYGRUJUBO-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- DWCZIOOZPIDHAB-UHFFFAOYSA-L methyl green Chemical compound [Cl-].[Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC(=CC=1)[N+](C)(C)C)=C1C=CC(=[N+](C)C)C=C1 DWCZIOOZPIDHAB-UHFFFAOYSA-L 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229960002421 minocycline hydrochloride Drugs 0.000 description 1
- 229950007856 mofetil Drugs 0.000 description 1
- 229960000429 mofezolac Drugs 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 208000008588 molluscum contagiosum Diseases 0.000 description 1
- 229960002744 mometasone furoate Drugs 0.000 description 1
- 229940126403 monoamine reuptake inhibitor Drugs 0.000 description 1
- 239000000472 muscarinic agonist Substances 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- NPGREARFJMFTDF-UHFFFAOYSA-N n-(3,5-dichloro-1-hydroxypyridin-4-ylidene)-8-methoxy-2-(trifluoromethyl)quinoline-5-carboxamide Chemical compound C12=CC=C(C(F)(F)F)N=C2C(OC)=CC=C1C(=O)N=C1C(Cl)=CN(O)C=C1Cl NPGREARFJMFTDF-UHFFFAOYSA-N 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- ZESIAEVDVPWEKB-ORCFLVBFSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O ZESIAEVDVPWEKB-ORCFLVBFSA-N 0.000 description 1
- YDTNDBLWQKZYMO-UHFFFAOYSA-N n-butyl-n-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]-3,4-dihydro-2h-quinoline-1-carboxamide Chemical compound C1CCC2=CC=CC=C2N1C(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 YDTNDBLWQKZYMO-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 229960003808 nadifloxacin Drugs 0.000 description 1
- JYJTVFIEFKZWCJ-UHFFFAOYSA-N nadifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)CCC3=C1N1CCC(O)CC1 JYJTVFIEFKZWCJ-UHFFFAOYSA-N 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 230000007383 nerve stimulation Effects 0.000 description 1
- 230000001703 neuroimmune Effects 0.000 description 1
- 239000002742 neurokinin 1 receptor antagonist Substances 0.000 description 1
- PCJGZPGTCUMMOT-ISULXFBGSA-N neurotensin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 PCJGZPGTCUMMOT-ISULXFBGSA-N 0.000 description 1
- 239000004082 neurotensin receptor antagonist Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- JFNLZVQOOSMTJK-KNVOCYPGSA-N norbornene Chemical compound C1[C@@H]2CC[C@H]1C=C2 JFNLZVQOOSMTJK-KNVOCYPGSA-N 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005447 octyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000005069 octynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 229940060184 oil ingredients Drugs 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- OTLYTKRAADUASA-UHFFFAOYSA-N oxadiazepane Chemical compound C1CCONNC1 OTLYTKRAADUASA-UHFFFAOYSA-N 0.000 description 1
- RYDICHIKLKVOEJ-UHFFFAOYSA-N oxadiazepine Chemical compound O1C=CC=CN=N1 RYDICHIKLKVOEJ-UHFFFAOYSA-N 0.000 description 1
- XCRJTRCPEJKXLR-UHFFFAOYSA-N oxadiazinane Chemical compound C1CNNOC1 XCRJTRCPEJKXLR-UHFFFAOYSA-N 0.000 description 1
- IVMHDOBGNQOUHO-UHFFFAOYSA-N oxathiane Chemical compound C1CCSOC1 IVMHDOBGNQOUHO-UHFFFAOYSA-N 0.000 description 1
- AQNQGBUEVCAVML-UHFFFAOYSA-N oxazepane Chemical compound C1CCNOCC1 AQNQGBUEVCAVML-UHFFFAOYSA-N 0.000 description 1
- SFJGCXYXEFWEBK-UHFFFAOYSA-N oxazepine Chemical compound O1C=CC=CC=N1 SFJGCXYXEFWEBK-UHFFFAOYSA-N 0.000 description 1
- UHHKSVZZTYJVEG-UHFFFAOYSA-N oxepane Chemical compound C1CCCOCC1 UHHKSVZZTYJVEG-UHFFFAOYSA-N 0.000 description 1
- ATYBXHSAIOKLMG-UHFFFAOYSA-N oxepin Chemical compound O1C=CC=CC=C1 ATYBXHSAIOKLMG-UHFFFAOYSA-N 0.000 description 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229960000649 oxyphenbutazone Drugs 0.000 description 1
- HFHZKZSRXITVMK-UHFFFAOYSA-N oxyphenbutazone Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 HFHZKZSRXITVMK-UHFFFAOYSA-N 0.000 description 1
- 229960004368 oxytetracycline hydrochloride Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- DJWYOLJPSHDSAL-ROUUACIJSA-N pantethine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO DJWYOLJPSHDSAL-ROUUACIJSA-N 0.000 description 1
- 229960000903 pantethine Drugs 0.000 description 1
- 235000008975 pantethine Nutrition 0.000 description 1
- 239000011581 pantethine Substances 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001769 paralizing effect Effects 0.000 description 1
- 229960000865 paramethasone acetate Drugs 0.000 description 1
- 208000022196 parasitic skin disease Diseases 0.000 description 1
- 210000005037 parasympathetic nerve Anatomy 0.000 description 1
- 239000000734 parasympathomimetic agent Substances 0.000 description 1
- 229940127242 parasympathomimetic drug Drugs 0.000 description 1
- DXHYQIJBUNRPJT-UHFFFAOYSA-N parsalmide Chemical compound CCCCNC(=O)C1=CC(N)=CC=C1OCC#C DXHYQIJBUNRPJT-UHFFFAOYSA-N 0.000 description 1
- HHXMXAQDOUCLDN-RXMQYKEDSA-N penem Chemical compound S1C=CN2C(=O)C[C@H]21 HHXMXAQDOUCLDN-RXMQYKEDSA-N 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- GUVXZFRDPCKWEM-UHFFFAOYSA-N pentalene Chemical compound C1=CC2=CC=CC2=C1 GUVXZFRDPCKWEM-UHFFFAOYSA-N 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 125000005327 perimidinyl group Chemical group N1C(=NC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 229960003893 phenacetin Drugs 0.000 description 1
- XDJOIMJURHQYDW-UHFFFAOYSA-N phenalene Chemical compound C1=CC(CC=C2)=C3C2=CC=CC3=C1 XDJOIMJURHQYDW-UHFFFAOYSA-N 0.000 description 1
- GJSGGHOYGKMUPT-UHFFFAOYSA-N phenoxathiine Chemical compound C1=CC=C2OC3=CC=CC=C3SC2=C1 GJSGGHOYGKMUPT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- SFLGSKRGOWRGBR-UHFFFAOYSA-N phthalane Chemical compound C1=CC=C2COCC2=C1 SFLGSKRGOWRGBR-UHFFFAOYSA-N 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 125000005633 phthalidyl group Chemical group 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- LYKMMUBOEFYJQG-UHFFFAOYSA-N piperoxan Chemical compound C1OC2=CC=CC=C2OC1CN1CCCCC1 LYKMMUBOEFYJQG-UHFFFAOYSA-N 0.000 description 1
- 229960001369 piroxicam cinnamate Drugs 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229940072033 potash Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- ZUFQCVZBBNZMKD-UHFFFAOYSA-M potassium 2-ethylhexanoate Chemical compound [K+].CCCCC(CC)C([O-])=O ZUFQCVZBBNZMKD-UHFFFAOYSA-M 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- CHWRSCGUEQEHOH-UHFFFAOYSA-N potassium oxide Chemical compound [O-2].[K+].[K+] CHWRSCGUEQEHOH-UHFFFAOYSA-N 0.000 description 1
- 229910001950 potassium oxide Inorganic materials 0.000 description 1
- 229960002943 prednisolone sodium phosphate Drugs 0.000 description 1
- VJZLQIPZNBPASX-OJJGEMKLSA-L prednisolone sodium phosphate Chemical compound [Na+].[Na+].O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP([O-])([O-])=O)[C@@H]4[C@@H]3CCC2=C1 VJZLQIPZNBPASX-OJJGEMKLSA-L 0.000 description 1
- FKKAEMQFOIDZNY-CODXZCKSSA-M prednisolone sodium succinate Chemical compound [Na+].O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COC(=O)CCC([O-])=O)[C@@H]4[C@@H]3CCC2=C1 FKKAEMQFOIDZNY-CODXZCKSSA-M 0.000 description 1
- 229960002176 prednisolone sodium succinate Drugs 0.000 description 1
- APGDTXUMTIZLCJ-CGVGKPPMSA-N prednisolone succinate Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COC(=O)CCC(O)=O)[C@@H]4[C@@H]3CCC2=C1 APGDTXUMTIZLCJ-CGVGKPPMSA-N 0.000 description 1
- 229950004597 prednisolone succinate Drugs 0.000 description 1
- 229960004259 prednisolone tebutate Drugs 0.000 description 1
- DGYSDXLCLKPUBR-SLPNHVECSA-N prednisolone valerate acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(C)=O)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O DGYSDXLCLKPUBR-SLPNHVECSA-N 0.000 description 1
- 229950008480 prednisolone valerate acetate Drugs 0.000 description 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
- 229960003912 probucol Drugs 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- XXPDBLUZJRXNNZ-UHFFFAOYSA-N promethazine hydrochloride Chemical compound Cl.C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 XXPDBLUZJRXNNZ-UHFFFAOYSA-N 0.000 description 1
- 229960002244 promethazine hydrochloride Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 229940043274 prophylactic drug Drugs 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 230000001185 psoriatic effect Effects 0.000 description 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- QBERHIJABFXGRZ-UHFFFAOYSA-M rhodium;triphenylphosphane;chloride Chemical compound [Cl-].[Rh].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 QBERHIJABFXGRZ-UHFFFAOYSA-M 0.000 description 1
- 229950001574 riboflavin phosphate Drugs 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 description 1
- 229960002586 roflumilast Drugs 0.000 description 1
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 1
- 229950005741 rolipram Drugs 0.000 description 1
- 229960005224 roxithromycin Drugs 0.000 description 1
- WEMQMWWWCBYPOV-UHFFFAOYSA-N s-indacene Chemical compound C=1C2=CC=CC2=CC2=CC=CC2=1 WEMQMWWWCBYPOV-UHFFFAOYSA-N 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 1
- 239000003523 serotonin 4 antagonist Substances 0.000 description 1
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 description 1
- 239000000387 serotonin 5-HT4 receptor agonist Substances 0.000 description 1
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 description 1
- 239000000952 serotonin receptor agonist Substances 0.000 description 1
- 229950000112 serrapeptase Drugs 0.000 description 1
- 108010038132 serratiopeptidase Proteins 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- DZDQZIGQNZVJPV-VFGMFICWSA-M sodium 4-[4-[[[(1S,2R,5S)-6,6-dimethyl-2-bicyclo[3.1.1]heptanyl]methyl-(4-methoxybenzoyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(OC)=CC=C1C(=O)N(CC=1C=CC(=CC=1)C=1C=CC(=CC=1)C([O-])=O)C[C@H]1[C@@H](C2(C)C)C[C@@H]2CC1 DZDQZIGQNZVJPV-VFGMFICWSA-M 0.000 description 1
- XZODNSZQERGLIK-OUKLVGRUSA-M sodium 4-[4-[[[(1S,2R,5S)-6,6-dimethyl-2-bicyclo[3.1.1]heptanyl]methyl-pentanoylamino]methyl]phenyl]benzoate Chemical compound [Na+].C([C@H]1[C@@H]2C[C@@H](C2(C)C)CC1)N(C(=O)CCCC)CC(C=C1)=CC=C1C1=CC=C(C([O-])=O)C=C1 XZODNSZQERGLIK-OUKLVGRUSA-M 0.000 description 1
- FNDCVDQAPCLSSB-JCVJZEPNSA-M sodium 4-[4-[[cyclopentanecarbonyl-[[(1S,2R,5S)-6,6-dimethyl-2-bicyclo[3.1.1]heptanyl]methyl]amino]methyl]phenyl]benzoate Chemical compound [Na+].C([C@H]1[C@@H]2C[C@H](CC1)C2(C)C)N(C(=O)C1CCCC1)CC(C=C1)=CC=C1C1=CC=C(C([O-])=O)C=C1 FNDCVDQAPCLSSB-JCVJZEPNSA-M 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- 229940074404 sodium succinate Drugs 0.000 description 1
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- HJHVQCXHVMGZNC-JCJNLNMISA-M sodium;(2z)-2-[(3r,4s,5s,8s,9s,10s,11r,13r,14s,16s)-16-acetyloxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-17-ylidene]-6-methylhept-5-enoate Chemical compound [Na+].O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C([O-])=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C HJHVQCXHVMGZNC-JCJNLNMISA-M 0.000 description 1
- DOZOPSLNCNXCNU-UHFFFAOYSA-M sodium;2-[2-[(n-(4-chlorobenzoyl)anilino)methyl]phenyl]benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1C1=CC=CC=C1CN(C=1C=CC=CC=1)C(=O)C1=CC=C(Cl)C=C1 DOZOPSLNCNXCNU-UHFFFAOYSA-M 0.000 description 1
- ICVAGEPSSOEGIU-UHFFFAOYSA-M sodium;2-[2-[[(2-phenylacetyl)-(3-phenylpropyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1C1=CC=CC=C1CN(C(=O)CC=1C=CC=CC=1)CCCC1=CC=CC=C1 ICVAGEPSSOEGIU-UHFFFAOYSA-M 0.000 description 1
- SDXNLHDLHJHBEF-UHFFFAOYSA-M sodium;2-[2-[[(4-chlorobenzoyl)-(3-phenylpropyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1C1=CC=CC=C1CN(C(=O)C=1C=CC(Cl)=CC=1)CCCC1=CC=CC=C1 SDXNLHDLHJHBEF-UHFFFAOYSA-M 0.000 description 1
- ZJWSOEPJXDCINV-UHFFFAOYSA-M sodium;2-[2-[[(4-chlorobenzoyl)-heptan-4-ylamino]methyl]phenyl]benzoate Chemical compound [Na+].C=1C=C(Cl)C=CC=1C(=O)N(C(CCC)CCC)CC1=CC=CC=C1C1=CC=CC=C1C([O-])=O ZJWSOEPJXDCINV-UHFFFAOYSA-M 0.000 description 1
- UAWFWHBPAVGFTI-UHFFFAOYSA-M sodium;2-[2-[[(4-methoxybenzoyl)-(3-phenylpropyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(OC)=CC=C1C(=O)N(CC=1C(=CC=CC=1)C=1C(=CC=CC=1)C([O-])=O)CCCC1=CC=CC=C1 UAWFWHBPAVGFTI-UHFFFAOYSA-M 0.000 description 1
- GAWVCZLGKQWQAT-UHFFFAOYSA-M sodium;2-[2-[[2-phenylethyl(3-phenylpropanoyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1C1=CC=CC=C1CN(C(=O)CCC=1C=CC=CC=1)CCC1=CC=CC=C1 GAWVCZLGKQWQAT-UHFFFAOYSA-M 0.000 description 1
- VVGPPHWFPYYGPQ-UHFFFAOYSA-M sodium;2-[2-[[3-phenylpropanoyl(3-phenylpropyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1C1=CC=CC=C1CN(C(=O)CCC=1C=CC=CC=1)CCCC1=CC=CC=C1 VVGPPHWFPYYGPQ-UHFFFAOYSA-M 0.000 description 1
- GEQJMINZRKCRPI-UHFFFAOYSA-M sodium;2-[2-[[benzyl-(2-phenylacetyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1C1=CC=CC=C1CN(C(=O)CC=1C=CC=CC=1)CC1=CC=CC=C1 GEQJMINZRKCRPI-UHFFFAOYSA-M 0.000 description 1
- NPULVZXNNSGOQW-UHFFFAOYSA-M sodium;2-[2-[[heptan-4-yl(3-phenylpropanoyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C=1C=CC=CC=1CCC(=O)N(C(CCC)CCC)CC1=CC=CC=C1C1=CC=CC=C1C([O-])=O NPULVZXNNSGOQW-UHFFFAOYSA-M 0.000 description 1
- DHFRPTLPJUVNCU-UHFFFAOYSA-M sodium;2-[2-[[n-(3-phenylpropanoyl)anilino]methyl]phenyl]benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1C1=CC=CC=C1CN(C=1C=CC=CC=1)C(=O)CCC1=CC=CC=C1 DHFRPTLPJUVNCU-UHFFFAOYSA-M 0.000 description 1
- YUZHNKYPBOXLKX-UHFFFAOYSA-M sodium;2-[3-[(n-(2-phenylacetyl)anilino)methyl]phenyl]benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1C1=CC=CC(CN(C(=O)CC=2C=CC=CC=2)C=2C=CC=CC=2)=C1 YUZHNKYPBOXLKX-UHFFFAOYSA-M 0.000 description 1
- VYPDUQYOLCLEGS-UHFFFAOYSA-M sodium;2-ethylhexanoate Chemical compound [Na+].CCCCC(CC)C([O-])=O VYPDUQYOLCLEGS-UHFFFAOYSA-M 0.000 description 1
- KFQKMWJWANIVIB-UHFFFAOYSA-M sodium;3-[3-[(n-(4-chlorobenzoyl)anilino)methyl]phenyl]benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC(C=2C=C(CN(C(=O)C=3C=CC(Cl)=CC=3)C=3C=CC=CC=3)C=CC=2)=C1 KFQKMWJWANIVIB-UHFFFAOYSA-M 0.000 description 1
- ZIFMLRFJFTZAFM-UHFFFAOYSA-M sodium;3-[3-[(n-(4-methoxybenzoyl)anilino)methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(OC)=CC=C1C(=O)N(C=1C=CC=CC=1)CC1=CC=CC(C=2C=C(C=CC=2)C([O-])=O)=C1 ZIFMLRFJFTZAFM-UHFFFAOYSA-M 0.000 description 1
- KTZZAPBDUAYMTO-UHFFFAOYSA-M sodium;3-[3-[[(4-chlorobenzoyl)-(2-phenylethyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC(C=2C=C(CN(CCC=3C=CC=CC=3)C(=O)C=3C=CC(Cl)=CC=3)C=CC=2)=C1 KTZZAPBDUAYMTO-UHFFFAOYSA-M 0.000 description 1
- DXRWDPPQMJFQFY-UHFFFAOYSA-M sodium;3-[3-[[(4-chlorobenzoyl)-heptan-4-ylamino]methyl]phenyl]benzoate Chemical compound [Na+].C=1C=C(Cl)C=CC=1C(=O)N(C(CCC)CCC)CC(C=1)=CC=CC=1C1=CC=CC(C([O-])=O)=C1 DXRWDPPQMJFQFY-UHFFFAOYSA-M 0.000 description 1
- KHCLTYBPOCIPHE-UHFFFAOYSA-M sodium;3-[3-[[(4-methoxybenzoyl)-(4-phenylbutyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(OC)=CC=C1C(=O)N(CC=1C=C(C=CC=1)C=1C=C(C=CC=1)C([O-])=O)CCCCC1=CC=CC=C1 KHCLTYBPOCIPHE-UHFFFAOYSA-M 0.000 description 1
- LESOVJYQZKRPBC-UHFFFAOYSA-M sodium;3-[3-[[2-phenylethyl(3-phenylpropanoyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC(C=2C=C(CN(CCC=3C=CC=CC=3)C(=O)CCC=3C=CC=CC=3)C=CC=2)=C1 LESOVJYQZKRPBC-UHFFFAOYSA-M 0.000 description 1
- JKIQWLJVUPNYAC-UHFFFAOYSA-M sodium;3-[3-[[3-phenylpropanoyl(3-phenylpropyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC(C=2C=C(CN(CCCC=3C=CC=CC=3)C(=O)CCC=3C=CC=CC=3)C=CC=2)=C1 JKIQWLJVUPNYAC-UHFFFAOYSA-M 0.000 description 1
- JXDLUXUDUPQFLX-UHFFFAOYSA-M sodium;3-[3-[[benzyl(3-phenylpropanoyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC(C=2C=C(CN(CC=3C=CC=CC=3)C(=O)CCC=3C=CC=CC=3)C=CC=2)=C1 JXDLUXUDUPQFLX-UHFFFAOYSA-M 0.000 description 1
- FVFIGZLXUQHPSC-UHFFFAOYSA-M sodium;3-[3-[[benzyl-(4-chlorobenzoyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC(C=2C=C(CN(CC=3C=CC=CC=3)C(=O)C=3C=CC(Cl)=CC=3)C=CC=2)=C1 FVFIGZLXUQHPSC-UHFFFAOYSA-M 0.000 description 1
- YANQFBCURKPYAU-UHFFFAOYSA-M sodium;3-[3-[[butyl(3-phenylpropanoyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C=1C=CC=CC=1CCC(=O)N(CCCC)CC(C=1)=CC=CC=1C1=CC=CC(C([O-])=O)=C1 YANQFBCURKPYAU-UHFFFAOYSA-M 0.000 description 1
- YBQFXXQZMTWXEC-UHFFFAOYSA-M sodium;3-[3-[[heptan-4-yl(3-phenylpropanoyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C=1C=CC=CC=1CCC(=O)N(C(CCC)CCC)CC(C=1)=CC=CC=1C1=CC=CC(C([O-])=O)=C1 YBQFXXQZMTWXEC-UHFFFAOYSA-M 0.000 description 1
- NDMPTGTXJABWOT-UHFFFAOYSA-M sodium;3-[3-[[heptan-4-yl-(2-phenylacetyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C=1C=CC=CC=1CC(=O)N(C(CCC)CCC)CC(C=1)=CC=CC=1C1=CC=CC(C([O-])=O)=C1 NDMPTGTXJABWOT-UHFFFAOYSA-M 0.000 description 1
- HTOYRHNYJROOTH-UHFFFAOYSA-M sodium;3-[3-[[n-(3-phenylpropanoyl)anilino]methyl]phenyl]benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC(C=2C=C(CN(C(=O)CCC=3C=CC=CC=3)C=3C=CC=CC=3)C=CC=2)=C1 HTOYRHNYJROOTH-UHFFFAOYSA-M 0.000 description 1
- FPVVBJSQCHPXMN-UHFFFAOYSA-M sodium;3-[3-[[pentanoyl(3-phenylpropyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C=1C=CC(C=2C=C(C=CC=2)C([O-])=O)=CC=1CN(C(=O)CCCC)CCCC1=CC=CC=C1 FPVVBJSQCHPXMN-UHFFFAOYSA-M 0.000 description 1
- PCOOCQPSMCUVMG-UHFFFAOYSA-M sodium;4-[3-[[(2-phenylacetyl)-(2-phenylethyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(C(=O)[O-])=CC=C1C1=CC=CC(CN(CCC=2C=CC=CC=2)C(=O)CC=2C=CC=CC=2)=C1 PCOOCQPSMCUVMG-UHFFFAOYSA-M 0.000 description 1
- MKSRIDMJKRFMEL-UHFFFAOYSA-M sodium;4-[3-[[(2-phenylacetyl)-(3-phenylpropyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(C(=O)[O-])=CC=C1C1=CC=CC(CN(CCCC=2C=CC=CC=2)C(=O)CC=2C=CC=CC=2)=C1 MKSRIDMJKRFMEL-UHFFFAOYSA-M 0.000 description 1
- BEPNMMPKARZBCK-UHFFFAOYSA-M sodium;4-[3-[[(4-chlorobenzoyl)-(2-phenylethyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(C(=O)[O-])=CC=C1C1=CC=CC(CN(CCC=2C=CC=CC=2)C(=O)C=2C=CC(Cl)=CC=2)=C1 BEPNMMPKARZBCK-UHFFFAOYSA-M 0.000 description 1
- FAKMOHWQPIWFBS-UHFFFAOYSA-M sodium;4-[3-[[(4-chlorobenzoyl)-(3-phenylpropyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(C(=O)[O-])=CC=C1C1=CC=CC(CN(CCCC=2C=CC=CC=2)C(=O)C=2C=CC(Cl)=CC=2)=C1 FAKMOHWQPIWFBS-UHFFFAOYSA-M 0.000 description 1
- NARFFMGCFNOHIB-UHFFFAOYSA-M sodium;4-[3-[[(4-methoxybenzoyl)-(3-phenylpropyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(OC)=CC=C1C(=O)N(CC=1C=C(C=CC=1)C=1C=CC(=CC=1)C([O-])=O)CCCC1=CC=CC=C1 NARFFMGCFNOHIB-UHFFFAOYSA-M 0.000 description 1
- CHTUOEPWLUGYLD-UHFFFAOYSA-M sodium;4-[3-[[2-phenylethyl(3-phenylpropanoyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(C(=O)[O-])=CC=C1C1=CC=CC(CN(CCC=2C=CC=CC=2)C(=O)CCC=2C=CC=CC=2)=C1 CHTUOEPWLUGYLD-UHFFFAOYSA-M 0.000 description 1
- QKBHILJEJZFXKD-UHFFFAOYSA-M sodium;4-[3-[[3-phenylpropanoyl(3-phenylpropyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(C(=O)[O-])=CC=C1C1=CC=CC(CN(CCCC=2C=CC=CC=2)C(=O)CCC=2C=CC=CC=2)=C1 QKBHILJEJZFXKD-UHFFFAOYSA-M 0.000 description 1
- YBPLIAYNOKDIMO-UHFFFAOYSA-M sodium;4-[3-[[benzyl(3-phenylpropanoyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(C(=O)[O-])=CC=C1C1=CC=CC(CN(CC=2C=CC=CC=2)C(=O)CCC=2C=CC=CC=2)=C1 YBPLIAYNOKDIMO-UHFFFAOYSA-M 0.000 description 1
- KSGKDGWTSFRIEI-UHFFFAOYSA-M sodium;4-[3-[[benzyl(cyclopentanecarbonyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(C(=O)[O-])=CC=C1C1=CC=CC(CN(CC=2C=CC=CC=2)C(=O)C2CCCC2)=C1 KSGKDGWTSFRIEI-UHFFFAOYSA-M 0.000 description 1
- YFMYBQJXAKKRKQ-UHFFFAOYSA-M sodium;4-[3-[[benzyl-(2-phenylacetyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(C(=O)[O-])=CC=C1C1=CC=CC(CN(CC=2C=CC=CC=2)C(=O)CC=2C=CC=CC=2)=C1 YFMYBQJXAKKRKQ-UHFFFAOYSA-M 0.000 description 1
- MBBHVBMDXHESRZ-UHFFFAOYSA-M sodium;4-[3-[[benzyl-(4-chlorobenzoyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(C(=O)[O-])=CC=C1C1=CC=CC(CN(CC=2C=CC=CC=2)C(=O)C=2C=CC(Cl)=CC=2)=C1 MBBHVBMDXHESRZ-UHFFFAOYSA-M 0.000 description 1
- UHAUAYHTAWYTEU-UHFFFAOYSA-M sodium;4-[3-[[benzyl-(4-methoxybenzoyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(OC)=CC=C1C(=O)N(CC=1C=C(C=CC=1)C=1C=CC(=CC=1)C([O-])=O)CC1=CC=CC=C1 UHAUAYHTAWYTEU-UHFFFAOYSA-M 0.000 description 1
- BGQHZRNMUUCJRV-UHFFFAOYSA-M sodium;4-[3-[[cyclopentanecarbonyl(3-phenylpropyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(C(=O)[O-])=CC=C1C1=CC=CC(CN(CCCC=2C=CC=CC=2)C(=O)C2CCCC2)=C1 BGQHZRNMUUCJRV-UHFFFAOYSA-M 0.000 description 1
- BTRSWYFRGJTPDO-UHFFFAOYSA-M sodium;4-[3-[[heptan-4-yl-(2-phenylacetyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C=1C=CC=CC=1CC(=O)N(C(CCC)CCC)CC(C=1)=CC=CC=1C1=CC=C(C([O-])=O)C=C1 BTRSWYFRGJTPDO-UHFFFAOYSA-M 0.000 description 1
- NTTYWQYCTXXTII-UHFFFAOYSA-M sodium;4-[3-[[n-(3-phenylpropanoyl)anilino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(C(=O)[O-])=CC=C1C1=CC=CC(CN(C(=O)CCC=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NTTYWQYCTXXTII-UHFFFAOYSA-M 0.000 description 1
- LZZGUCRXLKFNMO-UHFFFAOYSA-M sodium;4-[3-[[pentanoyl(3-phenylpropyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C=1C=CC(C=2C=CC(=CC=2)C([O-])=O)=CC=1CN(C(=O)CCCC)CCCC1=CC=CC=C1 LZZGUCRXLKFNMO-UHFFFAOYSA-M 0.000 description 1
- XLIYSIRKJPWFQD-UHFFFAOYSA-M sodium;4-[4-[(n-(4-chlorobenzoyl)anilino)methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(C(=O)[O-])=CC=C1C(C=C1)=CC=C1CN(C=1C=CC=CC=1)C(=O)C1=CC=C(Cl)C=C1 XLIYSIRKJPWFQD-UHFFFAOYSA-M 0.000 description 1
- HOXPNTAMLMKADN-UHFFFAOYSA-M sodium;4-[4-[[(2-phenylacetyl)-(2-phenylethyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(C(=O)[O-])=CC=C1C(C=C1)=CC=C1CN(C(=O)CC=1C=CC=CC=1)CCC1=CC=CC=C1 HOXPNTAMLMKADN-UHFFFAOYSA-M 0.000 description 1
- WKVROEGBHRETRD-UHFFFAOYSA-M sodium;4-[4-[[(2-phenylacetyl)-(3-phenylpropyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(C(=O)[O-])=CC=C1C(C=C1)=CC=C1CN(C(=O)CC=1C=CC=CC=1)CCCC1=CC=CC=C1 WKVROEGBHRETRD-UHFFFAOYSA-M 0.000 description 1
- DZDNXFOWOWGVJR-UHFFFAOYSA-M sodium;4-[4-[[(4-chlorobenzoyl)-(2-phenylethyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(C(=O)[O-])=CC=C1C(C=C1)=CC=C1CN(C(=O)C=1C=CC(Cl)=CC=1)CCC1=CC=CC=C1 DZDNXFOWOWGVJR-UHFFFAOYSA-M 0.000 description 1
- XQXDBYWYXQPSSH-UHFFFAOYSA-M sodium;4-[4-[[(4-chlorobenzoyl)-(3-phenylpropyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(C(=O)[O-])=CC=C1C(C=C1)=CC=C1CN(C(=O)C=1C=CC(Cl)=CC=1)CCCC1=CC=CC=C1 XQXDBYWYXQPSSH-UHFFFAOYSA-M 0.000 description 1
- YZOQYFVBCPKFHI-UHFFFAOYSA-M sodium;4-[4-[[(4-methoxybenzoyl)-(4-phenylbutyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(OC)=CC=C1C(=O)N(CC=1C=CC(=CC=1)C=1C=CC(=CC=1)C([O-])=O)CCCCC1=CC=CC=C1 YZOQYFVBCPKFHI-UHFFFAOYSA-M 0.000 description 1
- SLKKKKFRNXNZLN-UHFFFAOYSA-M sodium;4-[4-[[2,2-diphenylethyl(pentanoyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C=1C=C(C=2C=CC(=CC=2)C([O-])=O)C=CC=1CN(C(=O)CCCC)CC(C=1C=CC=CC=1)C1=CC=CC=C1 SLKKKKFRNXNZLN-UHFFFAOYSA-M 0.000 description 1
- NQQHOXQHKAPGLU-UHFFFAOYSA-M sodium;4-[4-[[2,2-diphenylethyl-(4-methoxybenzoyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(OC)=CC=C1C(=O)N(CC=1C=CC(=CC=1)C=1C=CC(=CC=1)C([O-])=O)CC(C=1C=CC=CC=1)C1=CC=CC=C1 NQQHOXQHKAPGLU-UHFFFAOYSA-M 0.000 description 1
- USRCCZWJICNTLT-UHFFFAOYSA-M sodium;4-[4-[[2-(2-chlorophenyl)ethyl-pentanoylamino]methyl]phenyl]benzoate Chemical compound [Na+].C=1C=C(C=2C=CC(=CC=2)C([O-])=O)C=CC=1CN(C(=O)CCCC)CCC1=CC=CC=C1Cl USRCCZWJICNTLT-UHFFFAOYSA-M 0.000 description 1
- BPWKQDZOTBOCEV-UHFFFAOYSA-M sodium;4-[4-[[2-(2-methoxyphenyl)ethyl-pentanoylamino]methyl]phenyl]benzoate Chemical compound [Na+].C=1C=C(C=2C=CC(=CC=2)C([O-])=O)C=CC=1CN(C(=O)CCCC)CCC1=CC=CC=C1OC BPWKQDZOTBOCEV-UHFFFAOYSA-M 0.000 description 1
- HYDLJWODWDDUEQ-UHFFFAOYSA-M sodium;4-[4-[[2-(4-chlorophenyl)ethyl-pentanoylamino]methyl]phenyl]benzoate Chemical compound [Na+].C=1C=C(C=2C=CC(=CC=2)C([O-])=O)C=CC=1CN(C(=O)CCCC)CCC1=CC=C(Cl)C=C1 HYDLJWODWDDUEQ-UHFFFAOYSA-M 0.000 description 1
- OUOXPJHQMRYSDZ-UHFFFAOYSA-M sodium;4-[4-[[2-(cyclohexen-1-yl)ethyl-(4-methoxybenzoyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(OC)=CC=C1C(=O)N(CC=1C=CC(=CC=1)C=1C=CC(=CC=1)C([O-])=O)CCC1=CCCCC1 OUOXPJHQMRYSDZ-UHFFFAOYSA-M 0.000 description 1
- WFSIYFBMESHUMK-UHFFFAOYSA-M sodium;4-[4-[[2-ethylhexyl-(4-methoxybenzoyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C=1C=C(OC)C=CC=1C(=O)N(CC(CC)CCCC)CC(C=C1)=CC=C1C1=CC=C(C([O-])=O)C=C1 WFSIYFBMESHUMK-UHFFFAOYSA-M 0.000 description 1
- HIKNUELQKHFDCK-UHFFFAOYSA-M sodium;4-[4-[[2-phenylethyl(3-phenylpropanoyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(C(=O)[O-])=CC=C1C(C=C1)=CC=C1CN(C(=O)CCC=1C=CC=CC=1)CCC1=CC=CC=C1 HIKNUELQKHFDCK-UHFFFAOYSA-M 0.000 description 1
- ZYBAOGZRYMMLNP-UHFFFAOYSA-M sodium;4-[4-[[3-phenylpropanoyl(3-phenylpropyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(C(=O)[O-])=CC=C1C(C=C1)=CC=C1CN(C(=O)CCC=1C=CC=CC=1)CCCC1=CC=CC=C1 ZYBAOGZRYMMLNP-UHFFFAOYSA-M 0.000 description 1
- YTIREDCEDYXYHN-UHFFFAOYSA-M sodium;4-[4-[[benzoyl(3-phenylpropyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(C(=O)[O-])=CC=C1C(C=C1)=CC=C1CN(C(=O)C=1C=CC=CC=1)CCCC1=CC=CC=C1 YTIREDCEDYXYHN-UHFFFAOYSA-M 0.000 description 1
- UVBIJMFKLVSNOV-UHFFFAOYSA-M sodium;4-[4-[[benzyl-(2-phenylacetyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(C(=O)[O-])=CC=C1C(C=C1)=CC=C1CN(C(=O)CC=1C=CC=CC=1)CC1=CC=CC=C1 UVBIJMFKLVSNOV-UHFFFAOYSA-M 0.000 description 1
- SMEQROSZUKRCDO-UHFFFAOYSA-M sodium;4-[4-[[butyl(3-phenylpropanoyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C=1C=CC=CC=1CCC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=C(C([O-])=O)C=C1 SMEQROSZUKRCDO-UHFFFAOYSA-M 0.000 description 1
- OUKKYUNOWLEMJQ-UHFFFAOYSA-M sodium;4-[4-[[butyl-(2-phenylacetyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C=1C=CC=CC=1CC(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=C(C([O-])=O)C=C1 OUKKYUNOWLEMJQ-UHFFFAOYSA-M 0.000 description 1
- SAEQFTNUPKIMJX-UHFFFAOYSA-M sodium;4-[4-[[butyl-(4-chlorobenzoyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C=1C=C(Cl)C=CC=1C(=O)N(CCCC)CC(C=C1)=CC=C1C1=CC=C(C([O-])=O)C=C1 SAEQFTNUPKIMJX-UHFFFAOYSA-M 0.000 description 1
- UNPZXDCOPNNYPQ-UHFFFAOYSA-M sodium;4-[4-[[cyclopentanecarbonyl(2,2-diphenylethyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1=CC(C(=O)[O-])=CC=C1C(C=C1)=CC=C1CN(C(=O)C1CCCC1)CC(C=1C=CC=CC=1)C1=CC=CC=C1 UNPZXDCOPNNYPQ-UHFFFAOYSA-M 0.000 description 1
- QLFDSZIZKXPXLU-UHFFFAOYSA-M sodium;4-[4-[[cyclopentanecarbonyl(heptan-4-yl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C1CCCC1C(=O)N(C(CCC)CCC)CC(C=C1)=CC=C1C1=CC=C(C([O-])=O)C=C1 QLFDSZIZKXPXLU-UHFFFAOYSA-M 0.000 description 1
- GLCHMNQPQXXABB-UHFFFAOYSA-M sodium;4-[4-[[heptan-4-yl(3-phenylpropanoyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C=1C=CC=CC=1CCC(=O)N(C(CCC)CCC)CC(C=C1)=CC=C1C1=CC=C(C([O-])=O)C=C1 GLCHMNQPQXXABB-UHFFFAOYSA-M 0.000 description 1
- DNWXRLHWMZZTON-UHFFFAOYSA-M sodium;4-[4-[[heptan-4-yl-(2-phenylacetyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C=1C=CC=CC=1CC(=O)N(C(CCC)CCC)CC(C=C1)=CC=C1C1=CC=C(C([O-])=O)C=C1 DNWXRLHWMZZTON-UHFFFAOYSA-M 0.000 description 1
- VFUZRHMYIMVYGR-UHFFFAOYSA-M sodium;4-[4-[[pentanoyl(3-phenylpropyl)amino]methyl]phenyl]benzoate Chemical compound [Na+].C=1C=C(C=2C=CC(=CC=2)C([O-])=O)C=CC=1CN(C(=O)CCCC)CCCC1=CC=CC=C1 VFUZRHMYIMVYGR-UHFFFAOYSA-M 0.000 description 1
- XHFLOLLMZOTPSM-UHFFFAOYSA-M sodium;hydrogen carbonate;hydrate Chemical compound [OH-].[Na+].OC(O)=O XHFLOLLMZOTPSM-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- NECLQTPQJZSWOE-UHFFFAOYSA-N spiro[5.5]undecane Chemical compound C1CCCCC21CCCCC2 NECLQTPQJZSWOE-UHFFFAOYSA-N 0.000 description 1
- CTDQAGUNKPRERK-UHFFFAOYSA-N spirodecane Chemical compound C1CCCC21CCCCC2 CTDQAGUNKPRERK-UHFFFAOYSA-N 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229960004533 streptodornase Drugs 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- GECHUMIMRBOMGK-UHFFFAOYSA-N sulfapyridine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CC=CC=N1 GECHUMIMRBOMGK-UHFFFAOYSA-N 0.000 description 1
- 229960002211 sulfapyridine Drugs 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- OPYGFNJSCUDTBT-PMLPCWDUSA-N sultamicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(=O)OCOC(=O)[C@H]2C(S(=O)(=O)[C@H]3N2C(C3)=O)(C)C)(C)C)=CC=CC=C1 OPYGFNJSCUDTBT-PMLPCWDUSA-N 0.000 description 1
- 229960001636 sultamicillin tosylate Drugs 0.000 description 1
- 229950011082 suplatast tosilate Drugs 0.000 description 1
- 239000003447 supported reagent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- BJYLYJCXYAMOFT-RSFVBTMBSA-N tacalcitol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CC[C@@H](O)C(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C BJYLYJCXYAMOFT-RSFVBTMBSA-N 0.000 description 1
- 229960004907 tacalcitol Drugs 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229960002871 tenoxicam Drugs 0.000 description 1
- WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 description 1
- YUSMZDVTEOAHDL-NTMALXAHSA-N tert-butyl (3z)-3-(dimethylaminomethylidene)-4-oxopiperidine-1-carboxylate Chemical compound CN(C)\C=C1\CN(C(=O)OC(C)(C)C)CCC1=O YUSMZDVTEOAHDL-NTMALXAHSA-N 0.000 description 1
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 1
- 229940072172 tetracycline antibiotic Drugs 0.000 description 1
- 229960004989 tetracycline hydrochloride Drugs 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- ZXLDQJLIBNPEFJ-UHFFFAOYSA-N tetrahydro-beta-carboline Natural products C1CNC(C)C2=C1C1=CC=C(OC)C=C1N2 ZXLDQJLIBNPEFJ-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- KHVCOYGKHDJPBZ-WDCZJNDASA-N tetrahydrooxazine Chemical compound OC[C@H]1ONC[C@@H](O)[C@@H]1O KHVCOYGKHDJPBZ-WDCZJNDASA-N 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical class C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- ZYXWYDDFNXBTFO-UHFFFAOYSA-N tetrazolidine Chemical compound C1NNNN1 ZYXWYDDFNXBTFO-UHFFFAOYSA-N 0.000 description 1
- DASUJKKKKGHFBF-UHFFFAOYSA-L thallium(i) carbonate Chemical compound [Tl+].[Tl+].[O-]C([O-])=O DASUJKKKKGHFBF-UHFFFAOYSA-L 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- RWXZKKKYLRFREK-UHFFFAOYSA-N thiadiazepane Chemical compound C1CCSNNC1 RWXZKKKYLRFREK-UHFFFAOYSA-N 0.000 description 1
- BXVYJQULAWJPSR-UHFFFAOYSA-N thiadiazepine Chemical compound S1C=CC=CN=N1 BXVYJQULAWJPSR-UHFFFAOYSA-N 0.000 description 1
- TVQOEGVBMRCMFR-UHFFFAOYSA-N thiadiazinane Chemical compound C1CNNSC1 TVQOEGVBMRCMFR-UHFFFAOYSA-N 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- GVIJJXMXTUZIOD-UHFFFAOYSA-N thianthrene Chemical compound C1=CC=C2SC3=CC=CC=C3SC2=C1 GVIJJXMXTUZIOD-UHFFFAOYSA-N 0.000 description 1
- NYERMPLPURRVGM-UHFFFAOYSA-N thiazepine Chemical compound S1C=CC=CC=N1 NYERMPLPURRVGM-UHFFFAOYSA-N 0.000 description 1
- AJZGFFKDLABHDD-UHFFFAOYSA-N thiazinane Chemical compound C1CCSNC1 AJZGFFKDLABHDD-UHFFFAOYSA-N 0.000 description 1
- JWCVYQRPINPYQJ-UHFFFAOYSA-N thiepane Chemical compound C1CCCSCC1 JWCVYQRPINPYQJ-UHFFFAOYSA-N 0.000 description 1
- BISQTCXKVNCDDA-UHFFFAOYSA-N thiepine Chemical compound S1C=CC=CC=C1 BISQTCXKVNCDDA-UHFFFAOYSA-N 0.000 description 1
- XSROQCDVUIHRSI-UHFFFAOYSA-N thietane Chemical compound C1CSC1 XSROQCDVUIHRSI-UHFFFAOYSA-N 0.000 description 1
- VOVUARRWDCVURC-UHFFFAOYSA-N thiirane Chemical compound C1CS1 VOVUARRWDCVURC-UHFFFAOYSA-N 0.000 description 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
- 229940071127 thioglycolate Drugs 0.000 description 1
- CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- IBBLKSWSCDAPIF-UHFFFAOYSA-N thiopyran Chemical compound S1C=CC=C=C1 IBBLKSWSCDAPIF-UHFFFAOYSA-N 0.000 description 1
- MIMJSJSRRDZIPW-UHFFFAOYSA-N tilmacoxib Chemical compound C=1C=C(S(N)(=O)=O)C(F)=CC=1C=1OC(C)=NC=1C1CCCCC1 MIMJSJSRRDZIPW-UHFFFAOYSA-N 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- YEZNLOUZAIOMLT-UHFFFAOYSA-N tolfenamic acid Chemical compound CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O YEZNLOUZAIOMLT-UHFFFAOYSA-N 0.000 description 1
- 229960002905 tolfenamic acid Drugs 0.000 description 1
- 229960001017 tolmetin Drugs 0.000 description 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229950008187 tosufloxacin Drugs 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 229940126307 triamcinolone acetate Drugs 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- DBGVGMSCBYYSLD-UHFFFAOYSA-N tributylstannane Chemical compound CCCC[SnH](CCCC)CCCC DBGVGMSCBYYSLD-UHFFFAOYSA-N 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- PCFIPYFVXDCWBW-UHFFFAOYSA-N tricyclo[3.3.1.03,7]nonane Chemical group C1C(C2)C3CC2CC1C3 PCFIPYFVXDCWBW-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- MWKJTNBSKNUMFN-UHFFFAOYSA-N trifluoromethyltrimethylsilane Chemical compound C[Si](C)(C)C(F)(F)F MWKJTNBSKNUMFN-UHFFFAOYSA-N 0.000 description 1
- BUUOVHURLSNWBF-UHFFFAOYSA-N trioxepine-4,7-dione Chemical compound O=C1OOOC(=O)C=C1 BUUOVHURLSNWBF-UHFFFAOYSA-N 0.000 description 1
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
- 229960001593 triprolidine hydrochloride Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- CYHOMWAPJJPNMW-JIGDXULJSA-N tropine Chemical compound C1[C@@H](O)C[C@H]2CC[C@@H]1N2C CYHOMWAPJJPNMW-JIGDXULJSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-L tyrosinate(2-) Chemical compound [O-]C(=O)C(N)CC1=CC=C([O-])C=C1 OUYCCCASQSFEME-UHFFFAOYSA-L 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 235000011912 vitamin B7 Nutrition 0.000 description 1
- 239000011735 vitamin B7 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- CPYIZQLXMGRKSW-UHFFFAOYSA-N zinc;iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+3].[Fe+3].[Zn+2] CPYIZQLXMGRKSW-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/38—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/51—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C233/63—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/87—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/52—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
- C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
(1)BLT2結合活性を有する化合物、その塩、その溶媒和物またはそれらのプロドラッグを含有してなる皮膚疾患の予防および/または治療剤、
(2)BLT2結合活性を有する化合物が、BLT2アゴニスト作用を有する化合物である前記(1)記載の剤、
(3)BLT2結合活性を有する化合物が、BLT2アンタゴニスト作用を有する化合物である前記(1)記載の剤、
(4)皮膚疾患が、乾癬、皮膚炎、皮膚癌、角化症、色素沈着症または脱毛症である前記(1)記載の剤、
(5)BLT2結合活性を有する化合物が、一般式(I)
(6)BLT2結合活性を有する化合物が、一般式(I−1)
(7)BLT2結合活性を有する化合物、その塩、その溶媒和物またはそれらのプロドラッグと免疫抑制薬、抗生物質、抗ヒスタミン薬および副腎皮質ステロイドから選択される1種以上とを組み合わせてなる医薬、
(8)一般式(I)
(9)BLT2結合剤が、BLT2アゴニスト作用剤である前記(8)記載の剤、
(10)BLT2結合剤が、BLT2アンタゴニスト作用剤である前記(8)記載の剤、
(11)BLT2介在性疾患の予防および/または治療剤である前記(8)記載の剤、
(12)BLT2介在性疾患が、移植に対する拒絶反応、移植臓器廃絶、移植片対宿主病、自己免疫疾患、アレルギー性疾患、炎症、感染症、潰瘍、リンパ腫、悪性腫瘍、白血病、動脈硬化、肝炎、肝硬変または癌である前記(11)記載の剤、
(13)BLT2介在性疾患が、腸疾患またはヒト免疫不全ウイルス感染である前記(11)記載の剤、
(14)前記(8)記載の一般式(I)で示される化合物、その塩、その溶媒和物またはそれらのプロドラッグと非ステロイド系抗炎症薬、疾患修飾性抗リウマチ薬、副腎皮質ステロイド、免疫抑制薬、消炎酵素薬、軟骨保護薬、T細胞阻害薬、TNF−α阻害薬、プロスタグランジン合成酵素阻害薬、IL−6阻害薬、インターフェロンγ作動薬、IL−1阻害薬、EDG−1作動薬、EDG−6作動薬、プロスタグランジン類、ホスホジエステラーゼ阻害薬、メタロプロテイナーゼ阻害薬およびケモカイン受容体拮抗薬から選択される1種以上とを組み合わせてなる医薬、
(15)一般式(I−1)
(16)BLT2結合活性を有する化合物、その塩、その溶媒和物またはそれらのプロドラッグの有効量を哺乳動物に投与することを特徴とする、哺乳動物における皮膚疾患の予防および/または治療方法、
(17)皮膚疾患の予防および/または治療剤を製造するための、BLT2結合活性を有する化合物、その塩、その溶媒和物またはそれらのプロドラッグの使用、
(18)一般式(I)
(19)BLT2介在性疾患の予防および/または治療剤を製造するための、一般式(I)
(1)O−(tert−ブチル)−N−[(ペンチル{[2’−(1H−テトラゾール−5−イル)ビフェニル−4−イル]メチル}アミノ)カルボニル]セリン、
(2)N−[(ペンチル{[2’−(1H−テトラゾール−5−イル)ビフェニル−4−イル]メチル}アミノ)カルボニル]セリン、
(3)N−ブチル−N’−[2−(4−メトキシフェニル)エチル]−N−{[2’−(1H−テトラゾール−5−イル)ビフェニル−4−イル]メチル}ウレア、
(4)ジエチル {[(ブチル{[2’−(1H−テトラゾール−5−イル)ビフェニル−4−イル]メチル}アミノ)カルボニル]アミノ}(2−シアノエチル)マロネート、
(5)N−ブチル−N’−(2−フェニルエチル)−N−{[2’−(1H−テトラゾール−5−イル)ビフェニル−4−イル]メチル}ウレア、
(6)N−ブチル−N’−(2,2−ジフェニルエチル)−N−{[2’−(1H−テトラゾール−5−イル)ビフェニル−4−イル]メチル}ウレア、
(7)N−ブチル−N’−イソプロピル−N−{[2’−(1H−テトラゾール−5−イル)ビフェニル−4−イル]メチル}ウレア、
(8)メチル 2−{[(ブチル{[2’−(1H−テトラゾール−5−イル)ビフェニル−4−イル]メチル}アミノ)カルボニル]オキシ}−3−フェニルプロパノエート、
(9)N−ブチル−N’−[2−(4−ヒドロキシフェニル)エチル]−N−{[2’−(1H−テトラゾール−5−イル)ビフェニル−4−イル]メチル}ウレア、
(10)メチル N−[(ブチル{[2’−(1H−テトラゾール−5−イル)ビフェニル−4−イル]メチル}アミノ)カルボノチオイル]グリシネート、
(11)N,N’−ジブチル−N−{[2’−(1H−テトラゾール−5−イル)ビフェニル−4−イル]メチル}ウレア、
(12)N−ブチル−N’−シクロヘキシル−N−{[2’−(1H−テトラゾール−5−イル)ビフェニル−4−イル]メチル}ウレア、
(13)N−ブチル−N’−フェニル−N−{[2’−(1H−テトラゾール−5−イル)ビフェニル−4−イル]メチル}ウレア、
(14)デシル N−[(ブチル{[2’−(1H−テトラゾール−5−イル)ビフェニル−4−イル]メチル}アミノ)カルボニル]チロシネート、
(15)N’−ビフェニル−2−イル−N−ブチル−N−{[2’−(1H−テトラゾール−5−イル)ビフェニル−4−イル]メチル}ウレア、
(16)N−ブチル−N’−(3−メトキシフェニル)−N−{[2’−(1H−テトラゾール−5−イル)ビフェニル−4−イル]メチル}ウレア、
(17)N−ブチル−N’−(4−メトキシフェニル)−N−{[2’−(1H−テトラゾール−5−イル)ビフェニル−4−イル]メチル}ウレア、
(18)エチル 2−{[(ブチル{[2’−(1H−テトラゾール−5−イル)ビフェニル−4−イル]メチル}アミノ)カルボニル]アミノ}ベンゾエート、
(19)エチル 3−{[(ブチル{[2’−(1H−テトラゾール−5−イル)ビフェニル−4−イル]メチル}アミノ)カルボニル]アミノ}ベンゾエート、
(20)N−ブチル−N’−(4−メチルフェニル)−N−{[2’−(1H−テトラゾール−5−イル)ビフェニル−4−イル]メチル}ウレア、
(21)N−ブチル−N’−[(1S)−1−フェニルエチル]−N−{[2’−(1H−テトラゾール−5−イル)ビフェニル−4−イル]メチル}ウレア、
(22)N’−ベンジル−N−ブチル−N−{[2’−(1H−テトラゾール−5−イル)ビフェニル−4−イル]メチル}ウレア、
(23)N−ブチル−N’−(3−エチルフェニル)−N−{[2’−(1H−テトラゾール−5−イル)ビフェニル−4−イル]メチル}ウレア、
(24)エチル N−ベンジル−N−[(ブチル{[2’−(1H−テトラゾール−5−イル)ビフェニル−4−イル]メチル}アミノ)カルボニル]グリシネート、
(25)N−ブチル−N’−(4−エチルフェニル)−N−{[2’−(1H−テトラゾール−5−イル)ビフェニル−4−イル]メチル}ウレア、
(26)N’−(2−ブロモフェニル)−N−ブチル−N−{[2’−(1H−テトラゾール−5−イル)ビフェニル−4−イル]メチル}ウレア、
(27)N’−ビフェニル−4−イル−N−ブチル−N−{[2’−(1H−テトラゾール−5−イル)ビフェニル−4−イル]メチル}ウレア、
(28)N−ブチル−N’−(2−エトキシフェニル)−N−{[2’−(1H−テトラゾール−5−イル)ビフェニル−4−イル]メチル}ウレア、
(29)N−ブチル−N−{[2’−(1H−テトラゾール−5−イル)ビフェニル−4−イル]メチル}−N’−[4−(トリフルオロメトキシ)フェニル]ウレア、
(30)N−ブチル−N’−(3,4−ジフルオロフェニル)−N−{[2’−(1H−テトラゾール−5−イル)ビフェニル−4−イル]メチル}ウレア、
(31)N−ブチル−N’−(2,6−ジイソプロピルフェニル)−N−{[2’−(1H−テトラゾール−5−イル)ビフェニル−4−イル]メチル}ウレア、
(32)エチル N−[(ブチル{[2’−(1H−テトラゾール−5−イル)ビフェニル−4−イル]メチル}アミノ)カルボニル]−O−エチル−α−メチルチロシネート、
(33)N−ブチル−N’−(2−ニトロフェニル)−N−{[2’−(1H−テトラゾール−5−イル)ビフェニル−4−イル]メチル}ウレア、
(34)エチル [(ブチル{[2’−(1H−テトラゾール−5−イル)ビフェニル−4−イル]メチル}アミノ)カルボニル]カーバメート、
(35)メチル 3−{[(ブチル{[2’−(1H−テトラゾール−5−イル)ビフェニル−4−イル]メチル}アミノ)カルボニル]アミノ}チオフェン−2−カルボキシレート、
(36)N−ブチル−N’−[(1R)−1−フェニルエチル]−N−{[2’−(1H−テトラゾール−5−イル)ビフェニル−4−イル]メチル}ウレア、
(37)N−ブチル−N’−(4−メチル−2−ニトロフェニル)−N−{[2’−(1H−テトラゾール−5−イル)ビフェニル−4−イル]メチル}ウレア、
(38)N−ブチル−N’−[1−(3−イソプロペニルフェニル)−1−メチルエチル]−N−{[2’−(1H−テトラゾール−5−イル)ビフェニル−4−イル]メチル}ウレア、
(39)N−ブチル−N’−(2−ヒドロキシフェニル)−N−{[2’−(1H−テトラゾール−5−イル)ビフェニル−4−イル]メチル}ウレア、
(40)2−{[(ブチル{[2’−(1H−テトラゾール−5−イル)ビフェニル−4−イル]メチル}アミノ)カルボニル]アミノ}−4,5,6,7−テトラヒドロ−1−ベンゾチオフェン−3−カルボン酸、
(41)エチル 2−{[(ブチル{[2’−(1H−テトラゾール−5−イル)ビフェニル−4−イル]メチル}アミノ)カルボニル]アミノ}−4−ニトロベンゾエート、
(42)メチル N−[(ブチル{[2’−(1H−テトラゾール−5−イル)ビフェニル−4−イル]メチル}アミノ)カルボニル]−N−(シクロヘキシルメチル)グリシネート、
(43)N−ブチル−N’−(テトラヒドロフラン−2−イルメチル)−N−{[2’−(1H−テトラゾール−5−イル)ビフェニル−4−イル]メチル}ウレア、
(44)N−ブチル−N−{[2’−(1H−テトラゾール−5−イル)ビフェニル−4−イル]メチル}−3,4−ジヒドロキノリン−1(2H)−カルボキサミド、
(45)N−ブチル−N’−(2−モルホリン−4−イルエチル)−N−{[2’−(1H−テトラゾール−5−イル)ビフェニル−4−イル]メチル}ウレア、または
(46)N−ブチル−N’−[2−(メチルチオ)フェニル]−N−{[2’−(1H−テトラゾール−5−イル)ビフェニル−4−イル]メチル}ウレア。
本発明においては、特に指示しない限り異性体はこれをすべて包含する。例えば、アルキル基、アルケニル基、アルキニル基、アルキルオキシ基、アルコキシ基、アルケニルオキシ基、アルキニルオキシ基、アルキルチオ基、アルキルスルフィニル基、アルキルスルホニル基、アルキレン基、アルケニレン基、アルキニレン基、アシル基およびアシルオキシ基には直鎖のものおよび分枝鎖のものが含まれる。さらに、二重結合、環、縮合環における異性体(E体、Z体、シス体、トランス体)、不斉炭素の存在等による異性体(R体、S体、α配置、β配置、エナンチオマー、ジアステレオマー)、旋光性を有する光学活性体(D体、L体、d体、l体)、クロマトグラフィー分離による極性体(高極性体、低極性体)、平衡化合物、回転異性体、およびこれらの任意の割合の混合物、ラセミ混合物は、すべて本発明に含まれる。また、本発明においては、互変異性体による異性体をもすべて包含する。
一般式(I)で示される化合物の塩には薬理学的に許容されるものすべてが含まれる。薬理学的に許容される塩は、毒性の少ない、水溶性のものが好ましい。適当な塩としては、例えば、アルカリ金属(例えば、カリウム、ナトリウム、リチウム等)の塩、アルカリ土類金属(例えば、カルシウム、マグネシウム等)の塩、アンモニウム塩(例えば、テトラメチルアンモニウム塩、テトラブチルアンモニウム塩等)、有機アミン(例えば、トリエチルアミン、メチルアミン、ジメチルアミン、シクロペンチルアミン、ベンジルアミン、フェネチルアミン、ピペリジン、モノエタノールアミン、ジエタノールアミン、トリス(ヒドロキシメチル)メチルアミン、リジン、アルギニン、N−メチル−D−グルカミン等)の塩、酸付加物塩(例えば、無機酸塩(例えば、塩酸塩、臭化水素酸塩、ヨウ化水素酸塩、硫酸塩、リン酸塩、硝酸塩等)、有機酸塩(例えば、酢酸塩、トリフルオロ酢酸塩、乳酸塩、酒石酸塩、シュウ酸塩、フマル酸塩、マレイン酸塩、安息香酸塩、クエン酸塩、メタンスルホン酸塩、エタンスルホン酸塩、ベンゼンスルホン酸塩、トルエンスルホン酸塩、イセチオン酸塩、グルクロン酸塩、グルコン酸塩等)等)が挙げられる。
一般式(I)で示される化合物のプロドラッグは、生体内において酵素や胃酸等による反応により一般式(I)で示される化合物に変換される化合物をいう。一般式(I)で示される化合物のプロドラッグとしては、例えば、一般式(I)で示される化合物がアミノ基を有する場合、該アミノ基がアシル化、アルキル化、リン酸化された化合物(例えば、一般式(I)で示される化合物のアミノ基がエイコサノイル化、アラニル化、ペンチルアミノカルボニル化、(5−メチル−2−オキソ−1,3−ジオキソレン−4−イル)メトキシカルボニル化、テトラヒドロフラニル化、ピロリジルメチル化、ピバロイルオキシメチル化、アセトキシメチル化、tert−ブチル化された化合物等);一般式(I)で示される化合物が水酸基を有する場合、該水酸基がアシル化、アルキル化、リン酸化、ホウ酸化された化合物(例えば、一般式(I)で示される化合物の水酸基がアセチル化、パルミトイル化、プロパノイル化、ピバロイル化、サクシニル化、フマリル化、アラニル化、ジメチルアミノメチルカルボニル化された化合物等);一般式(I)で示される化合物がカルボキシル基を有する場合、該カルボキシル基がエステル化、アミド化された化合物(例えば、一般式(I)で示される化合物のカルボキシル基がエチルエステル化、フェニルエステル化、カルボキシメチルエステル化、ジメチルアミノメチルエステル化、ピバロイルオキシメチルエステル化、エトキシカルボニルオキシエチルエステル化、フタリジルエステル化、(5−メチル−2−オキソ−1,3−ジオキソレン−4−イル)メチルエステル化、シクロヘキシルオキシカルボニルエチルエステル化、メチルアミド化、アルキルスルホニルアミド化(例えば、−CONHSO2CH3等)、アリールスルホニルアミド化された化合物(例えば、−CONHSO2Ph等)等)が挙げられる。これらの化合物は公知の方法によって製造することができる。また、一般式(I)で示される化合物のプロドラッグは水和物および非水和物のいずれであってもよい。また、一般式(I)で示される化合物のプロドラッグは、廣川書店1990年刊「医薬品の開発」第7巻「分子設計」163−198頁に記載されているような、生理的条件で一般式(I)で示される化合物に変化するものであってもよい。さらに、一般式(I)で示される化合物は同位元素(例えば、3H、14C、35S、125I等)等で標識されていてもよい。
本発明化合物は、それ自身公知であるか、または公知の方法、例えば欧州特許公開第0632008号明細書、国際公開第99/58513号パンフレット、国際公開第00/48982号パンフレット、国際公開第03/051852号パンフレット、国際公開第03/097851号パンフレット等に記載の方法、例えば、コンプリヘンシヴ・オーガニック・トランスフォーメーションズ:ア・ガイド・トゥー・ファンクショナル・グループ・プレパレーションズ、セカンド・エディション(リチャードC.ラロック、ジョンワイリーアンドサンズInc,1999)[Comprehensive Organic Transformations : A Guide to Functional Group Preparations, 2nd Edition (Richard C. Larock, John Wiley & Sons Inc, 1999)]に記載された方法等に従って、またはそれらの方法等を適宜組み合わせることにより製造することができる。
(1)アルカリ加水分解、
(2)酸性条件下における脱保護反応、
(3)加水素分解による脱保護反応、
(4)金属錯体を用いた脱保護反応、
(5)金属を用いた脱保護反応、
(6)シリル基の脱保護反応等が挙げられる。
(1)アルカリ加水分解による脱保護反応(例えば、トリフルオロアセチル基の脱保護反応等)は、例えば、有機溶媒(例えば、メタノール、テトラヒドロフラン、1,4−ジオキサン等)中、アルカリ金属の水酸化物(例えば、水酸化ナトリウム、水酸化カリウム、水酸化リチウム等)、アルカリ土類金属の水酸化物(例えば、水酸化バリウム、水酸化カルシウム等)または炭酸塩(例えば、炭酸ナトリウム、炭酸カリウム等)あるいはその水溶液もしくはこれらの混合物を用いて、0℃〜40℃の温度で行なわれる。
(1)酸ハライドを用いる方法、
(2)混合酸無水物を用いる方法、
(3)縮合剤を用いる方法等が挙げられる。
(1)酸ハライドを用いる方法は、例えば、カルボン酸を有機溶媒(例えば、クロロホルム、ジクロロメタン、ジエチルエーテル、テトラヒドロフラン等)中または無溶媒で、酸ハライド化剤(例えば、オキザリルクロライド、チオニルクロライド等)と−20℃〜還流温度で反応させ、得られた酸ハライドを塩基(例えば、ピリジン、トリエチルアミン、ジメチルアニリン、ジメチルアミノピリジン、ジイソプロピルエチルアミン等)の存在下、アミンと有機溶媒(例えば、クロロホルム、ジクロロメタン、ジエチルエーテル、テトラヒドロフラン等)中、0℃〜40℃の温度で反応させることにより行なわれる。また、得られた酸ハライドを有機溶媒(例えば、ジオキサン、テトラヒドロフラン等)中、アルカリ水溶液(例えば、重曹水または水酸化ナトリウム溶液等)を用いて、アミンと0℃〜40℃で反応させることにより行なうこともできる。また、市販の酸ハライドを用いてもよい。
本発明化合物の毒性は十分に低いものであり、医薬として使用するために十分に安全であることが確認された。
本発明化合物は、BLT2結合活性を有する化合物である。一方、BLT2は脾臓やリンパ球に最も強い発現がみられ、肝臓や卵巣をはじめ、多くの臓器に遍在的に分布しており、さらにBLT2はケラチノサイトや小腸に高発現しているため、哺乳動物(例えば、ヒト、非ヒト動物、例えば、サル、ヒツジ、ウシ、ウマ、イヌ、ネコ、ウサギ、ラット、マウス等)において、BLT2介在性疾患、例えば、皮膚疾患[例えば、湿疹、ケロイド、狼瘡付随皮膚外傷、座瘡(例:尋常性座瘡等)、皮膚炎(例:脂漏性皮膚炎、日光皮膚炎、接触性皮膚炎、アトピー性皮膚炎等)、乾癬(例:尋常性乾癬、滴状乾癬、膿疱性乾癬、関節症性乾癬、乾癬性紅皮症等)、角化症(例:脂漏性角化症、老人性角化症、光線性角化症、光誘発角化症、毛包性角化症等)、疣(例:コンジローム、尖形コンジローム、性病疣贅、ウイルス疣贅、伝染性軟属腫、白斑症、小水疱水疱性扁平苔癬のようなヒト乳頭腫ウイルス(HPV)感染を含む疣贅等)、皮膚癌(例:基底細胞癌、皮膚T細胞リンパ腫、局在性良性表皮腫瘍(例:角皮症、表皮母斑等)等)、脱毛症(例:先天性脱毛症(例:びまん性先天性脱毛症、先天性三角形脱毛症等)、後天性脱毛症(脱毛性毛包炎、円形脱毛症、毛包性ムチン沈着症等)等)、色素沈着症(例:しみ、そばかす、日焼け後の色素沈着等)等]、腸疾患(例えば、炎症性腸疾患(例えば、潰瘍性大腸炎、クローン病等)、過敏性腸症候群、大腸炎等)、HIV感染、後天性免疫不全症候群、移植に対する拒絶反応、移植臓器廃絶、移植片対宿主病、自己免疫疾患(例えば、全身性エリテマトーデス、関節リウマチ、重症筋無力症、多発性硬化症等)、アレルギー性疾患(例えば、アトピー性皮膚炎、喘息等)、炎症、感染症、潰瘍、リンパ腫、悪性腫瘍、白血病、動脈硬化、肝炎、肝硬変または癌等の予防および/または治療に有用である。
(1)条件A(分析)
使用機器:Waters LC/MS
カラム:Xterra(登録商標)MS C185μm,4.6x50mm I.D.
流速:3mL/min
溶媒:A液:0.1%トリフルオロ酢酸水溶液
B液:0.1%トリフルオロ酢酸−アセトニトリル溶液
<反応1>
Wang樹脂(アルゴノート テクノロジー社)をN,N−ジメチルホルムアミドで洗浄した。Wang樹脂のN,N−ジメチルホルムアミド懸濁液に相当するヨード安息香酸、1−エチル−3−[3−(ジメチルアミノ)プロピル]カルボジイミドおよび1−ヒドロキシベンゾトリアゾールをWang樹脂に対しそれぞれ3当量ずつ加え、ジイソプロピルエチルアミン(5当量)を加えた。反応混合液を室温で18時間反応させた。樹脂をろ過し、N,N−ジメチルホルムアミド、テトラヒドロフラン、メタノールおよび1,2−ジメトキシエタンで順次洗浄した。
<反応2>
得られた樹脂の脱気した1,2−ジメトキシエタン懸濁液に相当するホルミルフェニルボラン酸(2当量)および2mol/L炭酸カリウム水溶液(2当量)を加えた。そこに、触媒量の二塩化ビス(トリフェニルホスフィン)パラジウムを加えた。反応混合液を60℃で16時間反応させた。反応混合液を室温まで冷却し、ろ過した。樹脂を1,2−ジメトキシエタン/水(2:1)、1,2−ジメトキシエタン、N,N−ジメチルホルムアミド、テトラヒドロフランおよびメタノールで洗浄した。
<反応3>
得られた樹脂を1%酢酸/1,2−ジクロロエタンで洗浄した。ここに、相当する0.5mol/Lアミン化合物の1%酢酸/1,2−ジクロロエタン溶液(5当量)を加え、混合液を室温で5時間反応させた。混合液に0.5mol/L水素化ホウ素テトラブチルアンモニウムの1%酢酸/1,2−ジクロロエタン溶液(5当量)を加え、さらに一晩反応させた。樹脂をろ過し、メタノール、テトラヒドロフランおよびN,N−ジメチルホルムアミドで洗浄した。
<反応4>
得られた樹脂を1,2−ジクロロエタンで洗浄した。ここに、相当する1mol/Lアシルクロライドの1,2−ジクロロエタン溶液(5当量)およびジイソプロピルエチルアミンの1,2−ジクロロエタン溶液(7.5当量)を順次加えた。反応混合液を一晩反応させ、樹脂をろ過し、1,2−ジクロロエタン、メタノールおよびテトラヒドロフランで洗浄した。
<反応5>
得られた樹脂に0.1mol/Lナトリウムメトキシドの30%メタノール/テトラヒドロフラン溶液(1当量)を加えた。混合液に0.5mol/L水酸化ナトリウム水溶液(1当量)を加え、濃縮し、以下の本発明化合物を得た。
実施例1(1)
2’−{[ベンジル(フェニルアセチル)アミノ]メチル}−1,1’−ビフェニル−2−カルボン酸 ナトリウム塩
実施例1(2)
2’−{[(フェニルアセチル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−2−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.14分; MS : 328, 464 (M + H)+。
実施例1(3)
2’−{[フェニル(3−フェニルプロパノイル)アミノ]メチル}−1,1’−ビフェニル−2−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.12分; MS : 286, 436 (M + H)+。
実施例1(4)
2’−{[(2−フェニルエチル)(3−フェニルプロパノイル)アミノ]メチル}−1,1’−ビフェニル−2−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.16分; MS : 464 (M + H)+。
実施例1(5)
2’−{[(3−フェニルプロパノイル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−2−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.23分; MS : 478 (M + H)+。
実施例1(6)
2’−{[(3−フェニルプロパノイル)(1−プロピルブチル)アミノ]メチル}−1,1’−ビフェニル−2−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.37分; MS : 458 (M + H)+。
実施例1(7)
2’−{[(4−クロロベンゾイル)(フェニル)アミノ]メチル}−1,1’−ビフェニル−2−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.1分; MS : 232, 442 (M + H)+。
実施例1(8)
2’−{[(4−クロロベンゾイル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−2−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.23分; MS : 328, 484 (M + H)+。
実施例1(9)
2’−{[(4−クロロベンゾイル)(1−プロピルブチル)アミノ]メチル}−1,1’−ビフェニル−2−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.41分; MS : 464 (M + H)+。
実施例1(10)
2’−{[(4−メトキシベンゾイル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−2−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.09分; MS : 480 (M + H)+。
実施例1(11)
3’−{[フェニル(フェニルアセチル)アミノ]メチル}−1,1’−ビフェニル−2−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.02分; MS : 422 (M + H)+。
実施例1(12)
3’−{[(フェニルアセチル)(1−プロピルブチル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.31分; MS : 444 (M + H)+。
実施例1(13)
3’−{[フェニル(3−フェニルプロパノイル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.12分; MS : 436 (M + H)+。
実施例1(14)
3’−{[ベンジル(3−フェニルプロパノイル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.15分; MS : 450 (M + H)+。
実施例1(15)
3’−{[(2−フェニルエチル)(3−フェニルプロパノイル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.19分; MS : 464 (M + H)+。
実施例1(16)
3’−{[(3−フェニルプロパノイル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.24分; MS : 478 (M + H)+。
実施例1(17)
3’−{[ブチル(3−フェニルプロパノイル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.14分; MS : 416 (M + H)+。
実施例1(18)
3’−{[(3−フェニルプロパノイル)(1−プロピルブチル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.4分; MS : 458 (M + H)+。
実施例1(19)
3’−{[(4−クロロベンゾイル)(フェニル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.11分; MS : 442 (M + H)+。
実施例1(20)
3’−{[ベンジル(4−クロロベンゾイル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.19分; MS : 456 (M + H)+。
実施例1(21)
3’−{[(4−クロロベンゾイル)(2−フェニルエチル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.23分; MS : 470 (M + H)+。
実施例1(22)
3’−{[(4−クロロベンゾイル)(1−プロピルブチル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.43分; MS : 464 (M + H)+。
実施例1(23)
3’−{[(4−メトキシベンゾイル)(フェニル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸 ナトリウム塩
HPLC保持時間 : 3.96分; MS : 438 (M + H)+。
実施例1(24)
3’−{[ペンタノイル(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.21分; MS : 430 (M + H)+。
実施例1(25)
3’−{[ベンジル(フェニルアセチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.06分; MS : 436 (M + H)+。
実施例1(26)
3’−{[(フェニルアセチル)(2−フェニルエチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.1分; MS : 450 (M + H)+。
実施例1(27)
3’−{[(フェニルアセチル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.15分; MS : 464 (M + H)+。
実施例1(28)
3’−{[(フェニルアセチル)(1−プロピルブチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.31分; MS : 444 (M + H)+。
実施例1(29)
3’−{[フェニル(3−フェニルプロパノイル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.1分; MS : 436 (M + H)+。
実施例1(30)
3’−{[ベンジル(3−フェニルプロパノイル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.14分; MS : 450 (M + H)+。
実施例1(31)
3’−{[(2−フェニルエチル)(3−フェニルプロパノイル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.18分; MS : 464 (M + H)+。
実施例1(32)
3’−{[(3−フェニルプロパノイル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.23分; MS : 478 (M + H)+。
実施例1(33)
3’−{[ベンジル(4−クロロベンゾイル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.17分; MS : 456 (M + H)+。
実施例1(34)
3’−{[(4−クロロベンゾイル)(2−フェニルエチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.2分; MS : 470 (M + H)+。
実施例1(35)
3’−{[(4−クロロベンゾイル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.25分; MS : 484 (M + H)+。
実施例1(36)
3’−{[ベンジル(4−メトキシベンゾイル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.04分; MS : 452 (M + H)+。
実施例1(37)
3’−{[(4−メトキシベンゾイル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.11分; MS : 480 (M + H)+。
実施例1(38)
3’−{[ベンジル(シクロペンチルカルボニル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.13分; MS : 414 (M + H)+。
実施例1(39)
3’−{[(シクロペンチルカルボニル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.24分; MS : 442 (M + H)+。
実施例1(40)
3’−{[ペンタノイル(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.19分; MS : 430 (M + H)+。
実施例1(41)
4’−{[ベンゾイル(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.11分; MS : 450 (M + H)+。
実施例1(42)
4’−{[ベンジル(フェニルアセチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.06分; MS : 436 (M + H)+。
実施例1(43)
4’−{[(フェニルアセチル)(2−フェニルエチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.09分; MS : 450 (M + H)+。
実施例1(44)
4’−{[(フェニルアセチル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.16分; MS : 464 (M + H)+。
実施例1(45)
4’−{[ブチル(フェニルアセチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.04分; MS : 402 (M + H)+。
実施例1(46)
4’−{[(フェニルアセチル)(1−プロピルブチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.34分; MS : 444 (M + H)+。
実施例1(47)
4’−{[(2−フェニルエチル)(3−フェニルプロパノイル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.17分; MS : 464 (M + H)+。
実施例1(48)
4’−{[(3−フェニルプロパノイル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.23分; MS : 478 (M + H)+。
実施例1(49)
4’−{[ブチル(3−フェニルプロパノイル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.14分; MS : 416 (M + H)+。
実施例1(50)
4’−{[(3−フェニルプロパノイル)(1−プロピルブチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.42分; MS : 458 (M + H)+。
実施例1(51)
4’−{[(4−クロロベンゾイル)(フェニル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.09分; MS : 442 (M + H)+。
実施例1(52)
4’−{[(4−クロロベンゾイル)(2−フェニルエチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.18分; MS : 470 (M + H)+。
実施例1(53)
4’−{[(4−クロロベンゾイル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.24分; MS : 485 (M + H)+。
実施例1(54)
4’−{[ブチル(4−クロロベンゾイル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.17分; MS : 422 (M + H)+。
実施例1(55)
4’−{[(4−メトキシベンゾイル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.09分; MS : 480 (M + H)+。
実施例1(56)
4’−{[(シクロペンチルカルボニル)(2−フェニルエチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.17分; MS : 428 (M + H)+。
実施例1(57)
4’−{[(シクロペンチルカルボニル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.25分; MS : 442 (M + H)+。
実施例1(58)
4’−{[(シクロペンチルカルボニル)(1−プロピルブチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.43分; MS : 422 (M + H)+。
実施例1(59)
4’−{[ペンタノイル(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.19分; MS : 430 (M + H)+。
実施例1(60)
3’−{[(4−メトキシベンゾイル)(4−フェニルブチル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.15分; MS : 494 (M + H)+。
実施例1(61)
4’−{[(4−メトキシベンゾイル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.02分; MS : 480 (M + H)+。
実施例1(62)
4’−{[(4−メトキシベンゾイル)(4−フェニルブチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.11分; MS : 494 (M + H)+。
実施例1(63)
4’−{[(2,2−ジフェニルエチル)(4−メトキシベンゾイル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.15分; MS : 542 (M + H)+。
実施例1(64)
4’−{[(2−シクロヘキサ−1−エン−1−イルエチル)(4−メトキシベンゾイル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.19分; MS : 470 (M + H)+。
実施例1(65)
4’−{[{[(1S,2R,5S)−6,6−ジメチルビシクロ[3.1.1]ヘプタ−2−イル]メチル}(4−メトキシベンゾイル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.35分; MS : 498 (M + H)+。
実施例1(66)
4’−{[(2−エチルヘキシル)(4−メトキシベンゾイル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.33分; MS : 474 (M + H)+。
実施例1(67)
4’−{[[2−(4−クロロフェニル)エチル](ペンタノイル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.19分; MS : 450 (M + H)+。
実施例1(68)
4’−{[[2−(2−クロロフェニル)エチル](ペンタノイル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.21分; MS : 450 (M + H)+。
実施例1(69)
4’−{[[2−(2−メトキシフェニル)エチル](ペンタノイル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.10分; MS : 446 (M + H)+。
実施例1(70)
4’−{[(2,2−ジフェニルエチル)(ペンタノイル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.26分; MS : 492 (M + H)+。
実施例1(71)
4’−{[{[(1S,2R,5S)−6,6−ジメチルビシクロ[3.1.1]ヘプタ−2−イル]メチル}(ペンタノイル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.52分; MS : 448 (M + H)+。
実施例1(72)
4’−{[(シクロペンチルカルボニル)(2−フェニルエチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.11分; MS : 428 (M + H)+。
実施例1(73)
4’−{[(シクロペンチルカルボニル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.17分; MS : 442 (M + H)+。
実施例1(74)
4’−{[(シクロペンチルカルボニル)(2,2−ジフェニルエチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.28分; MS : 504 (M + H)+。
実施例1(75)
4’−[((シクロペンチルカルボニル){[(1S,2R,5S)−6,6−ジメチルビシクロ[3.1.1]ヘプタ−2−イル]メチル}アミノ)メチル]−1,1’−ビフェニル−4−カルボン酸 ナトリウム塩
HPLC保持時間 : 4.59分; MS : 460 (M + H)+。
実施例2(1)〜2(43)
実施例1の反応3で得られた樹脂を1%酢酸/N,N−ジメチルホルムアミド溶液で洗浄した。ここに、相当する0.5mol/Lアルデヒド誘導体の1%酢酸/N,N−ジメチルホルムアミド溶液(5当量)を加え、混合液を室温で5時間反応させた。混合液に0.5mol/L水素化トリアセトキシホウ素ナトリウムのN,N−ジメチルホルムアミド溶液(5当量)を加え、さらに一晩反応させた。樹脂をろ過し、メタノール、N,N−ジメチルホルムアミド、テトラヒドロフランおよび1,2−ジクロロエタンで洗浄した。得られた樹脂に20%トリフルオロ酢酸/1,2−ジクロロエタンを加え、30分間反応させた。混合液をろ過し、得られた溶液を濃縮し、以下の本発明化合物を得た。
実施例2(1)
3’−{[ベンジル(4−クロロベンジル)アミノ]メチル}−1,1’−ビフェニル−2−カルボン酸 トリフルオロ酢酸塩
実施例2(2)
4’−{[(4−シアノベンジル)(1−プロピルブチル)アミノ]メチル}−1,1’−ビフェニル−2−カルボン酸 トリフルオロ酢酸塩
HPLC保持時間 : 3.59分; MS : 441 (M + H)+。
実施例2(3)
2’−[(ジベンジルアミノ)メチル]−1,1’−ビフェニル−3−カルボン酸 トリフルオロ酢酸塩
HPLC保持時間 : 3.47分; MS : 408 (M + H)+。
実施例2(4)
2’−{[(4−クロロベンジル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸 トリフルオロ酢酸塩
HPLC保持時間 : 3.64分; MS : 470 (M + H)+。
実施例2(5)
2’−{[ベンジル(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸 トリフルオロ酢酸塩
HPLC保持時間 : 3.56分; MS : 436 (M + H)+。
実施例2(6)
2’−{[(2−フェニルエチル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸 トリフルオロ酢酸塩
HPLC保持時間 : 3.62分; MS : 450 (M + H)+。
実施例2(7)
3’−{[(4−シアノベンジル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸 トリフルオロ酢酸塩
HPLC保持時間 : 3.55分; MS : 461 (M + H)+。
実施例2(8)
3’−{[ベンジル(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸 トリフルオロ酢酸塩
HPLC保持時間 : 3.63分; MS : 436 (M + H)+。
実施例2(9)
3’−{[ビス(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸 トリフルオロ酢酸塩
HPLC保持時間 : 3.72分; MS : 464 (M + H)+。
実施例2(10)
4’−{[(4−メトキシベンジル)(2−フェニルエチル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸 トリフルオロ酢酸塩
HPLC保持時間 : 3.58分; MS : 452 (M + H)+。
実施例2(11)
2’−{[ベンジル(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 トリフルオロ酢酸塩
HPLC保持時間 : 3.51分; MS : 436 (M + H)+。
実施例2(12)
2’−{[(4−クロロベンジル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 トリフルオロ酢酸塩
HPLC保持時間 : 3.59分; MS : 470 (M + H)+。
実施例2(13)
2’−{[ブチル(4−クロロベンジル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 トリフルオロ酢酸塩
HPLC保持時間 : 3.46分; MS : 408 (M + H)+。
実施例2(14)
2’−{[ベンジル(4−シアノベンジル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 トリフルオロ酢酸塩
HPLC保持時間 : 3.55分; MS : 433 (M + H)+。
実施例2(15)
2’−{[(4−シアノベンジル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 トリフルオロ酢酸塩
HPLC保持時間 : 3.48分; MS : 461 (M + H)+。
実施例2(16)
2’−{[ビス(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 トリフルオロ酢酸塩
HPLC保持時間 : 3.61分; MS : 464 (M + H)+。
実施例2(17)
2’−{[ベンジル(シクロヘキシルメチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 トリフルオロ酢酸塩
HPLC保持時間 : 3.51分; MS : 414 (M + H)+。
実施例2(18)
3’−{[ベンジル(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 トリフルオロ酢酸塩
HPLC保持時間 : 3.57分; MS : 436 (M + H)+。
実施例2(19)
3’−{[(4−シアノベンジル)(2−フェニルエチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 トリフルオロ酢酸塩
HPLC保持時間 : 3.47分; MS : 447 (M + H)+。
実施例2(20)
3’−{[(シクロヘキシルメチル)(2−フェニルエチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 トリフルオロ酢酸塩
HPLC保持時間 : 3.64分; MS : 428 (M + H)+。
実施例2(21)
4’−[(ジベンジルアミノ)メチル]−1,1’−ビフェニル−4−カルボン酸 トリフルオロ酢酸塩
HPLC保持時間 : 3.46分; MS : 408 (M + H)+。
実施例2(22)
4’−{[ベンジル(2−フェニルエチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 トリフルオロ酢酸塩
HPLC保持時間 : 3.51分; MS : 422 (M + H)+。
実施例2(23)
4’−{[ベンジル(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 トリフルオロ酢酸塩
HPLC保持時間 : 3.56分; MS : 436 (M + H)+。
実施例2(24)
4’−{[ベンジル(ブチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 トリフルオロ酢酸塩
HPLC保持時間 : 3.4分; MS : 374 (M + H)+。
実施例2(25)
4’−{[(4−クロロベンジル)(2−フェニルエチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 トリフルオロ酢酸塩
HPLC保持時間 : 3.61分; MS : 456 (M + H)+。
実施例2(26)
4’−{[(4−クロロベンジル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 トリフルオロ酢酸塩
HPLC保持時間 : 3.66分; MS : 470 (M + H)+。
実施例2(27)
4’−{[(4−クロロベンジル)(2−メトキシエチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 トリフルオロ酢酸塩
HPLC保持時間 : 3.39分; MS : 410 (M + H)+。
実施例2(28)
4’−{[ブチル(4−クロロベンジル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 トリフルオロ酢酸塩
HPLC保持時間 : 3.51分; MS : 408 (M + H)+。
実施例2(29)
4’−{[(4−メトキシベンジル)(2−フェニルエチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 トリフルオロ酢酸塩
HPLC保持時間 : 3.52分; MS : 452 (M + H)+。
実施例2(30)
4’−{[(4−メトキシベンジル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 トリフルオロ酢酸塩
HPLC保持時間 : 3.58分; MS : 466 (M + H)+。
実施例2(31)
4’−{[(4−シアノベンジル)(2−フェニルエチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 トリフルオロ酢酸塩
HPLC保持時間 : 3.46分; MS : 447 (M + H)+。
実施例2(32)
4’−{[(4−シアノベンジル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 トリフルオロ酢酸塩
HPLC保持時間 : 3.53分; MS : 461 (M + H)+。
実施例2(33)
4’−{[ブチル(4−シアノベンジル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 トリフルオロ酢酸塩
HPLC保持時間 : 3.35分; MS : 399 (M + H)+。
実施例2(34)
4’−{[ベンジル(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 トリフルオロ酢酸塩
HPLC保持時間 : 3.55分; MS : 435 (M + H)+。
実施例2(35)
4’−{[(2−フェニルエチル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 トリフルオロ酢酸塩
HPLC保持時間 : 3.64分; MS : 450 (M + H)+。
実施例2(36)
4’−{[ビス(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 トリフルオロ酢酸塩
HPLC保持時間 : 3.69分; MS : 464 (M + H)+。
実施例2(37)
4’−{[(3−フェニルプロピル)(1−プロピルブチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 トリフルオロ酢酸塩
HPLC保持時間 : 3.75分; MS : 444 (M + H)+。
実施例2(38)
4’−{[ベンジル(シクロヘキシルメチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 トリフルオロ酢酸塩
HPLC保持時間 : 3.57分; MS : 414 (M + H)+。
実施例2(39)
4’−{[(シクロヘキシルメチル)(2−フェニルエチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 トリフルオロ酢酸塩
HPLC保持時間 : 3.63分; MS : 428 (M + H)+。
実施例2(40)
4’−{[ブチル(シクロヘキシルメチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 トリフルオロ酢酸塩
HPLC保持時間 : 3.52分; MS : 380 (M + H)+。
実施例2(41)
4’−{[ベンジル(ペンチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 トリフルオロ酢酸塩
HPLC保持時間 : 3.49分; MS : 388 (M + H)+。
実施例2(42)
4’−{[ペンチル(2−フェニルエチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 トリフルオロ酢酸塩
HPLC保持時間 : 3.59分; MS : 402 (M + H)+。
実施例2(43)
4’−{[(3−フェニルプロピル)(ピリジン−2−イルメチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸 トリフルオロ酢酸塩
HPLC保持時間 : 3.46分; MS : 437 (M + H)+。
実施例3
メチル 4’−(ブロモメチル)ビフェニル−2−カルボキシレート
メチル 4’−メチルビフェニル−2−カルボキシレート(8.78g)の四塩化炭素(500mL)溶液に、2,2’−アゾビスイソブチロニトリル(6.91g)とN−ブロモサクシンイミド(302mg)を加え、アルゴン雰囲気下、6時間還流した。室温に冷却後、ろ過し、濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(酢酸エチル:ヘキサン=1:5)で精製し、下記の物性値を有する標題化合物(9.30g)を得た。
TLC : Rf 0.59 (酢酸エチル:ヘキサン=1:4);
NMR (CDCl3) : δ 7.89-7.82 (m, 1H), 7.63-7.26 (m, 7H), 4.55 (s, 2H), 3.65 (s, 2H)。
実施例4
メチル 4’−ホルミルビフェニル−2−カルボキシレート
エタノール(50mL)にナトリウム(85mg)を少量ずつ加え溶液とし、2−ニトロプロパン(3.56g)を加えた。ここに、実施例3で製造した化合物(8.40g)のエタノール(10mL)溶液を加え、70℃で4時間攪拌した。反応混合液を濃縮し、水を加え、酢酸エチルで抽出した。抽出物を1mol/L水酸化ナトリウム水溶液、飽和食塩水で順次洗浄し、無水硫酸ナトリウムで乾燥し、濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(酢酸エチル:ヘキサン=1:5)で精製し、下記の物性値を有する標題化合物(5.02g)を得た。
TLC : Rf 0.50 (酢酸エチル:ヘキサン=1:2);
NMR (CDCl3) : δ 10.07 (s, 1H), 7.96-7.89 (m, 3H), 7.63-7.34 (m, 5H), 3.66 (s, 3H)。
実施例5
メチル 4’−[(ベンジルアミノ)メチル]ビフェニル−2−カルボキシレート
実施例4で製造した化合物(120mg)のメタノール(3mL)溶液に0℃でベンジルアミン(128mg)を加え、室温にて4時間攪拌した。反応混合液に水素化ホウ素シアノナトリウム(62mg)を加え、酢酸をpHが5.5付近になるまで滴下し、室温で1時間攪拌した。反応混合液を濃縮し、5mol/L水酸化ナトリウム水溶液でアルカリ性とし、酢酸エチルで抽出した。有機層を飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥し、濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(クロロホルム:メタノール=30:1)で精製し、下記の物性値を有する標題化合物(94mg)を得た。
TLC : Rf 0.51 (クロロホルム:メタノール=9:1);
NMR (CDCl3) : δ 7.85-7.79 (m, 1H), 7.58-7.22 (m, 12H), 3.87 (s, 2H), 3.86 (s, 2H), 3.65 (s, 3H)。
実施例6
メチル 4’−{[ベンジル(ペンタノイル)アミノ]メチル}ビフェニル−2−カルボキシレート
実施例5で製造した化合物(85mg)のピリジン(2mL)溶液にペンタノイル クロライド(62μL)を加え、室温で1.5時間攪拌した。反応混合液に水を加え、酢酸エチルで抽出した。抽出物を、1mol/L塩酸、飽和炭酸水素ナトリウム水溶液、飽和食塩水で順次洗浄し、無水硫酸ナトリウムで乾燥し、濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(酢酸エチル:ヘキサン=1:2)で精製し、下記の物性値を有する標題化合物(101mg)を得た。
TLC : Rf 0.55 (酢酸エチル:ヘキサン=1:2);
NMR (CDCl3) : δ 7.89-7.80 (m, 1H), 7.60-7.16 (m, 12H), 4.65 (s, 2H), 4.50 (s, 2H), 3.68 and 3.66 (s, 3H), 2.50-2.40 (m, 2H), 1.80-1.64 (m, 2H), 1.48-1.26 (m, 2H), 0.96-0.87 (m, 3H)。
実施例7
4’−{[ベンジル(ペンタノイル)アミノ]メチル}−1,1’−ビフェニル−2−カルボン酸
TLC : Rf 0.59 (クロロホルム:メタノール=9:1);
NMR (CDCl3) : δ 7.98-7.91 (m, 1H), 7.61-7.52 (m, 1H), 7.47-7.14 (m, 11H), 4.62 (s, 2H), 4.48 and 4.49 (s, 2H), 2.47-2.40 (m, 2H), 1.75-1.64 (m, 2H), 1.43-1.28 (m, 2H), 0.90 (t, J = 7.2 Hz, 3H)。
実施例8
メチル 4’−(アニリノメチル)ビフェニル−2−カルボキシレート
実施例4で製造した化合物(120mg)のメタノール(3mL)溶液にフェニルアミン(56mg)を加え、室温で4時間攪拌した。反応混合液に水素化ホウ素ナトリウム(37mg)を加え、1.5時間攪拌した。反応混合液を濃縮し、5mol/L水酸化ナトリウム水溶液でアルカリ性とし、酢酸エチルで抽出した。有機層を飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥し、濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(ジエチルエーテル:ヘキサン=1:2)で精製し、下記の物性値を有する標題化合物(124mg)を得た。
TLC : Rf 0.42 (酢酸エチル:ヘキサン=1:4);
NMR (CDCl3) : δ 7.86-7.80 (m, 1H), 7.58-7.14 (m, 9H), 6.78-6.64 (m, 3H), 4.38 (s, 2H), 4.20-4.00 (br, 1H), 3.65 (s, 3H)。
実施例9
4’−{[ペンタノイル(フェニル)アミノ]メチル}−1,1’−ビフェニル−2−カルボン酸
TLC : Rf 0.59 (クロロホルム:メタノール=9:1);
NMR (CDCl3) : δ 7.92 (dd, J = 7.6, 1.2 Hz, 1H), 7.60-7.51 (m, 1H), 7.46-7.16 (m, 9H), 7.00-6.93 (m, 2H), 4.90 (s, 2H), 2.06 (t, J = 7.6 Hz, 2H), 1.65-1.49 (m, 2H), 1.30-1.10 (m, 2H), 0.79 (t, J = 7.3 Hz, 3H)。
実施例10
メチル 4’−(ヒドロキシメチル)ビフェニル−2−カルボキシレート
実施例4で製造した化合物(400mg)のメタノール(10mL)溶液に水素化ホウ素ナトリウム(111mg)溶液を加え、室温で1時間攪拌した。反応混合液を濃縮し、1mol/L塩酸と酢酸エチルで抽出した。有機層を飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥し、濃縮し、下記の物性値を有する標題化合物(400mg)を得た。
TLC : Rf 0.33 (酢酸エチル:ヘキサン=1:1);
NMR (CDCl3) : δ 7.86-7.80 (m, 1H), 7.60-7.26 (m, 7H), 4.75 (s, 2H), 3.67 (s, 3H)。
実施例11
メチル 4’−(アジドメチル)ビフェニル−2−カルボキシレート
実施例10で製造した化合物(345mg)のN,N−ジメチルホルムアミド(15mL)溶液にアジ化ナトリウム(650mg)、トリフェニルホスフィン(935mg)および四臭化炭素(1.18g)を順次加え、室温で2時間攪拌した。反応混合液に水を加え、酢酸エチルで抽出した。抽出物を飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥し、濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー(酢酸エチル:ヘキサン=1:6)で精製し、下記の物性値を有する標題化合物(380mg)を得た。
TLC : Rf 0.53 (酢酸エチル:ヘキサン=1:4);
NMR (CDCl3) : δ 7.86 (dd, J = 7.7, 1.5 Hz, 1H), 7.60-7.30 (m, 7H), 4.40 (s, 2H), 3.64 (s, 3H)。
実施例12
メチル 4’−(アミノメチル)ビフェニル−2−カルボキシレート 塩酸塩
実施例11で製造した化合物(370mg)のメタノール(6mL)溶液に10%パラジウム−炭素(180mg)を加え、水素雰囲気下、室温で一晩攪拌した。反応混合液をアルゴン置換し、セライト(商品名)を通してろ過し、濃縮した。残渣を酢酸エチル(10mL)に溶解し、4mol/L塩酸の酢酸エチル溶液(1mL)を加えて攪拌し、濃縮した。得られた残渣を酢酸エチルとヘキサンの混合溶媒で洗浄し、下記の物性値を有する標題化合物(380mg)を得た。
NMR (CDCl3) : δ 8.40-8.10 (brs, 3H), 7.76 (dd, J = 7.6, 1.4 Hz, 1H), 7.68-7.59 (m, 1H), 7.55-7.31 (m, 6H), 4.14-4.02 (m, 2H), 3.61 (s, 3H)。
実施例13
4’−{[(フェニルアセチル)アミノ]メチル}−1,1’−ビフェニル−2−カルボン酸
TLC : Rf 0.67 (クロロホルム:メタノール=8:2);
NMR (CDCl3) : δ 7.94 (dd, J = 1.2, 7.6 Hz, 1H), 7.60-7.14 (m, 12H), 5.91-5.80 (br, 1H), 4.43 (d, J = 6.0 Hz, 2H), 3.63 (s, 2H)。
本発明化合物が、BLT2結合活性を有すること、ならびにケラチノサイトにおけるBLT2の発現およびその機能は、以下の実験によって証明された。
ヒトBLT2遺伝子を過剰発現させたチャイニーズハムスターオーバリー(Chinese Hamster Ovary、CHO)細胞(J.Exp.Med. Volume 192, Number 3 2000, 421-参照。)を用いて該受容体アンタゴニストの活性評価を行なった。BLT2発現細胞は、10%FBS(ウシ胎児血清)、ペニシリン/ストレプトマイシン、ブラスチサイジン(5μg/ml)含有Ham’sF12培地(GIBCO BRL社製、No.11765-047)を用いて培養した。まず、Fura2−AM(Dojindo社製、No.348-05831)を細胞内へ取り込ませるため、細胞を5μM Fura2−AM溶液(10%FBS、20mM HEPES緩衝液(pH7.4)、2.5mMプロベネシド(Sigma社製、No.P-8761)含有Ham’sF12培地)で、37℃、60分間インキュベーションした。次に20mM HEPES緩衝液(pH7.4)、2.5mM プロベネシドを含むHanks液で1回洗浄し、アッセイまで同Hanks液に浸した。蛍光ドラッグスクリーニングシステム(浜松ホトニクス社製、FDSS-2000)にプレートをセットし、30秒間無刺激で測定し、本発明化合物の溶液を添加した。その3分後にLTB4(終濃度:3μM)を添加して、添加前後の細胞内カルシウムイオン濃度を3秒間隔で測定した(励起波長340nmおよび380nm、蛍光波長500nm)。本発明化合物は、ジメチルスルホキシド(DMSO)に溶解し、終濃度が1nM〜10μMになるように添加した。BLT2拮抗活性は、本発明化合物を含まないDMSOを添加したウェルでのLTB4(終濃度:3μM)によるピーク値をコントロール値(A)とし、化合物で処理した細胞でのLTB4添加前の値から添加後の値の差(B)とを比較し、抑制率(%)={(A−B)/A}×100を算出した。
本発明化合物(終濃度:1nM〜10μM、ジメチルスルホキシド(DMSO)溶液)をBLT2過剰発現細胞に添加し、その3分後にLTB4(終濃度:3μM)を添加して、LTB4添加前後の細胞内カルシウムイオン濃度の上昇を3秒間隔で測定した(励起波長340nmおよび380nm、蛍光波長500nm)。
mBLT2のORFは、BamHIの制限酵素部位を有するセンスプライマー(sense primer ; 5'-CGGGATCCCGCATGTCTGTCTGCTACCGTC-3' (配列番号1))およびEcoRIの制限酵素部位を有するアンチセンスプライマー(antisense primer ; 5'-CGGAATTCTACCATTCTTGACTGTCTT-3' (配列番号2))を用いてPCRで増幅した。PCR産物はBamHIおよびEcoRIで切断し、発現プラスミド(pcDNA3 [Invitrogen])に組み込んだ。インサートの配列は、DNAシークエンスにより確認した。抗生物質(ストレプトマイシン(100μg/mL)、ペニシリン(100μg/mL))を含む10%ウシ胎児血清含有Ham’s F−12培地を用いて細胞培養用プレート(6cm)に培養したCHO細胞に、リポフェクタミンプラス(Life technologies)を用いてプラスミドDNA(3μg)をトランスフェクトし、抗生物質(G418 [wako]、1mg/mL)の存在下2週間培養することによって耐性株を得た。得られた19個の耐性株を限界希釈法により培養することで安定発現細胞株を得た。
マウス各組織でのBLT2mRNAの発現パターンを得るために、ノーザンブロッティングを行った。まず、マウス(C57Bl/6J Jcl [日本クレア])組織のトータルRNAを、RNA抽出用試薬(Isogen [Wako])を用いて抽出した。尚、マウス腹腔マクロファージは、マウス腹腔にチオグリコレート(4.05w/v%、2mL)を注入し、4日後に回収することで得た。また、マウス好中球は、マウス腹腔にカゼイン(2.0w/v%、2mL)を注入し、7時間後に回収することで得た。ポリ(A)+RNAは、mRNA抽出用キット(μMACS mRNA isolation kit [Miltenyi Biotec])を用いてトータルRNA(200μg)から単離した。
<結果>
ノーザンブロッティングによる解析を行った結果、mBLT2のmRNAは、小腸および皮膚に発現していることがわかった。主な転写産物は、1.5kbおよび6.7kbであった。結果を図1に示す。
マウス各組織でのBLT2mRNAの発現量を定量するために、定量的リアルタイムRT−PCRを行った。まずマウス組織mRNA(50ng)およびマクロファージ、好中球のトータルRNA(50ng)から、cDNAを合成(Superscript II [Invitrogen])し、蒸留水で100倍に希釈した。次に、希釈済みcDNA(5μL)、1× FastStart DNA Master SYBR Green I(Roche ; Molecular Biochemicals)、MgCl2(終濃度4mM)およびプライマー(0.5μM)をそれぞれ充填した20μLのマイクロキャピラリーをPCR反応液とし、PCR(ライトサイクラーシステム [Roche Molecular Biochemicals])を行った。尚、スタンダードとしては、pCXN2-mBLT2およびpcDNA3.1(mG3PDH cDNA含)を用い、プライマーとしては、以下のものを用いた;mBLT2 820+, 5'-ACAGCCTTGGCTTTCTTCAG-3' (配列番号3); mBLT2 1013-, 5'-TGCCCCATTACTTTCAGCTT-3' (配列番号4); GAPDH-1013+, GTGGACCTCATGGCCTACAT-5' (配列番号5); GAPDH-1226-, 5'-GGGTGCAGCGAACTTTATTG-3' (配列番号6)。PCR終了後、ライトサイクラー付属の解析ソフトを用いて、SYBR Green Iのシグナルとサイクル数とを指標に、BLT2mRNAおよびG3PDHmRNAの量を算出した。
<結果>
BLT2mRNAの量をG3PDHmRNAの量で補正した結果、BLT2mRNAは小腸に極めて多く発現しており、続いて皮膚に多く発現していることがわかった。また大腸や脾臓での発現量は低いものであった。結果を図2に示す。
マウス(C57Bl/6J Jcl [日本クレア])皮膚サンプルのパラフィン切片を、10%ホルマリン含有PBSで固定し、BLT2mRNAの発現をnon-radioactive in situハイブリダイゼーション法にて観察した。まず、パラフィン包埋したマウス組織を4μm厚に切断し、シランコートガラスにマウント後、脱パラフィン処理を行った。その後、プロテイナーゼK(5μg/mL in PBS)で処理(室温、10分間)し、グリシン(2mg/mL in PBS)で処理(室温、15分間)することによりサンプルを作製した。サンプルは、無水酢酸(1mL in 400mL of 0.1M triethanolamine、pH8.0)中、室温で15分間処理することによりアセチル化し、PBSで洗浄後、50%ホルムアミド含有2×SSCに浸し、ハイブリダイゼーションに付した。mBLT2のORFフラグメント(741−941)を、HindIIIの制限酵素部位を含むupstream primerおよびEcoRIの制限酵素部位を含むdownstream primer とを用いてPCRで増幅し、ディレクショナルクローニング法にてベクター(pSPT18)に組み込んだ。これをHindIIIで切断し、アンチセンスプローブを作製し、EcoRIで切断し、センスプローブを作製した。これらのプローブは、DIG RNAラベリングキット(Roche Molecular Biochemicals)を用いてジゴキシゲニン−11−UTPラベルした。ハイブリダイゼーションは、加湿下、42℃で16時間行った。サンプルは、50%ホルムアミド含有2×SSCを用いて、42℃で3回、20分間洗浄した。ハイブリダイズしなかったプローブは、酵素(RNaseA(20μg/mL) in NaCl(500mM)、EDTA(1mM)、Tris-HCl(10mM、pH8.0))を用いて30分間、37℃で処理することにより切断した。さらにサンプルを、0.1×SSCを用いて、42℃で3回、20分間洗浄した後、ジゴキシゲニンラベルしたプローブを、DIG nucleic acid検出キット(Roche Mollecular Biochemical)を用いてキット添付のマニュアルに従って可視化した。また、メチルグリーンによる対比染色も施した。
<結果>
In Situハイブリダイゼーションの結果を図3に示す。A、C、Eは、mBLT2のアンチセンスプローブを用いてハイブリダイゼーションを行った結果を表わし、B、D、Fはセンスコントロールプローブとハイブリダイゼーションを行った結果を表わす。(倍率:A、B=140倍;C、D=240倍;E、F=430倍)
mBLT2は、表皮の毛包ケラチノサイトや濾胞ケラチノサイトに発現していることがわかった。
生物学的実施例3で調製したmBLT2発現CHO細胞を、蛍光色素(Fura-2 AM [Dojin]、3μM)含有改変Hepes-Tyrode's BSA Buffer(Hepes-NaOH(25mM、pH7.4)、NaCl(140mM)、KCl(2.7mM)、CaCl2(1.0mM)、NaHCO3(12mM)、D-Glucose(5.6mM)、NaH2PO4(0.37mM)、MgCl2(0.49mM)、cremophour(0.01%)、fatty acid-free BSA(fraction V、0.1w/v%))中、37℃で2時間培養し、蛍光色素を取り込ませた。細胞を二回洗浄し、Hepes-Tyrode's BSA Bufferに再懸濁(106cells/mL)した。細胞懸濁液(0.5mL)を、蛍光強度計(CAF-100 system [Jasco])にアプライし、リガンドを含むジメチルスルホキシド(DMSO)溶液(5μL)を添加し、細胞内カルシウム濃度をモニタリング(励起波長340nmおよび380nm、蛍光波長510nm)した。
<結果>
リガンドとして、実施例9で製造した化合物(以下、化合物Aと略記する。)を用いた場合の、細胞内カルシウム濃度の上昇を示すグラフを図4に示す。化合物A(▲)は、LTB4(◆)に比べて、低いEC50値(化合物A:21nM;LTB4:121nM)を示した。尚、mBLT1を発現させたCHO細胞(▽)やmock(□)に化合物Aを加えても細胞内カルシウム濃度の上昇は観察されなかった。
4週齢マウス(C57Bl/6J Jcl [日本クレア])の皮膚切片を、ディスパーゼ溶液(250PU/mL dispase in PBS)中、4℃で一晩処理した。表皮を真皮より剥離し、0.05%trypsin-EDTAを用いて5分間、分離させた。トリプシンは、10%MEM培地(Sigma)を用いて不活化した。遠心分離し、細胞をEGF(10ng/mL)およびコレラ毒素(10pM)含有Defined keratinocyte−SFM培地に懸濁した。
生物学的実施例9:ERKリン酸化(1)
生物学的実施例3で調製したmBLT2発現CHO細胞を、12ウェル培養用プレートに2.0×105cells/wellの細胞密度で培養した。2日後、0.1%BSA含有F−12培地に置換し、12時間無血清培養を行った。細胞を0.1%BSA含有F−12培地中で10分間プレインキュベーションし、種々の濃度のリガンドに5分間曝露した。
<結果>
mBLT2発現CHO細胞およびmBLT1発現CHO細胞を用いて、LTB4または化合物Aで刺激した際のERKリン酸化のデータを図5に示す(図5上段:mBLT2発現CHO細胞;下段;mBLT1発現CHO細胞)。LTB4および化合物Aは、BLT1発現CHO細胞、BLT2発現CHO細胞ともにERKのリン酸化を誘導した。また、化合物AはBLT1発現CHO細胞ではERKのリン酸化を誘導しなかった。
生物学的実施例8で調製した細胞をチャンバースライドに培養し、固定液(メタノール:アセトン=1:1)で固定した。PBSで洗浄し、10%ヤギ血清および3%BSAを含有するPBSでブロッキングを行った。その後、マウスケラチン5(mouse keratin 5 [Covance Research Products])に対する抗体(1μg/mL)およびそれに対する蛍光標識二次抗体(Alexa Fluor R546 anti-rabbit IgG [Molecular probes]、10μg/mL)を用いて標本を染色し、蛍光顕微鏡を用いて観察を行った。
<結果>
マウスから調製した細胞は、殆どがマウスケラチン5陽性であった。従って、これらの細胞は、ケラチノサイトであることがわかった。結果を図6に示す。
また、生物学的実施例8で調製した初代培養ケラチノサイトを、12ウェル培養用プレートに4.0×105cells/wellの細胞密度で培養した。培養1日後、Defined keratinocyte SFM培地(GibcoBRL)に置換し、12時間無血清培養を行った。細胞を0.1%BSA含有Defined keratinocyte SFM培地中で10分間プレインキュベーションし、生物学的実施例9と同様に刺激を行い、ERKのリン酸化を観察した。
<結果>
マウス初代培養ケラチノサイトを用いて、LTB4または化合物Aで刺激した際のERKリン酸化のデータを図7に示す。LTB4および化合物Aは、ともにマウス初代培養ケラチノサイトのERKリン酸化を誘導した。
本発明に用いられる代表的な製剤例を以下に示す。
製剤例1:
4’−{[ペンタノイル(フェニル)アミノ]メチル}−1,1’−ビフェニル−2−カルボン酸(100g)、カルボキシメチルセルロースカルシウム(20.0g)、ステアリン酸マグネシウム(10.0g)および微結晶セルロース(870g)を常法により混合した後打錠して、一錠中に10mgの活性成分を含有する錠剤1万錠を得た。
製剤例2:
4’−{[ペンタノイル(フェニル)アミノ]メチル}−1,1’−ビフェニル−2−カルボン酸(200g)、マンニトール(2kg)および蒸留水(50L)を常法により混合した後、除塵フィルターでろ過し、5mlずつアンプルに充填し、オートクレーブで加熱滅菌して、1アンプル中20mgの活性成分を含有するアンプル1万本を得た。
Claims (5)
- 一般式(I−1)
R 1 は、水素原子またはC1−8アルキル基、フェニル基、ベンジル基、フェニルエチル基、フェニルプロピル基、フェニルブチル基、シクロヘキシルメチル基、およびシクロヘキセニルエチル基からなる群より選択される炭化水素基を表し、前記炭化水素基はハロゲン原子、ベンゼン環、および−OR 8 (ここでR 8 はC1〜8アルキル基を表す。)から選択される1〜5個の置換基で置換されていてもよく、
R 2 は、C1−8アルキル基、ベンジル基、フェニルエチル基、フェニルプロピル基、およびシクロペンチルメチル基からなる群より選択される、オキソ基で置換された炭化水素基を表し、前記炭化水素基はハロゲン原子、および−OR 8 (ここでR 8 はC1〜8アルキル基を表す。)から選択される1〜4個の置換基で置換されていてもよい。
ただし、R 1 が置換されていてもよいフェニル基以外を表す場合は、一般式(I−1)の化合物は以下の化合物を表す;
(1) 2’−{[ベンジル(フェニルアセチル)アミノ]メチル}−1,1’−ビフェニル−2−カルボン酸、
(2) 2’−{[(フェニルアセチル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−2−カルボン酸、
(3) 2’−{[(2−フェニルエチル)(3−フェニルプロパノイル)アミノ]メチル}−1,1’−ビフェニル−2−カルボン酸、
(4) 2’−{[(3−フェニルプロパノイル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−2−カルボン酸、
(5) 2’−{[(3−フェニルプロパノイル)(1−プロピルブチル)アミノ]メチル}−1,1’−ビフェニル−2−カルボン酸、
(6) 2’−{[(4−クロロベンゾイル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−2−カルボン酸、
(7) 2’−{[(4−クロロベンゾイル)(1−プロピルブチル)アミノ]メチル}−1,1’−ビフェニル−2−カルボン酸、
(8) 2’−{[(4−メトキシベンゾイル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−2−カルボン酸、
(9) 3’−{[(フェニルアセチル)(1−プロピルブチル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸、
(10) 3’−{[ベンジル(3−フェニルプロパノイル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸、
(11) 3’−{[(2−フェニルエチル)(3−フェニルプロパノイル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸、
(12) 3’−{[(3−フェニルプロパノイル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸、
(13) 3’−{[ブチル(3−フェニルプロパノイル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸、
(14) 3’−{[(3−フェニルプロパノイル)(1−プロピルブチル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸、
(15) 3’−{[ベンジル(4−クロロベンゾイル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸、
(16) 3’−{[(4−クロロベンゾイル)(2−フェニルエチル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸、
(17) 3’−{[(4−クロロベンゾイル)(1−プロピルブチル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸、
(18) 3’−{[ペンタノイル(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸、
(19) 3’−{[ベンジル(フェニルアセチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(20) 3’−{[(フェニルアセチル)(2−フェニルエチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(21) 3’−{[(フェニルアセチル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(22) 3’−{[(フェニルアセチル)(1−プロピルブチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(23) 3’−{[ベンジル(3−フェニルプロパノイル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(24) 3’−{[(2−フェニルエチル)(3−フェニルプロパノイル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(25) 3’−{[(3−フェニルプロパノイル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(26) 3’−{[ベンジル(4−クロロベンゾイル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(27) 3’−{[(4−クロロベンゾイル)(2−フェニルエチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(28) 3’−{[(4−クロロベンゾイル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(29) 3’−{[ベンジル(4−メトキシベンゾイル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(30) 3’−{[(4−メトキシベンゾイル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(31) 3’−{[ベンジル(シクロペンチルカルボニル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(32) 3’−{[(シクロペンチルカルボニル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(33) 3’−{[ペンタノイル(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(34) 4’−{[ベンゾイル(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(35) 4’−{[ベンジル(フェニルアセチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(36) 4’−{[(フェニルアセチル)(2−フェニルエチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(37) 4’−{[(フェニルアセチル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(38) 4’−{[ブチル(フェニルアセチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(39) 4’−{[(フェニルアセチル)(1−プロピルブチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(40) 4’−{[(2−フェニルエチル)(3−フェニルプロパノイル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(41) 4’−{[(3−フェニルプロパノイル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(42) 4’−{[ブチル(3−フェニルプロパノイル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(43) 4’−{[(3−フェニルプロパノイル)(1−プロピルブチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(44) 4’−{[(4−クロロベンゾイル)(2−フェニルエチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(45) 4’−{[(4−クロロベンゾイル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(46) 4’−{[ブチル(4−クロロベンゾイル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(47) 4’−{[(4−メトキシベンゾイル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(48) 4’−{[(シクロペンチルカルボニル)(2−フェニルエチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(49) 4’−{[(シクロペンチルカルボニル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(50) 4’−{[(シクロペンチルカルボニル)(1−プロピルブチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(51) 4’−{[ペンタノイル(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(52) 3’−{[(4−メトキシベンゾイル)(4−フェニルブチル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸、
(53) 4’−{[(4−メトキシベンゾイル)(4−フェニルブチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(54) 4’−{[(2,2−ジフェニルエチル)(4−メトキシベンゾイル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(55) 4’−{[(2−シクロヘキサ−1−エン−1−イルエチル)(4−メトキシベンゾイル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(56) 4’−{[{[(1S,2R,5S)−6,6−ジメチルビシクロ[3.1.1]ヘプタ−2−イル]メチル}(4−メトキシベンゾイル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(57) 4’−{[(2−エチルヘキシル)(4−メトキシベンゾイル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(58) 4’−{[[2−(4−クロロフェニル)エチル](ペンタノイル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(59) 4’−{[[2−(2−クロロフェニル)エチル](ペンタノイル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(60) 4’−{[[2−(2−メトキシフェニル)エチル](ペンタノイル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(61) 4’−{[(2,2−ジフェニルエチル)(ペンタノイル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(62) 4’−{[{[(1S,2R,5S)−6,6−ジメチルビシクロ[3.1.1]ヘプタ−2−イル]メチル}(ペンタノイル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(63) 4’−{[(シクロペンチルカルボニル)(2,2−ジフェニルエチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(64) 4’−[((シクロペンチルカルボニル){[(1S,2R,5S)−6,6−ジメチルビシクロ[3.1.1]ヘプタ−2−イル]メチル}アミノ)メチル]−1,1’−ビフェニル−4−カルボン酸、
(65) 3’−{[ベンジル(4−クロロベンジル)アミノ]メチル}−1,1’−ビフェニル−2−カルボン酸、
(66) 4’−{[(4−シアノベンジル)(1−プロピルブチル)アミノ]メチル}−1,1’−ビフェニル−2−カルボン酸、
(67) 2’−[(ジベンジルアミノ)メチル]−1,1’−ビフェニル−3−カルボン酸、
(68) 2’−{[(4−クロロベンジル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸、
(69) 2’−{[ベンジル(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸、
(70) 2’−{[(2−フェニルエチル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸、
(71) 3’−{[(4−シアノベンジル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸、
(72) 3’−{[ベンジル(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸、
(73) 3’−{[ビス(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸
(74) 4’−{[(4−メトキシベンジル)(2−フェニルエチル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸、
(75) 2’−{[ベンジル(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(76) 2’−{[(4−クロロベンジル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(77) 2’−{[ブチル(4−クロロベンジル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸
(78) 2’−{[ベンジル(4−シアノベンジル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(79) 2’−{[(4−シアノベンジル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(80) 2’−{[ビス(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(81) 2’−{[ベンジル(シクロヘキシルメチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(82) 3’−{[ベンジル(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(83) 3’−{[(4−シアノベンジル)(2−フェニルエチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(84) 3’−{[(シクロヘキシルメチル)(2−フェニルエチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(85) 4’−[(ジベンジルアミノ)メチル]−1,1’−ビフェニル−4−カルボン酸、
(86) 4’−{[ベンジル(2−フェニルエチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(87) 4’−{[ベンジル(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(88) 4’−{[ベンジル(ブチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(89) 4’−{[(4−クロロベンジル)(2−フェニルエチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(90) 4’−{[(4−クロロベンジル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(91) 4’−{[(4−クロロベンジル)(2−メトキシエチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(92) 4’−{[ブチル(4−クロロベンジル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(93) 4’−{[(4−メトキシベンジル)(2−フェニルエチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(94) 4’−{[(4−メトキシベンジル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(95) 4’−{[(4−シアノベンジル)(2−フェニルエチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(96) 4’−{[(4−シアノベンジル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(97) 4’−{[ブチル(4−シアノベンジル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(98) 4’−{[(2−フェニルエチル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(99) 4’−{[ビス(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(100) 4’−{[(3−フェニルプロピル)(1−プロピルブチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(101) 4’−{[ベンジル(シクロヘキシルメチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(102) 4’−{[(シクロヘキシルメチル)(2−フェニルエチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(103) 4’−{[ブチル(シクロヘキシルメチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(104) 4’−{[ベンジル(ペンチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(105) 4’−{[ペンチル(2−フェニルエチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(106) 4’−{[(3−フェニルプロピル)(ピリジン−2−イルメチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(107) 4’−{[ベンジル(ペンタノイル)アミノ]メチル}−1,1’−ビフェニル−2−カルボン酸、もしくは
(108) 4’−{[(フェニルアセチル)アミノ]メチル}−1,1’−ビフェニル−2−カルボン酸)
で示される化合物、その塩、またはその溶媒和物。 - 化合物が、
(109) 2’−{[フェニル(3−フェニルプロパノイル)アミノ]メチル}−1,1’−ビフェニル−2−カルボン酸、
(110) 2’−{[(4−クロロベンゾイル)(フェニル)アミノ]メチル}−1,1’−ビフェニル−2−カルボン酸、
(111) 3’−{[フェニル(フェニルアセチル)アミノ]メチル}−1,1’−ビフェニル−2−カルボン酸、
(112) 3’−{[フェニル(3−フェニルプロパノイル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸、
(113) 3’−{[(4−クロロベンゾイル)(フェニル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸、
(114) 3’−{[(4−メトキシベンゾイル)(フェニル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸、
(115) 3’−{[フェニル(3−フェニルプロパノイル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(116) 4’−{[(4−クロロベンゾイル)(フェニル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、または
(117) 4’−{[ペンタノイル(フェニル)アミノ]メチル}−1,1’−ビフェニル−2−カルボン酸である請求項1記載の化合物、その塩、またはその溶媒和物。 - (1) 2’−{[ベンジル(フェニルアセチル)アミノ]メチル}−1,1’−ビフェニル−2−カルボン酸、
(2) 2’−{[(フェニルアセチル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−2−カルボン酸、
(3) 2’−{[(2−フェニルエチル)(3−フェニルプロパノイル)アミノ]メチル}−1,1’−ビフェニル−2−カルボン酸、
(4) 2’−{[(3−フェニルプロパノイル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−2−カルボン酸、
(5) 2’−{[(3−フェニルプロパノイル)(1−プロピルブチル)アミノ]メチル}−1,1’−ビフェニル−2−カルボン酸、
(6) 2’−{[(4−クロロベンゾイル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−2−カルボン酸、
(7) 2’−{[(4−クロロベンゾイル)(1−プロピルブチル)アミノ]メチル}−1,1’−ビフェニル−2−カルボン酸、
(8) 2’−{[(4−メトキシベンゾイル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−2−カルボン酸、
(9) 3’−{[(フェニルアセチル)(1−プロピルブチル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸、
(10) 3’−{[ベンジル(3−フェニルプロパノイル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸、
(11) 3’−{[(2−フェニルエチル)(3−フェニルプロパノイル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸、
(12) 3’−{[(3−フェニルプロパノイル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸、
(13) 3’−{[ブチル(3−フェニルプロパノイル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸、
(14) 3’−{[(3−フェニルプロパノイル)(1−プロピルブチル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸、
(15) 3’−{[ベンジル(4−クロロベンゾイル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸、
(16) 3’−{[(4−クロロベンゾイル)(2−フェニルエチル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸、
(17) 3’−{[(4−クロロベンゾイル)(1−プロピルブチル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸、
(18) 3’−{[ペンタノイル(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸、
(19) 3’−{[ベンジル(フェニルアセチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(20) 3’−{[(フェニルアセチル)(2−フェニルエチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(21) 3’−{[(フェニルアセチル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(22) 3’−{[(フェニルアセチル)(1−プロピルブチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(23) 3’−{[ベンジル(3−フェニルプロパノイル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(24) 3’−{[(2−フェニルエチル)(3−フェニルプロパノイル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(25) 3’−{[(3−フェニルプロパノイル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(26) 3’−{[ベンジル(4−クロロベンゾイル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(27) 3’−{[(4−クロロベンゾイル)(2−フェニルエチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(28) 3’−{[(4−クロロベンゾイル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(29) 3’−{[ベンジル(4−メトキシベンゾイル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(30) 3’−{[(4−メトキシベンゾイル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(31) 3’−{[ベンジル(シクロペンチルカルボニル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(32) 3’−{[(シクロペンチルカルボニル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(33) 3’−{[ペンタノイル(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(34) 4’−{[ベンゾイル(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(35) 4’−{[ベンジル(フェニルアセチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(36) 4’−{[(フェニルアセチル)(2−フェニルエチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(37) 4’−{[(フェニルアセチル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(38) 4’−{[ブチル(フェニルアセチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(39) 4’−{[(フェニルアセチル)(1−プロピルブチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(40) 4’−{[(2−フェニルエチル)(3−フェニルプロパノイル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(41) 4’−{[(3−フェニルプロパノイル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(42) 4’−{[ブチル(3−フェニルプロパノイル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(43) 4’−{[(3−フェニルプロパノイル)(1−プロピルブチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(44) 4’−{[(4−クロロベンゾイル)(2−フェニルエチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(45) 4’−{[(4−クロロベンゾイル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(46) 4’−{[ブチル(4−クロロベンゾイル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(47) 4’−{[(4−メトキシベンゾイル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(48) 4’−{[(シクロペンチルカルボニル)(2−フェニルエチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(49) 4’−{[(シクロペンチルカルボニル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(50) 4’−{[(シクロペンチルカルボニル)(1−プロピルブチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(51) 4’−{[ペンタノイル(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(52) 3’−{[(4−メトキシベンゾイル)(4−フェニルブチル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸、
(53) 4’−{[(4−メトキシベンゾイル)(4−フェニルブチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(54) 4’−{[(2,2−ジフェニルエチル)(4−メトキシベンゾイル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(55) 4’−{[(2−シクロヘキサ−1−エン−1−イルエチル)(4−メトキシベンゾイル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(56) 4’−{[{[(1S,2R,5S)−6,6−ジメチルビシクロ[3.1.1]ヘプタ−2−イル]メチル}(4−メトキシベンゾイル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(57) 4’−{[(2−エチルヘキシル)(4−メトキシベンゾイル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(58) 4’−{[[2−(4−クロロフェニル)エチル](ペンタノイル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(59) 4’−{[[2−(2−クロロフェニル)エチル](ペンタノイル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(60) 4’−{[[2−(2−メトキシフェニル)エチル](ペンタノイル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(61) 4’−{[(2,2−ジフェニルエチル)(ペンタノイル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(62) 4’−{[{[(1S,2R,5S)−6,6−ジメチルビシクロ[3.1.1]ヘプタ−2−イル]メチル}(ペンタノイル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(63) 4’−{[(シクロペンチルカルボニル)(2,2−ジフェニルエチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(64) 4’−[((シクロペンチルカルボニル){[(1S,2R,5S)−6,6−ジメチルビシクロ[3.1.1]ヘプタ−2−イル]メチル}アミノ)メチル]−1,1’−ビフェニル−4−カルボン酸、
(65) 3’−{[ベンジル(4−クロロベンジル)アミノ]メチル}−1,1’−ビフェニル−2−カルボン酸、
(66) 4’−{[(4−シアノベンジル)(1−プロピルブチル)アミノ]メチル}−1,1’−ビフェニル−2−カルボン酸、
(67) 2’−[(ジベンジルアミノ)メチル]−1,1’−ビフェニル−3−カルボン酸、
(68) 2’−{[(4−クロロベンジル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸、
(69) 2’−{[ベンジル(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸、
(70) 2’−{[(2−フェニルエチル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸、
(71) 3’−{[(4−シアノベンジル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸、
(72) 3’−{[ベンジル(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸、
(73) 3’−{[ビス(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸
(74) 4’−{[(4−メトキシベンジル)(2−フェニルエチル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸、
(75) 2’−{[ベンジル(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(76) 2’−{[(4−クロロベンジル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(77) 2’−{[ブチル(4−クロロベンジル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸
(78) 2’−{[ベンジル(4−シアノベンジル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(79) 2’−{[(4−シアノベンジル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(80) 2’−{[ビス(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(81) 2’−{[ベンジル(シクロヘキシルメチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(82) 3’−{[ベンジル(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(83) 3’−{[(4−シアノベンジル)(2−フェニルエチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(84) 3’−{[(シクロヘキシルメチル)(2−フェニルエチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(85) 4’−[(ジベンジルアミノ)メチル]−1,1’−ビフェニル−4−カルボン酸、
(86) 4’−{[ベンジル(2−フェニルエチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(87) 4’−{[ベンジル(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(88) 4’−{[ベンジル(ブチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(89) 4’−{[(4−クロロベンジル)(2−フェニルエチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(90) 4’−{[(4−クロロベンジル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(91) 4’−{[(4−クロロベンジル)(2−メトキシエチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(92) 4’−{[ブチル(4−クロロベンジル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(93) 4’−{[(4−メトキシベンジル)(2−フェニルエチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(94) 4’−{[(4−メトキシベンジル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(95) 4’−{[(4−シアノベンジル)(2−フェニルエチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(96) 4’−{[(4−シアノベンジル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(97) 4’−{[ブチル(4−シアノベンジル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(98) 4’−{[(2−フェニルエチル)(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(99) 4’−{[ビス(3−フェニルプロピル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(100) 4’−{[(3−フェニルプロピル)(1−プロピルブチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(101) 4’−{[ベンジル(シクロヘキシルメチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(102) 4’−{[(シクロヘキシルメチル)(2−フェニルエチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(103) 4’−{[ブチル(シクロヘキシルメチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(104) 4’−{[ベンジル(ペンチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(105) 4’−{[ペンチル(2−フェニルエチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(106) 4’−{[(3−フェニルプロピル)(ピリジン−2−イルメチル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(107) 4’−{[ベンジル(ペンタノイル)アミノ]メチル}−1,1’−ビフェニル−2−カルボン酸、
(108) 4’−{[(フェニルアセチル)アミノ]メチル}−1,1’−ビフェニル−2−カルボン酸、
(109) 2’−{[フェニル(3−フェニルプロパノイル)アミノ]メチル}−1,1’−ビフェニル−2−カルボン酸、
(110) 2’−{[(4−クロロベンゾイル)(フェニル)アミノ]メチル}−1,1’−ビフェニル−2−カルボン酸、
(111) 3’−{[フェニル(フェニルアセチル)アミノ]メチル}−1,1’−ビフェニル−2−カルボン酸、
(112) 3’−{[フェニル(3−フェニルプロパノイル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸、
(113) 3’−{[(4−クロロベンゾイル)(フェニル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸、
(114) 3’−{[(4−メトキシベンゾイル)(フェニル)アミノ]メチル}−1,1’−ビフェニル−3−カルボン酸、
(115) 3’−{[フェニル(3−フェニルプロパノイル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、
(116) 4’−{[(4−クロロベンゾイル)(フェニル)アミノ]メチル}−1,1’−ビフェニル−4−カルボン酸、および
(117) 4’−{[ペンタノイル(フェニル)アミノ]メチル}−1,1’−ビフェニル−2−カルボン酸より選択される化合物、その塩、またはその溶媒和物。 - (117) 4’−{[ペンタノイル(フェニル)アミノ]メチル}−1,1’−ビフェニル−2−カルボン酸、その塩、またはその溶媒和物。
- 請求項1〜4のいずれか一項に記載の化合物、その塩、またはその溶媒和物を含有してなる医薬組成物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006512614A JP4793692B2 (ja) | 2004-04-26 | 2005-04-25 | 新規なblt2介在性疾患、blt2結合剤および化合物 |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004129638 | 2004-04-26 | ||
JP2004129638 | 2004-04-26 | ||
JP2004219533 | 2004-07-28 | ||
JP2004219533 | 2004-07-28 | ||
PCT/JP2005/007765 WO2005102388A1 (ja) | 2004-04-26 | 2005-04-25 | 新規なblt2介在性疾患、blt2結合剤および化合物 |
JP2006512614A JP4793692B2 (ja) | 2004-04-26 | 2005-04-25 | 新規なblt2介在性疾患、blt2結合剤および化合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2005102388A1 JPWO2005102388A1 (ja) | 2008-03-06 |
JP4793692B2 true JP4793692B2 (ja) | 2011-10-12 |
Family
ID=35196742
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006512614A Expired - Fee Related JP4793692B2 (ja) | 2004-04-26 | 2005-04-25 | 新規なblt2介在性疾患、blt2結合剤および化合物 |
Country Status (4)
Country | Link |
---|---|
US (1) | US8673889B2 (ja) |
EP (2) | EP2172222A3 (ja) |
JP (1) | JP4793692B2 (ja) |
WO (1) | WO2005102388A1 (ja) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7745477B2 (en) | 2006-02-07 | 2010-06-29 | Hoffman-La Roche Inc. | Heteroaryl and benzyl amide compounds |
JP2008031079A (ja) * | 2006-07-28 | 2008-02-14 | Sigma Soyaku Kk | 花粉症に伴う症状を抑えるための薬剤 |
US8288357B2 (en) | 2007-03-23 | 2012-10-16 | Korea University Research & Business Foundation | Use of inhibitors of leukotriene B4 receptor BLT2 for treating human cancers |
US8518889B2 (en) | 2007-03-23 | 2013-08-27 | Korea University Research & Business Foundation | Method of treating cancer with antibodies against long-form leukotriene B4 receptor BLT2 |
WO2009009041A2 (en) * | 2007-07-06 | 2009-01-15 | Kinex Pharmaceuticals, Llc | Compositions and methods for modulating a kinase cascade |
US7750027B2 (en) * | 2008-01-18 | 2010-07-06 | Oxagen Limited | Compounds having CRTH2 antagonist activity |
US9522873B2 (en) * | 2011-08-05 | 2016-12-20 | Dongguk University Industry-Academic Cooperation Foundation | Biphenyl derivative, pharmaceutically acceptable salt thereof, and methods for preventing or treating inflammatory diseases or autoimmune diseases |
WO2014008214A1 (en) * | 2012-07-02 | 2014-01-09 | Biogen Idec Ma Inc. | Biaryl-containing compounds as inverse agonists of ror-gamma receptors |
HUE037637T2 (hu) | 2012-08-30 | 2018-09-28 | Athenex Inc | N-(3-fluorobenzil)-2-(5-(4-morfolinofenil)piridin-2-IL) acetamid, mint fehérje tirozin kináz modulátorok |
GB201407807D0 (en) | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
GB201407820D0 (en) | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
EP3017813A1 (en) | 2014-11-04 | 2016-05-11 | Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. | BLT2 agonists for the treatment of pain |
KR101796390B1 (ko) * | 2015-07-24 | 2017-11-09 | 동국대학교 산학협력단 | Blt 저해 활성을 갖는 신규 화합물 및 이를 유효성분으로 포함하는 염증성 질환 예방 또는 치료용 조성물 |
WO2017018751A1 (ko) * | 2015-07-24 | 2017-02-02 | 동국대학교 산학협력단 | Blt 저해 활성을 갖는 신규 화합물 및 이를 유효성분으로 포함하는 염증성 질환 예방 또는 치료용 조성물 |
CN105294458B (zh) * | 2015-11-17 | 2017-07-11 | 中国人民解放军第四军医大学 | 一种抗肿瘤小分子化合物及其制备方法和应用 |
WO2018107158A1 (en) * | 2016-12-09 | 2018-06-14 | Celtaxsys, Inc. | Monamine and monoamine derivatives as inhibitors of leukotriene a4 hydrolase |
TWI683808B (zh) | 2017-07-18 | 2020-02-01 | 德商菲尼克斯 Fxr有限責任公司 | 含有胺或(硫)醯胺之lxr調節劑 |
JP6853406B1 (ja) * | 2020-10-05 | 2021-03-31 | 昌也 片山 | 抗毛嚢炎用外用組成物 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10512266A (ja) * | 1995-01-12 | 1998-11-24 | ユニバーシティ オブ ピッツバーグ | プレニルトランスフェラーゼの阻害剤 |
JP2000505445A (ja) * | 1996-02-13 | 2000-05-09 | ジー.ディー.サール アンド カンパニー | シクロオキシゲナーゼ―2インヒビターとロイコトリエンb▲下4▼受容体アンタゴニストの投与の免疫抑制作用 |
JP2002030080A (ja) * | 2000-06-08 | 2002-01-29 | Pfizer Prod Inc | (3s−トランス)−2−[3,4−ジヒドロ−4−ヒドロキシ−3−(フェニルメチル)−2h−1−ベンゾピラン−7−イル]−4−(トリフルオロメチル)−安息香酸の新規結晶形体 |
WO2002098840A1 (fr) * | 2001-06-04 | 2002-12-12 | Eisai Co., Ltd. | Derive de l'acide carboxylique et medicament comprenant un sel ou un ester dudit derive |
WO2004002530A1 (ja) * | 2002-06-26 | 2004-01-08 | Ono Pharmaceutical Co., Ltd. | 慢性疾患治療剤 |
US20040034064A1 (en) * | 2002-08-06 | 2004-02-19 | Kuduk Scott D. | 2-(biarylalkyl)amino-3-(alkanoylamino)pyridine derivatives |
WO2004031118A1 (ja) * | 2002-10-03 | 2004-04-15 | Ono Pharmaceutical Co., Ltd. | Lpa受容体拮抗剤 |
JP2004182657A (ja) * | 2002-12-04 | 2004-07-02 | Eisai Co Ltd | Hdlレベル上昇促進剤 |
JP2007516258A (ja) * | 2003-12-12 | 2007-06-21 | ワイス | 心臓血管の疾患治療に有用なキノリン誘導体 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3551414A (en) * | 1969-05-16 | 1970-12-29 | United States Steel Corp | 6,7-dihydro-5h-dibenz(c,e)azepin-7-ones |
DE122007000050I1 (de) * | 1990-02-19 | 2007-11-08 | Novartis Ag | Acylverbindungen |
US5789441A (en) | 1996-02-15 | 1998-08-04 | Virocell Inc. | Leukotriene B4 as an antiviral and anti-neoplastic agent |
JP4926310B2 (ja) | 1996-02-15 | 2012-05-09 | エルテーベー4・スウェーデン・アクチェボラーグ | 抗ウイルス薬および抗腫瘍薬としてのロイコトリエンb4またはその類似体の使用 |
US6228985B1 (en) * | 1998-05-21 | 2001-05-08 | Schering Corporation | Derivatives of aminobenzoic and aminobiphenylcarboxylic acids useful as anti-cancer agents |
AU1595101A (en) | 1999-11-11 | 2001-06-06 | Eli Lilly And Company | Oncolytic combinations for the treatment of cancer |
EP1270589A4 (en) * | 2000-03-21 | 2004-09-29 | Yamanouchi Pharma Co Ltd | NEW LEUKOTRIENB4 RECEPTOR |
MXPA03009130A (es) * | 2000-10-20 | 2004-02-26 | Biocryst Pharm Inc | Compuestos de biarilo que funcionan como inhibidores de proteasa serina. |
PL365443A1 (en) | 2001-01-31 | 2005-01-10 | Pfizer Products Inc. | Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of pde4 isozymes |
BR0116852A (pt) | 2001-01-31 | 2004-02-25 | Pfizer Prod Inc | Derivados biarilados de nicotinamida úteis como inibidores de isozimas pde4 |
-
2005
- 2005-04-25 US US11/587,664 patent/US8673889B2/en not_active Expired - Fee Related
- 2005-04-25 WO PCT/JP2005/007765 patent/WO2005102388A1/ja not_active Application Discontinuation
- 2005-04-25 EP EP10150486A patent/EP2172222A3/en not_active Withdrawn
- 2005-04-25 JP JP2006512614A patent/JP4793692B2/ja not_active Expired - Fee Related
- 2005-04-25 EP EP05734600A patent/EP1745800A4/en not_active Withdrawn
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10512266A (ja) * | 1995-01-12 | 1998-11-24 | ユニバーシティ オブ ピッツバーグ | プレニルトランスフェラーゼの阻害剤 |
JP2000505445A (ja) * | 1996-02-13 | 2000-05-09 | ジー.ディー.サール アンド カンパニー | シクロオキシゲナーゼ―2インヒビターとロイコトリエンb▲下4▼受容体アンタゴニストの投与の免疫抑制作用 |
JP2002030080A (ja) * | 2000-06-08 | 2002-01-29 | Pfizer Prod Inc | (3s−トランス)−2−[3,4−ジヒドロ−4−ヒドロキシ−3−(フェニルメチル)−2h−1−ベンゾピラン−7−イル]−4−(トリフルオロメチル)−安息香酸の新規結晶形体 |
WO2002098840A1 (fr) * | 2001-06-04 | 2002-12-12 | Eisai Co., Ltd. | Derive de l'acide carboxylique et medicament comprenant un sel ou un ester dudit derive |
WO2004002530A1 (ja) * | 2002-06-26 | 2004-01-08 | Ono Pharmaceutical Co., Ltd. | 慢性疾患治療剤 |
US20040034064A1 (en) * | 2002-08-06 | 2004-02-19 | Kuduk Scott D. | 2-(biarylalkyl)amino-3-(alkanoylamino)pyridine derivatives |
WO2004031118A1 (ja) * | 2002-10-03 | 2004-04-15 | Ono Pharmaceutical Co., Ltd. | Lpa受容体拮抗剤 |
JP2004182657A (ja) * | 2002-12-04 | 2004-07-02 | Eisai Co Ltd | Hdlレベル上昇促進剤 |
JP2007516258A (ja) * | 2003-12-12 | 2007-06-21 | ワイス | 心臓血管の疾患治療に有用なキノリン誘導体 |
Also Published As
Publication number | Publication date |
---|---|
EP2172222A3 (en) | 2010-06-23 |
EP2172222A2 (en) | 2010-04-07 |
US8673889B2 (en) | 2014-03-18 |
WO2005102388A1 (ja) | 2005-11-03 |
JPWO2005102388A1 (ja) | 2008-03-06 |
EP1745800A4 (en) | 2009-11-18 |
US20080132574A1 (en) | 2008-06-05 |
EP1745800A1 (en) | 2007-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4793692B2 (ja) | 新規なblt2介在性疾患、blt2結合剤および化合物 | |
TWI433830B (zh) | 胺基羧酸衍生物及其醫藥用途 | |
JP5397461B2 (ja) | S1p受容体結合能を有する化合物およびその用途 | |
US20070099938A1 (en) | Antistress drug and medical use thereof | |
JP4596314B2 (ja) | β−アラニン誘導体およびその用途 | |
JP6627835B2 (ja) | Kcnq2〜5チャネル活性化剤 | |
JPWO2004007472A1 (ja) | Ccr4アンタゴニストおよびその医薬用途 | |
WO2005035534A1 (ja) | 複素ビシクロ環および複素トリシクロ環化合物およびその医薬 | |
WO2005058790A1 (ja) | リゾホスファチジン酸受容体拮抗作用を有する化合物およびその用途 | |
WO2017131149A1 (ja) | テトラヒドロナフタレン誘導体 | |
US20110052612A1 (en) | Spiropiperidine compound and medicinal use thereof | |
JP6197971B1 (ja) | Kcnq2〜5チャネル関連疾患の予防および/または治療剤 | |
JPWO2004092136A1 (ja) | 含窒素複素環化合物およびその用途 | |
EP3327018A1 (en) | Compound having ep2 agonistic activity | |
JP2007001946A (ja) | ピロリジン誘導体 | |
JP2007015930A (ja) | 複素ビシクロ環および複素トリシクロ環化合物およびその医薬 | |
RU2811803C2 (ru) | Производное бензола | |
JP2005132761A (ja) | 含窒素複素環化合物およびその用途 | |
JP2007015927A (ja) | 複素ビシクロ環および複素トリシクロ環化合物およびその医薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080418 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110218 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110413 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110701 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110714 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140805 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140805 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |